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Abstract 
Within the UK severe sepsis is responsible for 29% of intensive care admissions and carries 
a mortality of 44.7%.  Decades of research have failed to deliver a single clinically successful 
immune modulating therapeutic agent.  These failings may be explained by fundamental 
methodological challenges of sepsis laboratory investigations, namely diagnostic uncertainty, 
an indeterminate onset and the identification of an immunologically similar control 
population.   
The underlying hypothesis for this thesis is that the translational investigation of surgical 
patients may overcome many of these methodological challenges, since surgical trauma 
generates a homogenous inflammatory insult at a planned time to a carefully phenotyped 
human population.  The biological basis for modelling sepsis with traumatic injury is 
discussed. 
Firstly, I reviewed the current literature to demonstrate the methodological advantages of 
studying surgical patients as a surrogate for sepsis. Next, I performed an observational study 
of neutrophil immune function following major elective surgery which identified a reduced 
neutrophil respiratory burst and changes in cell surface immune receptor expression. 
This impairment of activated neutrophil immune function was associated with resting 
neutrophil mitochondrial dysfunction, namely a raised mitochondrial membrane potential 
and increased production of reactive oxygen species.  Using two different models of 
mitochondrial dysfunction I demonstrated that neutrophil respiratory burst may be 
regulated by altered mitochondrial functionality.  
Finally, I provide evidence that the cytoplasmic target for this mitochondrial signal is the 
enzyme pyruvate kinase M2, which through oxidative inhibition reduces the production of 
the respiratory burst substrate NADPH by limiting flow of glucose through the hexose 
monophosphate shunt. 
In summary, major elective surgery provides a translational model of human sepsis.  Using 
this model, I demonstrate impairment of the neutrophil respiratory burst, and provide 
evidence that this is mediated through neutrophil mitochondrial dysfunction which 
promotes oxidative inhibition of the glycolytic regulatory enzyme pyruvate kinase. 
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1.1 The challenges of studying sepsis 
Sepsis is a clinical syndrome.  It was newly defined in February 2016 as organ dysfunction 
caused by a dysregulated host response to suspected infection, and carries a mortality of 
10% (Singer et al., 2016).  The previous definition of sepsis, used by much of the published 
literature, described a systemic inflammatory response (SIRS) in the context of presumed 
infection, with sub-classifications of severe sepsis and septic shock describing coexistent 
organ dysfunction and treatment resistant hypotension respectively (Dellinger et al., 2013).    
Within the United Kingdom severe sepsis accounts for 28.7% of intensive care admissions 
and confers a mortality of 44.7% (Harrison et al., 2006).  The international incidence of 
sepsis may be rising (Dombrovskiy et al., 2007; Martin et al., 2003). To date, enormous 
investment and decades of research have failed to deliver a single immune-modulating agent 
that has been reliably shown to improve outcome from human sepsis (Alejandria et al., 
2013; Angus et al., 2000; Lehmann et al., 2014; Ranieri et al., 2012; Sprung et al., 2008).  This 
thesis will explore how the methodological challenges presented by study of human sepsis 
may be responsible for these limitations, and if an alternative model of human inflammation 
– using blood samples taken from major elective surgery patients – can overcome these 
challenges. 
The methodological challenges of human sepsis research begin with the very diagnosis of 
sepsis itself. Sepsis definitions were designed to guide empirical bedside management of 
sepsis (Dellinger et al., 2013; Singer et al., 2016), not to facilitate the scientific interrogation 
of the pathophysiological mechanisms responsible.  As such they rely upon non-specific 
physiological and laboratory parameters to identify inflammation and clinical suspicion to 
identify infection.  Although the diagnostic accuracy maybe improved by the inclusion of 
latterly returned microbiological data, these data are often non-specific and the ‘dose’ of 
infection can never be known.  It follows that the relative contribution of infective burden, 
maladaptive inflammatory responses and therapeutic plus iatrogenic interventions to disease 
progression within individual patients cannot be determined. 
Identification of an appropriate control population presents the second key methodological 
challenge to human sepsis studies.  Cohort or longitudinal study design is methodologically 
advantageous because septic samples may be compared to an individual’s pre-illness control 
samples, improving the likelihood that the development of sepsis is responsible for observed 
changes to immune readouts.  However, such studies are neither economically feasible nor 
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practicable for a disease which is relatively infrequent and has such a capricious onset as 
sepsis.  Therefore, case-control investigations are often performed, where a separate 
control population – such as healthy volunteers - is identified.  However, septic patients may 
possess a range of immunologically relevant confounding factors that are not represented 
within the non-septic control population.  Specific examples include:  
• Age - Sepsis is more common in the elderly (Henriksen et al., 2015).  Advancing age 
is associated with reduced lymphocyte number and functionality (Montecino-
Rodriguez et al., 2013), and diminished granulocyte effector activities such as 
respiratory burst (Valente et al., 2009).   
• Gender - Sepsis is more common in men (McGowan et al., 1975; Offner et al., 
1999).  Enhanced protection during the proestrus period and following oestrogen 
replacement in postmenopausal women suggests oestrogen may confer direct 
protective effects  from sepsis (Weniger et al., 2015), possibly through oestrogen 
mediated attenuation of proinflammatory cytokine secretion (Angele et al., 2014).   
• Comorbid disease – Patients with overt immunosuppressive diseases such as Human 
Immunodeficiency Virus (HIV) are more likely to develop sepsis (Henriksen et al., 
2015).  Cancer is associated with an increased incidence of infection and a host of 
immunological changes, such as altered distribution of leukocytes across the gut and 
lung, natural killer cell depletion and lymphopenia (Ray-coquard et al., 2009; Snyder 
and Greenberg, 2010).  Other diseases and syndromes are also associated with 
changes in resting markers of inflammation such as erythrocyte sedimentation rate 
(ESR) and C-reactive peptide (CRP), e.g. chronic heart failure (Fildes et al., 2009).  
Many of these confounding diseases and conditions may be undiagnosed at the time 
of sepsis presentation and remain so throughout the patient’s intensive care unit 
(ICU) admission.  
• Therapeutic interventions.  Commonly administered therapies such as antibiotics 
(Kalghatgi et al., 2013; Kanoh, 2010), sedatives (Mikawa et al., 1998) and steroids 
(Clarke et al., 1993) have off-target immunological effects.  These include inhibition 
of NF-kB secretion (Kanoh, 2010), enhanced production of reactive oxygen species 
(Kalghatgi et al., 2013), impaired neutrophil respiratory burst activity (Mikawa et al., 
1998), and lymphocyte apoptosis (Clarke et al., 1993).  
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It follows that the overwhelming experimental noise present within clinical investigations 
may prevent real and relevant experimental signals from being identified.  Traditionally, 
translational research has employed a range of laboratory models that aim to overcome this 
experimental noise and in which preliminary observations may be made.   For example, the 
use of animal models, and healthy volunteer endotoxin/cytokine exposure are well 
established within sepsis research.  With these models, the timed administration of an 
inflammatory insult, coupled with carefully controlled laboratory conditions avoid many of 
the methodological challenges of real-world sepsis research.  However, these 
methodological advantages may be offset by their limited biological relevance.  The biology 
of animal model sepsis is different to that in humans, while healthy volunteer studies cannot 
reproduce the severity of real-world disease.  In principle, the use of patients undergoing 
major elective surgery provides many of the methodological benefits of animal model 
research coupled with the administration of a major inflammatory stimulus within human 
beings. 
 
1.2 Models of human sepsis 
 
1.2.1 Animal models 
Modern transgenic and knock-down technology allow control over the location and timing 
of gene expression.  Humanised models, where human myeloid cells are grafted into 
immunocompetent mice, reproduce specific features of human disease with greater 
accuracy.  Despite these developments there are inherent physiological, pathological and 
phenotypic differences that limit their applicability.  Murine metabolism (Radermacher, 
2013), cardiovascular regulation (Doevendans et al., 1998) and gut flora (Salzman et al., 
2002) are very different to humans.  Wide variations in survival of different mouse strains 
has been reported (De Maio et al., 2005; Stewart et al., 2002).  Pattern recognition receptor 
activation and signalling is fundamentally different (Lund et al., 2003; Rehli, 2002).  For 
example, 10,000-fold higher doses of lipopolysaccharide required to recreate sepsis 
syndrome in rats (Shultz et al., 2007).  In contrast to humans, circulating murine 
lymphocytes greatly outnumber circulating granulocytes.  While human leukocyte messenger 
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ribonucleic acid (mRNA) expression is highly conserved following trauma, burns and 
endotoxin, murine homologs show little correlation and much wider variation to these 
different stimuli (Xiao et al., 2011).  Immune effector functions differ, as do distribution of 
leukocyte subsets across gastrointestinal and pulmonary surfaces (Doeing et al., 2003; Rehli, 
2002).  The modality of septic death is also fundamentally different.  Model animals typically 
die early, as a direct consequence of the initial pathophysiological insult (Warren, 2009), 
whereas human death usually follows a delayed multisystem dysfunction some time after 
initial resuscitation and therapeutic support (Martin et al., 2003).   
Large animal models have also been developed.  For ethical reasons these models are rarely 
used for survival studies (Fink, 2014).  Similar to humans, sheep display marked changes in 
pulmonary artery pressure, cardiac output and lung microvascular permeability with 
nanomolar/kg doses of endotoxin (Traber et al., 1988) while pseudomonas aeruginosa 
infusions have been used to replicate sepsis itself (Booke et al., 2000).  Non-human 
primates, such as Papio anubis are incredibly resistant to endotoxin and bacterial infusion 
(Hinshaw et al., 1981), and the use of such models to test pharmacological agents have not 
correlated with outcomes in human sepsis trials (Fink, 2014). 
 
1.2.2 Healthy volunteer endotoxin and cytokine models 
The administration of endotoxin (1-4ng/kg iv) or specific cytokines to healthy volunteers 
mimics certain aspects of sepsis such as the loss of granulocyte tumour necrosis factor 
receptor (TNF-R) (Calvano and Coyle, 2012; van der Poll et al., 1995) and the early 
hyperdynamic circulatory response phase of sepsis (Andreasen et al., 2008; Bahador and 
Cross, 2007; Lowry, 2005).  However other aspects, such as the dynamic pattern of 
cytokine expression, differ markedly to patterns observed in established sepsis (Damas et 
al., 1992; Krabbe et al., 2002).  For obvious ethical reasons the magnitude and duration of 
organ dysfunction, therapeutic interventions and comorbidities which characterise human 
sepsis cannot be replicated within these models (Andreasen et al., 2008). 
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1.2.3 Major elective surgery 
Major elective surgery provides two distinct opportunities for cohort investigations of 
human sepsis.  Firstly, the inflammatory insult of surgery itself may serve as a model of 
infection, and secondly, postoperative sepsis is relatively common.  In both instances, the 
planned nature of elective surgery overcomes the methodological challenges of studying 
humans with established sepsis.   
The planned nature of elective surgery permits cohort study design, enabling comparison of 
accurately timed post-insult samples with individualised control samples.  By specifying 
operation types and surgical teams the ‘dose’ of surgery is relatively controlled.  Such 
patients typically undergo extensive preoperative investigation, and are therefore carefully 
phenotyped (Stringer, 2010).  Large numbers of patients may be recruited, with an 
estimated 234 million surgical procedures performed each year (Weiser et al., 2008).  
Surgical procedures themselves allow the acquisition of body tissue samples (Brealey et al., 
2002; Henriksen et al., 2003; Kobayashi et al., 2008) the placement of indwelling catheters 
for future sampling (Moore et al., 1991) and access to non-invasive imaging modalities 
(Izquierdo et al., 2013; Purdon et al., 2009), while routine perioperative blood sampling 
allows serial collection of data without added risk.  When these aspects are considered, 
major elective surgery may be considered to bring the methodological precision of 
laboratory research to real-world human inflammatory disease. 
 
1.2.3.1 Modelling human sepsis with a surgical insult.   
Experimental observations from postoperative patients are directly relevant to those with 
sepsis because human responses to infective and traumatic injury are highly conserved at 
molecular, genomic and clinical levels. 
The molecular similarities begin with the very first checkpoint of inflammation, the release 
and detection of danger signals (Nathan, 2006).  Endogenous danger signals are termed 
damage-associated molecular patterns (DAMPs), and consist of a diverse range of 
compartmentalised molecules/compounds whose presence out-with their usual location 
signals cellular injury.  Exogenous danger signals are termed pathogen associated molecular 
patterns (PAMPs).  DAMPs and PAMPs bind to membrane and cytoplasmic receptors 
termed pattern recognition receptors (PRR).  Ultimately, both DAMPs and PAMPs promote 
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the assembly of shared signalling platforms, such as the inflammasome and apoptosome, and 
the activation of identical transcription factors, such as Nuclear Factor -kB (NF-kB).  Shared 
responses to these infective and traumatic injury signals are apparent at many levels of the 
inflammatory cascade (Fig 1.1).  Inflammation is not an all or nothing response, and exists on 
a homeostatic continuum.  Some DAMPs, such as endotoxin are continuously released and 
the complex receptor signalling systems more similar to endogenous hormone-receptor 
interactions than those of bacterial toxins (Marshall, 2005).   
 
Figure 1.1 Molecular recognition of infective and traumatic injury.   
Adapted from (Mollen et al., 2006) 
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Similarities between the molecular recognition of infective and traumatic injury include: 
• Shared activation of the same PRR by multiple DAMPs and PAMPs.  
Some PRRs respond to both DAMP and PAMP ligands (Matzinger, 1994; 
Medzhitov and Janeway, 2002).   This may be achieved through multiple ligand 
domains on the receptor itself, conserved molecular motifs on ligands, such as 
uncovered hydrophobic portions (Seong and Matzinger, 2004), the use of adapter 
proteins plus co-receptors and co-activation at lipid rafts (Pfeiffer et al., 2001; 
Triantafilou and Triantafilou, 2002).  Toll-like receptor 4 (TLR4) is the most 
heavily investigated PRR, and is critical to the host response across a multitude of 
experimental paradigms (Ayala et al., 2002; Barsness et al., 2004). The TLR4 
ligand repertoire is vast (Table 1.1).  
Exogenous Endogenous 
Lipopolysaccharide High Mobility Group Box I 
Lipid A Heparin sulphate 
 Extra domain A of fibronectin 
 Heat proteins 60, 70, Gp96 
 Surfactant Protein A 
 Β-Defensin 2 
 Fibrinogen 
 Biglycan 
 Hyaluronan oligomers 
Table 1.1 Exogenous and endogenous Toll-like Receptor 4 agonists. 
Adapted from (Mollen et al., 2006) 
• Shared signal transduction machinery by different PRR. Toll like 
receptors and other PRR activate a highly conserved number of intracellular 
adapter proteins, such as MyD88 and TIRAP (Henneke and Golenbock, 2001; 
Tamassia et al., 2007). MyD88 recruits the IRAK family kinases, and subsequently 
MAPK and NF-kB.  The transcription factor NF-kB is a key activator of innate 
immunity, and is a complex of Rela (p65)/p50 heterodimers which remain in the 
cytoplasm bound to inhibitory kB (IkB).  Upon activation, IkB dissociates and NF-
kB translocate to the nucleus, binding to gene promotors (Ghosh and Karin, 
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2002).  Some of these down-stream pathways, such as Hypoxia Inducible Factor 
(HIF) are also directly activated by commonly used anaesthetic agents (Cramer et 
al., 2003; Peyssonnaux et al., 2005). 
• Co-release of DAMPs and PAMPs.  Tissue injury provides a portal for 
infection which will cause further tissue injury.  Therefore, the release of DAMPs 
will be accompanied by PAMPs and vice versa.  
• Translocation of endotoxin.  The physiological redistribution of blood flow 
away from the gut which accompanies severe systemic inflammation may lead to 
translocation of PAMPs (such as endotoxin) to the systemic circulation (Ackland 
et al., 2000; Van Leeuwen et al., 1994).   
• Mitochondrial DAMPs are structurally similar to bacterial PAMPs.  
Mitochondria contain molecular signatures of their protobacterial origins, such as 
circular Deoxyribonucleic Acid (DNA) with CpG repeats and formyl-peptides 
which activate TLR9 and formyl-peptide receptors respectively, and exemplify 
the evolutionary relationship between DAMPs and PAMPs (Bianchetti et al., 
1977; Taanman, 1999).  Plasma levels of mitochondrial DAMPs maybe elevated a 
thousand-fold higher in trauma patients (Zhang et al. 2010; Haimovich et al. 
2014) and correlate with mortality (Simmons et al., 2013).  The infusion of 
mitochondrial DAMPs into rats leads to the accumulation of fluid, albumin and 
neutrophils within the lungs, which maybe prevented by the co-administration of 
blocking antibodies, while the in vitro incubation of neutrophils with 
mitochondrial DAMPs leads to an activated neutrophil phenotype, with Ca influx, 
p38 MAP-kinase phosphorylation and IL-8 release (Q. Zhang et al., 2010).     
 
The molecular similarities between infective and non-infective inflammation are supported 
by genomic investigations of circulating leukocyte mRNA expression.  Highly conserved 
responses within the circulating leukocyte transcriptome have been identified following 
trauma, burns and endotoxin administration [(Xiao et al., 2011), with endotoxin-exposed 
volunteers and trauma patients demonstrating an 88% concordance in expression.  Such 
observations provide genomic support to the clinical similarities between major surgery and 
sepsis patients.   
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These investigations have identified genome wide changes in expression – one investigation 
found that 16,820 of 20,720 reported genes changed expression (Xiao et al., 2011), while 
studies of more limited expression have also identified changes in many non-immune genes, 
such as glycolytic and circadian clock modules (Haimovich et al., 2014).  Genomic studies of 
circulating leukocyte mRNA expression have shown strong concordance despite using 
different technologies (Fessler et al., 2002; Malcolm et al., 2003; Zhang et al., 2004).  
The correlation between transcriptome and proteome expression is less clear.  de Godoy 
et al found a strong relationship when investigating yeast replication (de Godoy et al., 2008), 
however a similar investigation of inflammatory gene/protein expression found little 
correlation (Fessler et al., 2002).  The alternative approach to these ‘bottom-up’ 
technologies is to measure specific cellular functions that may be expected to alter clinical 
outcomes, such as assays of immune cell effector activities.  For example, the investigation 
of sepsis induced lymphocyte apoptosis (Boomer et al., 2011; Hotchkiss et al., 1997). 
These molecular and genomic data may therefore explain why patients with primarily 
traumatic or infective injury appear clinically similar (Matzinger, 1994; Seong and Matzinger, 
2004). In contrast to the robust evidence base supporting the biological basis for modelling 
human sepsis with traumatic injury, it is unclear whether the theoretical methodological 
advantages of studying surgical patients are realised within the translational literature. 
 
1.2.3.2 Modelling sepsis with postoperative infectious complications.    
Postoperative sepsis is sufficiently common to make cohort investigations feasible.  Even in 
prospective randomized controlled trials investigating surgical site infections, the incidence 
often exceeds 15% (Belda et al., 2005; Melling et al., 2001).  
Postoperative sepsis is more common in patients with immunosuppressive disease 
(Charlson et al., 1994) cancer (Bateman et al., 2010; Charlson et al., 1994; Copeland et al., 
1991), advanced age (Charlson et al., 1994; Copeland et al., 1991; Gupta et al., 2013; 
Manilich et al., 2013), malnutrition (Warnold and Lundholm, 1984; Windsor and Hill, 1988) 
and congestive cardiac failure (Charlson et al. 1994; T. H. Lee et al. 1999; Bateman et al. 
2010).   All of these conditions are common in non-surgical patients who develop sepsis 
(Angus et al., 2001).  
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 1.3 Neutrophils as key players in sepsis and organ injury  
Neutrophils are the predominant cell type of the early SIRS response, readily entering 
inflamed tissues and possessing a powerful antimicrobial arsenal (Smith, 1994).  Inherited 
deficiencies of neutrophil function, such as chronic granulomatous disease and leukocyte 
adhesion deficiency, predispose to life-threatening bacterial infection.  While an appropriate 
response to infection is necessary for survival, such powerful antimicrobial functions may 
also cause harm.  
The experimental and clinical literature supports the autotoxic potential of neutrophils.  
Experimental data from animal models suggest that the timing of neutrophil activity in 
response to an index insult is critical in determining outcome, however this cannot be 
reliably tested within human sepsis patients because the time at which sepsis began is not 
known. 
Autotoxic neutrophil behaviour may be associated with every stage of neutrophil activation 
and activity.  Accumulation of neutrophils within the vasculature has been demonstrated 
during systemic illness (Brown et al., 2006).  Migration of neutrophils through venules may 
directly damage endothelium, and promote further tissue injury (Abe et al., 1990).  The 
passage of neutrophils into distant tissues, such as the lung (Mallick et al., 1989) and liver 
(Holman and Saba, 1988), may promote distant organ dysfunction.  The release of toxic 
granules within infected tissues may damage local tissues.  Through these mechanisms 
neutrophils may promote continued release of DAMPs, sustaining the inflammatory 
response and leading to a state of chronic non-resolving inflammation (Nathan, 2006).  Due 
to the large numbers of neutrophils released each day, small changes in the rate of apoptosis 
may increase both circulating and tissue neutrophil numbers dramatically. 
Neutrophils are also key regulators of the adaptive immune response.  They may recruit 
classical antigen presenting cells through outside-in integrin signalling (Pillay et al., 2012), the 
release of granule contents (Chertov et al., 2000) and the secretion of 
cytokines/chemokines (Pelletier et al., 2010).  Neutrophils may possibly present antigen 
directly, through cell surface Human Leukocyte Antigen-DR (HLA-DR) (Gosselin et al., 
1993).  Finally, neutrophils may polarise macrophage differentiation into pro and anti-
inflammatory subtypes (Nathan, 2006), dependent upon prevalent conditions.   
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These potentially autotoxic behaviours may be offset by anti-inflammatory processes.  
Neutrophil extracellular traps are networks of extruded DNA that concentrate killing 
power, and in doing so, prevent the systemic spread of granule contents.  The generation of 
an early robust neutrophil response may be necessary for the transition to the timely 
resolution of inflammation.  Patients with chronic granulomatous disease, an inherited defect 
of the neutrophil respiratory burst, have foci of sterile inflammation and a predisposition to 
soft tissue abscesses.  This observation is supported by mouse models that show 
unrestrained ɣ∆ lymphocyte activity, enhanced IL-17 production and defective regulatory T-
cell production, plus and a predisposition to autoimmune disease (Romani et al., 2008). 
Within animal models neutrophil function has been dynamically manipulated through the 
timed depletion of the circulating pool with cytotoxic vinblastine or anti–GR1 antibodies.  
Within a model of ischaemia-reperfusion injury, pre-insult vinblastine increased the systemic 
translocation of gut bacteria, while post-insult depletion reduced distant organ injury 
(Deitch et al., 1990; Hoesel et al., 2005).  Delayed neutrophil depletion may confer 
protection by reducing delayed injury to distant organs such as the lung and liver (Poggetti 
et al., 1992; Raghavendran et al., 2005).  Within murine models of pancreatitis (Chen et al., 
2015) and hepatitis (Liu et al., 2006), GR-1 antibody-mediated neutrophil depletion 
consistently reduces local tissue injury and systemic markers of inflammation.  Similarly, 
pharmacological inhibition of neutrophil activation confers protection within murine models 
of endotoxic shock (Lowell and Berton, 1998; Nathens et al., 1997). 
Definitive conclusions regarding the role of neutrophils in human sepsis have been 
frustrated by variability in experimental results.  Bronchoalveolar lavage samples from 
patients with established lung injury reveal a correlation between alveolar neutrophil 
numbers and clinical outcome (Chollet-Martin et al., 1996; Miller et al., 1992; Steinberg et 
al., 1994), and similarly the presence of neutrophil precursors on admission to critical care is 
associated with both the presence of sepsis and worse clinical outcomes (Mare et al., 2015).  
Tests of actual neutrophil function, such as the neutrophil respiratory burst may be  
increased (Bass et al., 1986; Martins et al., 2003) or decreased (Wenisch and Graninger, 
1995) in septic patients.  Furthermore, the functional significance of the widespread 
reprogramming of the circulating leukocyte transcriptome, which includes metabolic as well 
as classical immune genes, remains unknown.  Therefore, the surgical model of inflammation 
provides an opportunity to readdress these studies, using precisely timed clinical samples to 
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investigate the proposed dynamic interaction between neutrophil function in relation to an 
index inflammatory insult.  
 
 
1.4 The metabolic nature of sepsis   
The sepsis literature describes a hypometabolic and oxidative stress phenotype, present 
throughout bodily organs and circulating cells.  Septic patient tissues demonstrate 
diminished ATP production with preserved dissolved oxygen tensions, (Carré and Singer, 
2008; Fink, 2001; Padfield et al., 2005; Svistunenko et al., 2006), implying impaired 
cellular/mitochondrial utilisation of oxygen - a state termed cytopathic dysoxia.  Patients 
with severe sepsis consume less oxygen than those with uncomplicated sepsis (Kreymann et 
al., 1993).  Ex vivo interrogation of septic mitochondria has identified a broad range of 
functional changes across the full range of established mitochondrial activities. 
The hypometabolic septic phenotype is supported by clinical trial data from studies of goal 
directed therapy, where the manipulation of oxygen delivery to peripheral tissues in sepsis 
does not appear to improve clinical outcome, suggesting that dysoxia is an important cellular 
feature of sepsis/tissue injury (Gattinoni et al., 1995; Hayes et al., 1993; Mouncey et al., 
2015; Peake et al., 2014; Yealy et al., 2014) 
The interpretation of these sepsis metabolic studies is limited by the absence of reliable 
control data.  Like immune function, age, comorbid disease and therapeutic interventions 
may all alter metabolic function.  Off target mitochondrial effects have been demonstrated 
with volatile anaesthetic agents (Cohen, 1973; Eckenhoff and Johansson, 1997; Hanley et al., 
2002; Mazzanti et al., 1979), lignocaine (Werdehausen et al., 2007), antibiotics (Gootz et al., 
1990; Pochini et al., 2008) and propofol (Marian et al., 1997; Schenkman and Yan, 2000; 
Stevanato et al., 2002).  Anaesthetic agents also inhibit central nervous system glycolytic 
enzymes (Webb and Elliott, 1951).  The surgical model of inflammation may therefore 
support the investigation of these (likely) dynamic metabolic changes by providing accurately 
timed patient samples. 
How the hypometabolic phenotype affects circulating immune cells is less clear.  Within 
lymphocytes a hypometabolic phenotype has been previously shown to be associated with 
both diminished circulating numbers and multiple deficiencies of lymphocyte function, such 
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as cellular proliferation, cytokine production and a tendency to apoptosis (Edwards et al., 
2015).  This phenotype was associated with excess postoperative morbidity. 
A hypometabolic phenotype would be directly relevant to neutrophils.  Activated 
neutrophils are critically dependent upon glycolysis and the hexose monophosphate shunt 
to provide bioenergetic adenine triphosphate (ATP) (chemotaxis/phagocytosis) and 
nicotinamide adenine dinucleotide phosphate (NADPH) (the respiratory burst).  ATP is also 
required for gene regulation and protein synthesis within activated neutrophils (Kobayashi 
et al., 2003; McDonald et al., 1997).  
Transcriptional and metabolic profiling of peripheral blood mononuclear cells has identified a 
shift from oxidative phosphorylation to aerobic glycolysis following addition of 
lipopolysaccharide (LPS) and C.albicans (Cheng et al., 2016) i.e. the same metabolic 
phenotype observed in cancer cells, termed the Warburg effect. 
1.4.1 Mitochondria and sepsis 
Mitochondrial dysfunction underlies the hypometabolism and oxidative stress of sepsis, as 
well as the increasing likelihood of cellular apoptosis.  Mitochondria produce ATP through 
oxidative phosphorylation, where electrons are transferred from high energy substrates 
across four respiratory complexes to the terminal acceptor oxygen (Fig 1.2). The passage of 
electrons liberates protons that are pumped across the inner mitochondrial membranes, 
thereby creating a mitochondrial membrane potential (MMP).  These protons pass back into 
the mitochondrial matrix through F1F0 ATP synthase, synthesising ATP from ADP.   
Beyond production of bioenergetic ATP, the MMP also supports the transfer of other ions 
(such as calcium) and compounds into and out of mitochondria.  The MMP is necessary for 
osmotic regulation and therefore mitochondrial viability, which in turn activates cellular 
apoptosis.  Control of oxidative phosphorylation is mediated through substrate level 
allosteric control – i.e. ATP/Pi, NAD:NADH and O2 - but remains incompletely understood 
(Balaban et al., 2005; Brown, 1992; Hüttemann et al., 2008).  
Within the inner membrane individual respiratory complexes are grouped into larger super 
complexes which facilitate efficient electron transfer.  Despite this, between 0.1% and 5% of 
electrons escape and react with local oxygen to form reactive oxygen species (ROS) 
(Boveris et al., 1972; Fridovich, 2004).  Mitochondrial ROS are principally generated as 
superoxide during oxidative phosphorylation, mostly  at respiratory complex III (Vincent et 
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al., 2004), but also from complex I (Lambert and Brand, 2004; Lenaz et al., 2006) and II 
(Dikalov, 2011). 
Several processes have been identified which regulate and maintain the MMP.  Obstructions 
to electron flow, including hypoxia and pharmacological inhibition of complexes, will 
increase ROS production and dissipate the membrane potential (Madesh and Hajnóczky, 
2001; Zoratti and Szabb, 1995).  This process may be actively regulated by promotion of 
reverse electron flow through the respiratory complexes (Lambert and Brand, 2004) and 
mitochondrial ATP levels (Costa and Garlid, 2008; Queliconi et al., 2011).  Similarly, if 
mitochondrial respiration is compromised the F1F0 ATP-synthase may maintain the MMP 
through ATP consumption and reverse transport of hydrogen ions (Campanella et al., 2008).   
Figure 1.2 Mitochondrial Oxidative Phosphorylation.                                           
The red line represents the route of electron flow.  Blue shaded area depicts the intermembrane space. 
 
Dysfunction of mitochondrial respiratory complexes has been demonstrated within muscle 
samples from septic patients (Brealey et al., 2002).  This dysfunction may be reversibly 
regulated by small molecular mediators such as ROS, nitric oxide (NO) and carbon 
monoxide (CO) (Brunori et al., 1999). 
Specific pharmacological inhibitors of respiratory complexes are commercially available, and 
maybe used as to create laboratory models of mitochondrial dysfunction.  These inhibitors 
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demonstrate dose dependency, with lower doses causing hyperpolarisation and ROS 
production and higher doses leading to lipid peroxidation and super complex disaggregation 
(Lenaz et al., 2006).  Hyperpolarisation of the MMP may lead to ROS production at 
complexes proximal to the inhibited complex (Chen et al., 2003).  The addition of the 
respiratory complex I inhibitor metformin to human peripheral blood mononuclear cells 
leads to decreased cytokine production in presence of C.albicans, and decreased survival 
within a murine model of bacterial sepsis (Cheng et al., 2016). 
The principal mitochondrial ROS product is O2
-, which is charged and may only leave the 
mitochondrion following dismutation to lipid permeable H2O2 by mitochondrial manganese 
superoxide dismutase (MnSOD/SOD2).  As well as affecting mitochondrial energy 
production, mitochondrial ROS may also affect cellular redox balance (Ballinger, 2005). 
In addition to ROS production, the proton gradient across the inner mitochondrial 
membrane may be dissipated through membrane uncoupling proteins, which permit the 
facilitated transport of hydrogen ions along concentration gradients and essentially 
‘uncouple’ proton movement from ATP production (Boss et al., 1998; Clapham et al., 2000).  
They may provide an alternative route to dissipating the proton gradient and limiting 
hyperpolarisation mediated ROS production (Brownlee, 2001; Kim-Han et al., 2001).   
Within neutrophils, mitochondria have an established role in the regulation of neutrophil 
lifespan through a process termed constitutive apoptosis.  The presence of neutrophil 
mitochondrial dysfunction may therefore plausibly alter their immune functionality.   
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1.5 Reactive oxygen species – a cellular signal   
Reactive oxygen species (ROS) produced during these metabolic reactions may activate 
several cellular signalling processes.  ROS reversibly oxidize specific amino acid residues 
(Dröge, 2002; Janssen-Heininger et al., 2008; Jones, 2008) at concentrations which occur 
during physiological metabolism, for example cysteine group oxidation by H2O2 (McDonagh 
et al., 2009).  Any protein/enzyme system with exposed cysteine residues at the receptor or 
allosteric site may be subject to oxidative regulation; sequential reducing/non-reducing SDS 
PAGE western blotting has identified many cellular proteins that are sensitive to disulphide 
oxidation (Cumming et al., 2004).     
The specific nature of these molecular interactions means ROS species should be 
considered individually, since their affinities for different targets will vary at these low doses.  
This molecular specificity – rather than ligand/receptor specificity of classical signalling 
pathways – may permit ROS to simultaneously alter multiple signalling pathways, 
transmitting a signal both widely and quickly.   
The amplitude of ROS signals depends upon the rate of ROS detoxification as well as ROS 
production.  These detoxification pathways are cellular compartment and species specific.  
The dismutation of O2
- is catalysed by copper and zinc superoxide dismutase in the 
cytoplasm (McCord and Fridovich, 1969), and by manganese superoxide dismutase in 
mitochondria (Fosslien, 2003; Lebovitz et al., 1996).  H2O2 is catalysed by catalase (Klichko 
et al., 2004), peroxiredoxins (Rhee et al., 2005) and glutathione peroxidase (Hellmich et al., 
2005).  Within an in-vitro endothelial model of sepsis, the peroxiredoxin/thioredoxin 
pathway appears more important than mitochondrial GSH for preventing mitochondrial 
dysfunction (Lowes and Galley, 2011).  The glutathione pathway requires NADPH, and is 
essential for cellular ROS regulation (Pandolfi et al., 1995). NADPH synthesis is upregulated 
during oxidative stress, possibly through NADPH:NAD mediated control of glucose-6-
phosphate dehydrogenase (G6PDH) activity (Filosa et al., 2003). 
Figure 1.3 Redox regulation of enzyme function. 
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1.6 Neutrophil metabolism in health and sepsis 
The intense metabolic requirements of activated neutrophils suggest that changes in supply 
of ATP and NADPH may alter neutrophil immune function, life span and, ultimately, sepsis 
outcome.  The presence of such changes is supported by genomic investigations of the 
circulating leukocyte transcriptome, which describe a general increase in glycolytic gene 
expression and depression of mitochondrial gene expression.  However, the functional 
consequence of these changes remains relatively underexplored.  Many investigations have 
examined resting and ex-vivo activated neutrophil metabolism, and the genomic changes to 
metabolic genes, however few have addressed how the neutrophil metabolic profile alters 
during an inflammatory insult.    
 
1.6.1 Neutrophil glycolysis and the hexose monophosphate shunt 
Resting neutrophil ATP is principally supplied by glycolysis (Fig 1.4), and is readily 
demonstrated through use of metabolic inhibitors and radio-labelled carbon studies 
(Borregaard and Herlin, 1982; Cohn and Morse, 1959; Kakinuma, 1970; Reed and 
Tepperman, 1969; Sbarra and Karnovsky, 1959).  Fractional CO2 production is 5% in 
isolated human leukocytes (Beck, 1958), 8% in resting guinea pig leukocytes (Sbarra and 
Karnovsky, 1959) and 2% in resting DMSO differentiated HL60 cells (Ahmed et al., 1993).  
There is evidence to support reciprocal regulation between glycolysis and oxidative 
phosphorylation, with high levels of glucose reducing CO2 formation, while high levels of 
oxygen impede glycolysis (Sbarra and Karnovsky, 1959).   
Whether activated neutrophils utilise cytoplasmic ATP reserves (Borregaard and Herlin, 
1982) or increase glycolytic ATP production is unclear (Sbarra and Karnovsky, 1959). 
Similarly, depending upon experimental conditions, glycolytic glucose may be obtained from 
endogenous glycogen stores or passively transported from the extracellular space via the 
Glucose transporter 1 (GLUT1) (Tan et al., 1998).  Different sources of glucose may be 
used for different functions, for example extracellular glucose for chemotaxis and 
intracellular glycogen for phagocytosis (Weisdorf et al., 1982). 
Neutrophils possess a propensity for the hexose monophosphate shunt pathway, with low 
fructose 1,6, bis-phosphate activity and six-fold higher G6PDH activity (Beck, 1958).  
Inhibition of G6PDH reduces activated neutrophil ROS production, but does not affect 
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other functions (Bender and Van Epps, 1985).  The rate-limiting step of glycolysis is the 
conversion of phosphophenylpyruvate to pyruvate, by the enzyme pyruvate kinase 
(Minakami, 1968).  Therefore, regulation of pyruvate kinase activity could exert substrate 
level control over the neutrophil respiratory burst (Olsen et al., 2003; Petty, 2001).   
 
Figure 1.4. Neutrophil metabolism: glycolysis, the hexose monophosphate shunt 
and the respiratory burst.   
Size of arrows represents enzyme activities (Fauth et al., 1993).  Thick arrows = 400-2000 mU/mg; dashed 
arrows <100mU/mg.   G6P=glucose-6-phosphate; G6PDH=glucose-6-phosphate dehydrogenase; 
GA3P=glyceraldehyde-3-phosphate; PEP=phosphoenolpyruvate; PK=pyruvate kinase.  Adapted from Oehler 
et al 2000. 
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1.6.2 The role of neutrophil mitochondria 
Although neutrophils are reliant upon glycolytic ATP, they do contain functional 
mitochondria. The addition of fluorescent mitochondrial probes, such as JC-1, Mitotracker 
and dihydrorhodamine-123 (DHR-123), reveals a complex mitochondrial network.  These 
mitochondria can be depolarised by the uncoupling agent FCCP (Fossati et al., 2003; 
Maianski et al., 2004). 
Neutrophil mitochondria demonstrate important differences to those from cells which rely 
mainly upon mitochondria for bioenergetic ATP production.  Cytochrome c is poorly 
expressed (Maianski et al., 2004), while supracomplex organisation is absent in differentiated 
neutrophils and DMSO-differentiated HL-60 cells (van Raam et al., 2008).  This may explain 
the relatively high levels of mitochondrial O2
- (Maianski et al., 2004; Murphy et al., 2003).  
Inhibition of ATP transport into mitochondria and of glycolysis does not affect neutrophil 
mitochondrial MMP, suggesting it is maintained through de novo oxidative phosphorylation. 
Ablation of the MMP with FCCP immediately inhibits neutrophil chemotaxis, but not the 
respiratory burst (Fossati et al., 2003).  By contrast, PMA stimulation of the respiratory 
burst was inhibited following a two-hour incubation with the F1F0 ATP synthase inhibitor 
oligomycin.  Although the loss of MMP is an early feature of apoptosis, addition of FCCP and 
oligomycin were not associated with an increased rate of in vitro apoptosis (Fossati et al., 
2003).  Neutrophils isolated from patients 12 hours after major surgery demonstrate MMP 
hyperpolarisation, increased mitochondrial ROS and an increased rate of apoptosis (using 7-
AAD staining) which normalised at 24 hours (Delogu et al., 2001). 
Inhibition of neutrophil mitochondrial complex I (rotenone, metformin) and complex III 
(antimycin-A, myxothiazol) are both associated with increased cytoplasmic H2O2, reduced 
activation of NF-kB and inflammatory cytokine production – as for exogenous H2O2 – which 
is reversed by polyethylene glycol-catalase.  The systemic administration of these inhibitors 
conferred survival benefit within a murine LPS model, although no effector assays of 
neutrophil function were performed (Zmijewski et al., 2009, 2008) 
Neutrophil mitochondria have an established role in mediating neutrophil apoptosis.  Given 
the extended and interlinked roles of mitochondria within other cell types, mitochondria 
may therefore play a wider role within the regulation of neutrophil function.  For example, 
within other cells mitochondria mediate ROS signalling, O2 sensing (Brunelle et al., 2005), 
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calcium homeostasis, anion flux through the voltage-dependent anion channel (VDAC) 
family (Colombini, 2004), integrin signal transduction and the target of many drugs.  VDAC 
activity and calcium exchange are critical for ROS production, with inhibition of VDAC 
reducing mitochondrial ROS (Zhou et al., 2011).  These non-energetic processes may utilise 
respiratory complexes independently of oxidative phosphorylation, such as oxygen tension 
sensing at mitochondrial complex III (Brunelle et al., 2005).   
 
 
1.6.3 Neutrophil metabolism during sepsis 
Studies of neutrophil metabolism in septic patients have provided inconsistent results 
(Martins et al., 1999; Sheth et al., 2001; Watts et al., 2004).  This may be partly explained by 
the many confounding factors of sepsis research. By contrast, the studies from trauma 
patients and healthy volunteers given endotoxin support highly conserved changes within 
the circulating leukocyte transcriptome to inflammatory stimuli.  These extend far beyond 
those genes classically involved with immunity, such as those involved in metabolic function.   
Exposure of healthy volunteers to low dose endotoxin increases circulating leukocyte 
transcription of glycolytic genes and decreases the expression of mitochondrial genes 
encoding for proteins within respiratory complexes I-V and pyruvate dehydrogenase 
(Calvano et al., 2005; Talwar et al., 2006).  Changes in glycolytic genes are accompanied by 
increased expression of genes coding for components of the respiratory burst pathway.  
These changes are associated with a fall in leukocyte ATP, a signal for activation of AMP 
activated protein kinase (AMPK), an increase in Hypoxia inducible factor alpha (HIF-1α) and 
prolongation of autophagy (Haimovich et al., 2014).  AMPK and HIF-1 alpha have distinct, 
yet synergistic effects upon cellular metabolism.  AMPK regulates mitochondrial biogenesis 
(Jäger et al., 2007; Kim et al., 2006) and is activated by the build-up of AMP, a signal for 
diminished energetic substrate availability.  It acts in synergy with the growth signal 
integrating mammalian target of rapamycin (mTOR) (Papandreou et al., 2006; Semenza et al., 
1994; Zhang et al., 2007).  HIF-1 regulates cellular oxygen consumption by promoting 
glycolysis and inhibition of mitochondrial biogenesis and function (Papandreou et al., 2006), 
as well as by activating neutrophil immune functions (Peyssonnaux et al., 2005) .  
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Rather than a secondary phenomenon, these metabolic changes may even precede the 
classical immunological changes of inflammation.   Healthy volunteers exposed to low doses 
of endotoxin demonstrate an altered metabolic transcriptome in the absence of measurable 
increases in systemic cytokine expression (Haimovich et al., 2014).  Collectively these 
alternative models of human sepsis describe how inflammation, immunity and metabolism 
are intrinsically linked aspects of the cellular response to damage, and that the metabolic 
changes within circulating leukocytes may parallel those within solid organs/tissues during 
established critical illness.    
The genomic evidence for upregulation of glycolytic activity is supported by a study of 
trauma patient neutrophil metabolic function (Oehler et al., 2000).  The authors 
demonstrated an increase in pyruvate kinase expression – a rate-limiting step in resting 
neutrophil metabolism - associated with a 600-fold increase in enzyme activity on post injury 
days 5-7 post injury which was supported by increased glucose utilisation.  Neutrophils 
isolated at 48 hours and incubated in presence of glucose had twice the respiratory burst 
capacity.  This was abolished by addition of the G6PDH inhibitor dehydroepiandrosterone 
(DHEA) (Oehler et al., 2000).  No other studies have addressed the impact of metabolic 
changes upon neutrophil immune functionality.  
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1.7 Neutrophil immune function 
Neutrophil activation leads to the coordinated upregulation of several cellular immune 
processes, including phagocytic ingestion of bacteria, rapid production of ROS through the 
respiratory burst and the mobilisation of granule contents.  These processes rely upon 
cellular remodelling, which, in turn, depends upon bioenergetic ATP.  Tests of these effector 
processes are not routinely available in clinical practice, instead neutrophil function is 
commonly equated to circulating neutrophil numbers (Melvan et al., 2010). 
 
1.7.1 Neutrophil surface receptors 
 
1.7.1.1 Adhesion receptors 
 
CD62L (L-selectin), and the CD11/CD18 family of integrins are the principal receptors 
responsible for neutrophil adhesion to endothelium, and the initiation of transmigration. 
CD62L is a single chain transmembrane glycoprotein responsible for low-affinity 
carbohydrate interactions (McEver and Zhu, 2010). Following receptor cleavage, signalling 
occurs via the retained membrane fragment through protein kinase C (PKC) and p38 MAPK 
(Smolen et al., 2000).  
Integrins are heterodimeric transmembrane glycoproteins.  Of the four CD11 subtypes, 
CD11b/CD18 (MAC-I complement receptor) has the broadest functional role, mediating 
adhesion to endothelium (Smith et al., 1989) plus fibrinogen (Pluskota et al., 2004), Fc 
receptor mediated cytotoxicity (Van Spriel et al., 2001) and initiating a cascade of 
intracellular signalling processes (Plow et al., 2000; Schymeinsky et al., 2007; Walzog et al., 
1995), including activation of the Src-family kinases.  CD11b/CD18 signalling is ligand 
dependent.  While ICAM-1, fibrinogen and myeloperoxidase may suppress apoptosis 
through CD11b/CD18, MAC-1 mediated phagocytosis hastens apoptosis (El Kebir and Filep, 
2013).   
Congenital deficiency of CD18 causes leukocyte adhesion deficiency syndrome, where 
patients have grossly reduced tissue neutrophil numbers (Anderson et al., 1985), which may 
be recreated by the addition of blocking antibodies to cells from healthy volunteers.  Within 
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experimental models blockade of CD11/18 abolishes tissue plasma leakage and oedema 
(Lindbom, 2003; Wedmore and Williams, 1981). CD11b/CD18 has been identified as the 
target for the pro-resolving mediators lipoxin A4 and E1(El Kebir and Filep, 2013).   
Dynamic changes in neutrophil cell surface CD11b and CD62L are well characterised.  Both 
cytokine and PMA stimulation leads to a rapid (20 minutes) cleavage or “shedding” of L-
selectin (Killock and Ivetić, 2010), with associated rise in soluble L-selectin (McGill et al., 
1996; Smalley and Ley) and a more delayed increase in cell surface CD11b. 
Following trauma the magnitude of CD11b rise and CD62 fall is correlated with the Injury 
Severity Score and the likelihood of postoperative complications (Rinder, 2006; Seekamp et 
al., 2001).  These changes may persist for up to one week, although some authors have 
demonstrated a decrease (Chishti et al., 2004; McGill et al., 1996).  Following vascular 
(Foulds et al., 2001) and orthopaedic surgery (Hughes et al., 2010) CD11b increase and 
CD62 decrease may persist for up to 3 days. 
1.7.1.2 G protein coupled receptors  
CXC chemokine receptor 2 (CXCR2) is a G-protein coupled IL-8 (CXCL8) receptor 
(Stadtmann and Zarbock, 2012) and has a demonstrable role within many inflammatory 
conditions.  It is the most functionally diverse of all the neutrophil chemokine receptors 
(Chapman et al., 2009; Kurdowska et al., 2001).  Activation of the receptor triggers 
dissociation into Gα and Gβɣ subunits which regulate adenylyl cyclase and phospholipase 
Cβ (PLCβ) plus phosphatidylinositol-3-kinases respectively (PI3K) (Stadtmann and Zarbock, 
2012). PLCβ is believed to initiate a biphasic change in intracellular Ca2+, and PI3K leads to 
PIP3 and PKB/Akt activation (Futosi et al., 2013). These messengers then target membranous 
integrins (Stadtmann and Zarbock, 2012), Extracellular signal-regulated kinase (ERK) plus 
p38 MAP kinases (Mócsai et al., 2000), and the Src family of tyrosine kinases.   
Within experimental models blockade of CXCR2 substantially reduces leukocyte 
recruitment, tissue damage and mortality (Stadtmann and Zarbock, 2012), possibly through 
reduction in CXCL-1 mediated CXCR2 signalling, following the release of IL-1α from 
necrotic cells (Chen and Nuñez, 2010).  In established sepsis neutrophil cell surface CXCR2 
expression is reduced by 50% (Cummings et al., 1999), and these cells displayed diminished 
responses to established CXCR2 ligands.  Following blunt chest trauma CXCR2 is reduced 
at 24hrs (Visser et al., 2011) 
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1.7.1.3 Pattern recognition receptors (PRR) 
The majority of PRR characterisation has been performed in cell types other than 
neutrophils and there is evidence for cell specific aspects of apparently identical receptors 
(Sabroe et al., 2002).  Neutrophil TLR stimulation activates neutrophils, causing 
cytokine/chemokine production and delayed apoptosis (Hayashi et al., 2003).  Neutrophil 
TLR4 is downregulated following cardiopulmonary bypass, and returns to baseline at 24hrs 
(Hadley et al., 2007) and may be upregulated in sepsis (Härter et al., 2004).  
Lipopolysaccharide detection by TLR is dependent upon the CD14 co-receptor (Chow et 
al., 1999; Qureshi et al., 1999), which in turn requires plasma lipopolysaccharide binding 
protein for efficient binding (Wright et al., 1991).  CD14 may also enhance TLR2 signals.  In 
vitro addition of cytokines causes a two-fold increase in neutrophil cell surface CD14 over 
twenty minutes (Wright et al., 1991).  Following cardiopulmonary bypass neutrophil CD14 
transiently increases, before returning to baseline values at 24 hours (Kawasaki et al., 2001).  
While the down-regulation of monocyte CD14 is well established, the relevance in 
neutrophils has not been determined (Hadley et al., 2007). 
The triggering receptor expressed on myeloid cells (TREM-1) is expressed on blood 
neutrophils, and through the adapter protein DAP12, serves to amplify TLR signalling 
pathways, with both TREM-1 and TLR4 being recruited to the same lipid rafts (Baruah et al., 
2015; El Mezayen et al., 2007).  Lipid rafts are dynamic, nanoscale, organised areas of cell 
membrane focussed around sphingolipids and cholesterol (Simons and Gerl, 2010). Signalling 
receptors may be concentrated within lipid rafts, which facilitates inter-receptor 
interactions. 
Surface TREM-1 activation promotes neutrophil degranulation, the release of IL-8 plus TNF-
α and activation of the phagocytosis/respiratory burst processes (Baruah et al., 2015; 
Bouchon et al., 2000).  Conversely, soluble TREM-1 is released from neutrophil granules and 
appears to have counterregulatory properties (Baruah et al., 2015).   Soluble TREM-1 is 
increased following LPS exposure in humans, however neutrophil surface TREM1 may be 
either increased or remain unchanged (Bouchon et al., 2000; Mahdy et al., 2006).  Within 
septic patients samples both soluble and neutrophil surface TREM-1are raised (Gibot et al., 
2005). TREM-1 blockade is protective within murine models of lipopolysaccharide 
administration and abdominal sepsis (Bouchon et al., 2001).   
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1.7.1.4 Fcɣ receptors.  
These are responsible for phagocytosis of immunoglobulin-G opsonised pathogens and 
immune complexes.  They belong to the immunoglobulin superfamily, and are sub-classified 
by ligand affinity.  The low affinity receptors, which include CD16 (FcɣRIII) and CD32 
(FcɣRII) are most important to neutrophil phagocytosis.  Young neutrophils, with banded 
nuclei, express lower levels of cell surface CD16, termed CD16dim, when compared to 
mature counterparts (Brown et al., 1989).   Some authors have suggested CD16dim is a 
reliable marker of neutrophil immaturity, and recent bone marrow release (Orr et al., 
2005). Following healthy volunteer endotoxin exposure, the circulating CD16dim population 
is increased, and these cells demonstrate impaired functionality when compared to pre-
endotoxin control cells.  Blood neutrophil CD16 cell surface receptor density is reduced 
following major trauma and maybe reduced (Fung et al., 2008; Holzer et al., 2010) or 
unchanged after major elective surgery (Wakefield et al., 1995).  Preoperative and 
postoperative CD16 levels are higher in patients who develop postoperative sepsis than 
those who do not (Wakefield et al., 1995).  Neutrophil apoptosis is accompanied by a 90% 
down-regulation of cell surface CD16, with no other cell surface markers showing such 
dramatic change (Dransfield et al., 1994). 
 
1.7.1.5 Cytokine receptors   
Cytokine receptors are grouped according to structure and ligand specificity into Type I, 
Type II, IL-1 and TNF families (Futosi et al., 2013).  Type I and II receptors activate the 
constitutively associated JAK-STAT pathway (Ghoreschi et al., 2009) plus the Src-family, PI3-
kinase-Akt and ERK/p38 MAP kinase.  The activation of ERK promotes neutrophil survival in 
response to oxidative challenges (Midwinter et al., 2001).  Phosphorylated STAT shuttles to 
the nucleus and regulates gene transcription. The IL-1 receptor family detect the early pro-
inflammatory mediators IL-1 and IL-18.  Within neutrophils IL-1 in neutrophils principally 
extends life span (Colotta et al., 1993). IL-18 has wider range of effects, including autocrine 
neutrophil activation (Fortin et al., 2009).   TNF-α is a major cytokine triggering neutrophil 
activation (Nathan, 1987) through Janus kinase (JNK) and NF-kB activation (MacEwan, 
2002).  The TNF family includes the Fas receptors, which receive extracellular pro-
apoptotic signalling through Fas-ligand. 
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1.7.2 Phagocytosis 
Following engagement of Fc and complement receptors the plasma membrane extends 
around particulate matter, creating a phagocytic vacuole that then fuses with cellular 
granules.  Phagocytosis requires extensive cytoskeletal rearrangement, activates the  
respiratory burst and ultimately commits the neutrophil to apoptosis (Rotstein et al., 2000; 
Watson et al., 1996).  Neutrophils from a NADPH oxidase murine knockout (PHOX-/-) 
demonstrate impaired salmonella phagocytosis (Huang et al., 2009).   
Neutrophils may engulf IgG coated latex beads within 20 seconds (Segal et al., 1980), and 
phagocytose up to 50 individual bacteria in total.  Circulating neutrophil phagocytosis is 
impaired following major abdominal surgery (Kawasaki et al., 2007) and lung resection 
surgery (Jones et al., 2014), but much more so in patients with established sepsis (Jones et 
al., 2014).  Within critically ill patients diminished neutrophil phagocytosis is an independent 
risk factor for the acquisition of nosocomial infection (Morris et al., 2011).   
 
1.7.3 Respiratory burst 
The respiratory burst describes production of O2
- by cell membrane and vesicle-bound 
NADPH oxidase (PHOX, or NOX2) (Fig 1.5).  It is so called because of the rapid 
consumption of oxygen by activated neutrophils.  p47phox translocation from cytoplasm to 
membrane causes a 100-fold increase in oxygen consumption (Guzik and Griendling, 2009).  
These intense metabolic demands suggest that the respiratory burst maybe substrate limited 
(Kindzelskii and Petty, 2002; Petty, 2001).  Within macrophages, hexokinase localises with 
PHOX during the respiratory burst (Pedley et al., 1993).  Genomic data from healthy 
volunteers exposed to LPS (Calvano et al., 2005) and proteomic analysis of trauma patients 
(Oehler et al., 2000) have identified an increase in the expression and activity of neutrophil 
glycolytic enzymes during human inflammatory responses. 
Neutrophil ROS support more complex immunological processes than just the direct 
oxidation of pathogenic organisms. The potential difference across the vacuole membrane 
created by movement of O2
- is compensated by movement of intracellular ions which create 
the osmotic and electrochemical conditions that favour activation of many enzymes and 
proteins contained within neutrophil granules (Segal, 2005), and formation of neutrophil 
extracellular traps (NETs) (Fuchs et al., 2007).    
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NETs are extracellular DNA structures released from viable neutrophils that serve to 
concentrate and localise neutrophil killing power.  By localising and degrading cytokines 
NETs may also serve to limit inflammation (Schauer et al., 2014).  The respiratory burst may 
therefore be considered a ‘master switch’ of neutrophil killing.  Genomic investigations from 
healthy volunteer endotoxin studies support an early increase in burst machinery expression 
(Calvano et al., 2005). 
The signal transduction pathways leading to PHOX activation is stimulus dependent. For 
example p38 MAPK is essential for TNF-α induced activation and for approximately 70% of 
the fMLP response, but is unnecessary following activation by complement–opsonised 
zymosan (Brown et al., 2004). Specific agents may therefore be used to investigate changes 
in O2
- production, such as the protein kinase c activator phorbol myristate acetate (PMA) 
which maximally stimulates the sub-membrane burst machinery (Tyagi et al., 1988) by 
directly phosphorylating p47phox (Wyche et al., 2004) in the presence of Ca2+ (El Jamali et al., 
2010). H2O2 stimulation of PHOX is likely upstream of PKC, acting through Ca
2+ influx and 
c-Abl tyrosine kinase signalling (El Jamali et al., 2010).  Initiation of NADPH oxidase activity 
has a lag phase of approximately 20 seconds (Briggs et al., 1986; Segal et al., 1980) 
Excessive neutrophil ROS is associated with organ dysfunction [(Brown et al., 2006; Chabot 
et al., 1998; Crimi et al., 2006; Kolls, 2006; Strassheim et al., 2002).  Paradoxically, studies of 
patients with chronic granulomatous disease - who possess functional mutations in PHOX 
subunits - and associated animal models have identified important anti-inflammatory roles 
for neutrophil ROS.  As well as being predisposed to infection, chronic granulomatous 
disease patients also demonstrate sterile inflammatory lesions (Morgenstern et al., 1997) 
and an increased incidence of inflammatory bowel disease, granulomatous genitourinary 
obstruction and wound dehiscence (Almyroudis et al., 2013).   Neutrophils isolated from 
these patients reveal enhanced secretion of IL-8 (Hatanaka et al., 2004), prolonged survival 
(Kasahara et al., 1997) and reduced uptake by macrophages (Hampton et al., 2002).   
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Figure 1.5 The neutrophil respiratory burst. 
Adapted from (Segal, 2005) PHOX is activated by phosphorylation and translocation of cytoplasmic subunits 
p47phox, p67phox, p40phox and p21rac to membranous electron transporting flavocytochrome b558 (gp91phox 
heterodimer and p22phox) (Lambeth, 2004), as well as PKC and hexokinase (Nixon and McPhail, 1999).  
Hexomonophosphate shunt derived NADPH provides electrons that pass through flavocytochrome b558 to 
combine with vacuolar oxygen, generating O2- (Cross 2004). A proton pump completes the circuit 
(Henderson and Chappell, 1992; Henderson and Meech, 1999).   
 
Murine models of chronic granulomatous disease consistently demonstrate sustained and 
exaggerated lung inflammation (Davidson et al., 2013; Deng et al., 2012; Schauer et al., 2014; 
Segal, 2007; Segal et al., 2010), and predisposition to autoimmune arthritis that may be 
prevented through reactivation of PHOX (Hultqvist et al., 2004).  These observations may 
be explained by the associated impairment of phagocytosis and NET formation (Darrah and 
Andrade, 2012). These roles appear to require neutrophil activation, since baseline energy 
metabolism and glycolytic rate are unaffected in chronic granulomatous disease neutrophils 
(Borregaard and Herlin, 1982). 
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PHOX is now appreciated to be part of a wider NOX family.  The unifying feature of NOX 
function is the transfer of electrons from NADPH to oxygen.  NOX isoforms are expressed 
out-with professional phagocytes, have distinct subcellular location, regulatory factors and 
synthesise distinct ROS species, and have established roles in signalling and ion homeostasis 
(Lambeth, 2004; Steinberg and Grinstein, 2007).   These observations suggest that PHOX 
may also possess an extended signalling role, through production of cellular ROS. 
 
1.8 Neutrophil activation, effector function and life span. 
Neutrophil life span is intrinsically linked to functional activity.  In the absence of pro-
inflammatory signals, unstimulated neutrophils readily enter constitutive apoptosis (Savill et 
al., 2002)], with an estimated life span of less than 1 day.  Similarly, successful phagocytosis  
also signals apoptosis (Gilroy et al., 2004; Nathan and Ding, 2010; Savill et al., 2002).  
Between these two extremes of stimulation, ‘activated’ neutrophils may display increased 
longevity.  Functional heterogeneity may exist within the wider circulating and sequestered 
neutrophil pool, as identified by variation within the circulatory and tissue pools of cell 
surface receptor expression, effector activities and life span. 
Neutrophil lifespan is estimated to be 8-20 hours (Maianski et al. 2004; Luo & Loison 2008; 
Pillay et al. 2010).  Without a survival signal neutrophils enter an automatic, or constitutive, 
death process that leads to reticuloendothelial (Savill et al., 2002, 1989) and tissue 
macrophage mediated removal.  This short life span means changes in survival/death 
patterns will rapidly alter blood and tissue numbers.  While prolonged neutrophil longevity 
may assist with pathogen removal (Nathan, 2006; Savill et al., 2002; Watson et al., 1997), 
inappropriate prolongation or failure to isolate dying neutrophils may perpetuate local tissue 
damage and prevent effective resolution of inflammation (Nathan, 2006; Nathan and Ding, 
2010; Serhan and Petasis, 2011). 
Established survival signals include many of the classical pro-inflammatory mediators 
governing activation and tissue migration, which act through a range of cell surface and 
cytoplasmic receptors.  In vitro culture of neutrophils from healthy volunteers leads to rapid 
death (Akgul et al., 2001; Moulding et al., 2001).  However the addition of inflammatory 
mediators or serum from septic/trauma patients may increase survival to 24-36 hours (Ertel 
et al., 1998; Haslett, 1992; Lee et al., 1993). These observations make in vitro neutrophil 
51 
 
investigations challenging, and the comparison of data from different laboratories difficult 
(Luo and Loison, 2008) with 6 hour apoptosis rates varying between 10% and 75% 
(Blomgran et al., 2007; Cowburn et al., 2005).  
Most clinical studies from patients with active inflammation have identified prolonged 
neutrophil survival when compared to healthy volunteers.  This includes sepsis (Ertel et al., 
1998; Jimenez et al., 1997; Keel et al., 1997; Taneja et al., 2004), non-infective SIRS (Melley 
et al., 2005), burns (Chitnis et al., 1996) and Acute respiratory distress syndrome (ARDS) 
(Matute-Bello et al., 1997), as well as chronic inflammatory diseases such as Chronic 
obstructive pulmonary disease (Brown et al., 2009) and coronary artery disease (Garlichs et 
al., 2004).   
In ARDS, worsening disease severity is associated with increased neutrophil survival 
(Feterowski et al., 2001; Matute-Bello et al., 1997).  Data from trauma patients suggest 
apoptosis may be suppressed for up to three weeks (Ogura et al., 1999).  Results from 
elective surgery are less clear, with apoptosis shown to be increased at 12 hours (Delogu et 
al., 2001) and decreased at 24 hours (Fanning et al., 1999).   
Despite this inflammation driven prolongation of neutrophil lifespan, the very process of 
phagocytosis initiates apoptosis.  Other morphological patterns of death include NETosis 
(Brinkmann et al., 2004; Fuchs et al., 2007), necrosis (Simon, 2003; von Gunten and Simon, 
2006) and autophagy (Remijsen et al., 2011). 
Neutrophil apoptosis promotes several processes that facilitate the timely resolution of 
inflammation.   Apoptotic neutrophils become unresponsive to agonists, stop producing 
inflammatory mediators (Kobayashi et al., 2003) and may act as cytokine sinks where cell 
surface receptors persist in the absence of functional transduction machinery (Ariel et al., 
2006).   Macrophages which ingest apoptotic neutrophils switch from a pro-inflammatory to 
a pro-resolution phenotype (Fadok et al., 1998), releasing FasL which may further promote 
neutrophil apoptosis (Brown and Savill, 1999).  Within a mouse model of endotoxic shock 
the infusion of apoptotic neutrophils improved survival, while infusion of necrotic 
neutrophils increased mortality (Ren et al., 2008). 
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Both intrinsic apoptosis (mitochondrial mediated, caspase-9 dependent) and extrinsic 
apoptosis (TNF, Fas-L dependent activation of caspase-8) occur within neutrophils.  
Constitutive neutrophil death represents a specialised form of intrinsic apoptosis.  There is 
significant overlap between these two apoptotic modes within neutrophils; addition of 
Fas/Fas-L antagonists partially inhibited constitutive neutrophil death, while preservation of 
mitochondrial membrane potential inhibited Fas-L mediated death (Brown and Savill, 1999; 
Liles et al., 1996; Renshaw et al., 2000).  
 
1.8.1 Constitutive neutrophil death  
The morphological appearance of constitutive neutrophil death resembles classical intrinsic 
apoptosis in other cell types, with exteriorization of phosphatidylserine, formation of 
cytoplasmic vacuoles, and nuclear condensation (Payne et al., 1994; Savill et al., 1989).  
While caspase inhibition is widely reported to inhibit neutrophil apoptosis, it is unclear if 
caspase activation is absolutely necessary for constitutive death (Luo and Loison, 2008). 
Neutrophil mitochondria appear essential for constitutive death.  In other cell types 
localisation of the pro-apoptotic Bcl-2 homologs Bid and Bax to the outer mitochondrial 
membrane permits release of cytochrome-c through the mitochondrial permeability 
transition pore, leading to activation of caspase 9.  However neutrophils express very low 
levels of cytochrome c (Liu et al., 2003; Maianski et al., 2004; Murphy et al., 2003; Pryde et 
al., 2000), and may compensate instead through the release of Apaf-1.  Wide variations in 
neutrophil Bcl-2 expression has been reported (Moulding et al., 2001).  The principal 
neutrophil anti-apoptotic Bcl-2 homolog, Mcl-1, has a very short half-life, and is regulated at 
transcriptional and translational levels by NF-kB and PI3K (Brenner and Mak, 2009; Edwards 
et al., 2004; Reed, 2006).  Mcl-1 may therefore provide a common explanation to early 
constitutive death, and its inhibition during inflammation. 
Neutrophil ROS contribute to apoptosis regulation.  Neutrophils from patients with chronic 
granulomatous disease (Kasahara et al., 1997; Yamamoto et al., 2002), and those from 
healthy volunteers exposed to PHOX inhibitors (Coxon et al., 1996; Lundqvist-Gustafsson 
and Bengtsson, 1999; Perskvist et al., 2002) and ROS scavengers (Kasahara et al., 1997) 
demonstrate reduced rates of apoptosis in vitro.  PHOX-independent ROS production may 
also occur (Fay et al., 2006) through hyperpolarisation of neutrophil mitochondria (Vincent 
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et al., 2004).  While intracellular non-phagosomal ROS trigger apoptosis, post-phagocytosis 
intraphagosomal ROS does not (Blomgran et al., 2007, 2004).  Possible ROS-dependent 
apoptotic targets include DNA damage/p54 (X. Zhang et al., 2003), MAPK/NF-kB 
(Fortenberry et al., 2001) and Fas-L independent Fas receptor clustering in lipid rafts.   
 
1.8.2 Survival signals and activation induced death 
Neutrophil functionality and survival are intrinsically linked, because most activation signals 
prolong lifespan.  Pro-survival signals include CD11b/CD18 (Ross et al., 2006), Granulocyte 
macrophage colony stimulating factor (GM-CSF) (Lee et al., 1993), Interferon gamma (IFN-
ɣ), leukotriene B4 ( a C. Lee et al., 1999), C5a (Lee et al., 1993), CRP (Khreiss et al., 2002), 
serum amyloid (El Kebir and Filep, 2013), LPS (Colotta et al., 1992) and bacterial DNA 
(József et al., 2004).  Many of these signals are situation dependent.  For example, while 
integrin-mediated adhesion prolongs neutrophil lifespan, so does the addition of 
CD11b/CD18 blocking antibodies to extravasated neutrophils (Coxon et al., 1996).   
Intracellular signalling pathways overlap but show considerable ligand specificity, including 
PKB/Akt, p38 MAP-kinase, and NF-kB (Francois et al., 2005).  Caspase-1 dependent cleavage 
of IL-1β may act as both a pro and anti-apoptotic signal in neutrophils (William et al., 1999). 
In contrast to the effects of pro-survival signals inhibiting apoptosis, phagocytosis of a range 
of microorganisms is a powerful apoptotic signal (Perskvist et al., 2002; Rotstein et al., 2000; 
Watson et al., 1996).  Phagocytosis driven apoptosis is prevented by antagonism of 
CD11b/CD18 (Coxon et al., 1996), and proceeds through PHOX and caspase-8 dependent 
pathways (Yamamoto et al., 2002; B. Zhang et al., 2003), possibly dependent upon ROS 
mediated lysosomal membrane permeabilisation (Blomgran et al., 2007). 
Neutrophil apoptosis research has predominantly focussed upon the fate of blood-derived 
cells.  It is less clear how tissue neutrophil survival is regulated.  Tissue neutrophils may 
migrate back to the circulation (Buckley et al., 2006; Hughes et al., 1997) or through the 
lymphatics (Schwab et al., 2007). 
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1.8.3 Functional phenotypes and heterogeneity 
The current literature describes a range of subtly different functional neutrophil phenotypes.  
It is unclear whether these exist within a spectrum, whether neutrophils move between 
them, and to what extent they may represent the product of experimental artefact.    
Subpopulations of differing functionality may exist within the wider neutrophil pool, although 
comparisons between studies are complicated by the different techniques and protocols 
used.  The molecular basis for these functional changes is unclear.  Possible explanations 
include variations in priming and tolerance phenomena, neutrophil maturity, and co-stimuli 
determined by neutrophil location acting through signal transduction modulation, 
preassembly of components such as PHOX, and genomic-driven changes in protein content. 
While routine laboratory tests provide some information about neutrophil age through 
morphological quantification of nuclear segmentation, tests of actual neutrophil function are 
not routinely available. Flow cytometric quantification of cell surface receptors is widely 
used to define lymphocyte subpopulations, however it is currently unclear whether 
neutrophil surface receptors equate to similar functional phenotypes (Fontes et al., 1995; 
Seely et al., 2003; Stocks et al., 1996).  Development of analogous neutrophil surface 
markers of function, or readily accessible functional assays may dramatically improve our 
understanding of an individual’s inflammatory response and permit delivery of immune 
tailored medications. 
 
1.8.4 Neutrophil priming and tolerance  
The serial application of DAMP/PAMP signals may promote enhanced (priming) or 
diminished (tolerance) inflammatory responses.  At a cellular level these responses may be 
partly explained by changes in neutrophil functionality (Condliffe et al., 1998).  Priming could 
explain the predisposition of trauma patients who receive apparently minor secondary 
insults to develop ARDS and multiorgan failure (Moore et al., 2005).  Similarly, a combined 
murine model of sequential gut ischaemic-reperfusion injury and endotoxin administration is 
consistently lethal, even though each insult alone is not (Koike et al., 1992).  Tolerance is 
exemplified by the anergic responses to coliform colonisation of the respiratory tract within 
the critically ill, and in a murine model of septic peritonitis, where prior administration of 
LPS improved survival (Feterowski et al., 2001).   
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In vitro investigations of priming with pure ligands have identified ligand specific signalling 
cascades.  For example, functional p38 MAPK is essential for TNF-α priming and responsible 
for 70% of the fMLP response but unnecessary for complement-opsonised zymosan 
stimulation (Brown et al., 2004).  It is also implicated in LPS and GM-CSF priming (Johnson 
and Gomez-Cambronero, 1995; McLeish et al., 1998; Nahas et al., 1996; Waterman and 
Sha’afi, 1995).  Lipopolysaccharide priming proceeds through TLR4 and CD14, with HMGB1 
also priming PHOX function through TLR4 (Fan et al., 2007).  At a cellular level LPS causes 
down-regulation of TLR4 within 30 mins, and this is magnified by a smaller priming dose of 
LPS (Parker et al., 2005).   
In vivo data are more complicated.  Within a single insult model of haemorrhagic shock, lung 
injury is TLR4 dependent (Ayala et al., 2002; Barsness et al., 2004).  However when a 
sequential LPS injury is applied whole lung TLR4 expression is maintained (Fan et al., 2002).  
Tolerance, as defined by diminished cytokine production, has been described at 24 hours 
following endotoxin exposure (van der Poll et al., 1996), and up to four weeks in those with 
established critical illness (McCall et al., 1993).   
The sub-cellular changes ultimately responsible for priming and tolerance are uncertain.  
While PHOX components are redistributed and partially phosphorylated following LPS and 
TNF-α application (DeLeo et al., 1998; Ward et al., 2000), preassembly of PHOX subunits 
does not seem to be responsible (Brown et al., 2004).  The hexose monophosphate shunt 
may be upregulated within primed cells (Bass et al., 1986). In combination with wide spread 
changes in ‘metabolic genes’, it is plausible that metabolic control of substrate supply may 
represent an essential but relatively underexplored regulatory mechanism  
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1.9 Conclusion 
 
The investigation of human immune function presents significant challenges.  Specifically, the 
study of septic patients is complicated by uncertainty surrounding the sepsis diagnosis, the 
time at which sepsis began, premorbid status and off-site effects of therapeutic 
interventions.  Healthy volunteer studies can never replicate the severity of real-world 
disease.  In contrast, the study of the surgical patient appears to offer a methodological rigor 
that these other studies lack.  Surgical patients are heavily phenotyped and receive a 
relatively homogenous insult at a known time, facilitating the acquisition of pre-insult control 
samples.  Biological plausibility for modelling sepsis with surgical patients is provided by 
genotyping investigations that describe a highly conserved genomic response of circulating 
leukocytes to both trauma and infection, and clinical similarities of these two populations. 
An appropriate inflammatory response to infection and trauma is essential so that the 
magnitude and duration of injury may be minimised, and autotoxic harm limited. Neutrophils 
are the most numerous cell type during the early, innate inflammatory response and possess 
a range of potent effector mechanisms. The respiratory burst appears to act as a master 
regulator by controlling the activation of these mechanisms and simultaneously serving to 
limit longer-term activity.  Therefore, the surgical model presents an opportunity to 
investigate how neutrophil function changes following a major inflammatory insult, and for 
the characterisation and description of the cellular mechanisms that may underlie these 
changes.   
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1.10 Hypothesis 
Patients undergoing major elective surgery demonstrate dynamic changes in neutrophil 
immune function, which may be mediated through alterations in neutrophil metabolic 
processes. 
 
1.11 Aims 
 
1. To determine whether the theoretical methodological advantages which the study of 
human surgical patients offers over the study of septic and trauma patients are 
realised in the translational surgical literature 
2. To characterise the temporal response of neutrophil effector functions following 
major elective surgery. 
3. To explore the metabolic processes which may underlie these changes in effector 
function. 
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Chapter 2 – General Methods 
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Patient samples were used throughout chapters 4, 5 and 6.  Chapters 4 and 5 present 
observational data, that describes the perioperative neutrophil phenotype.  All 
postoperative samples were compared to individualised preoperative controls.    Chapter 5 
and 6 provide mechanistic data, where chemical modulators of metabolic function were 
added to preoperative samples with the intention of mimicking the postoperative neutrophil 
phenotype. 
 
2.1 Clinical data collection 
Patient samples were collected from two clinical studies, following written informed 
consent, as detailed in Table 2.1 
 
2.1.1 Study conduct 
Patients were recruited from University College Hospital and The Royal Free Hospital 
between February 2011 and February 2014 from POMO and VISION-UK trials (Table 2.1)   
All postoperative samples were compared to their individual, matched preoperative control 
samples.  Preoperative and postoperative care was conducted as per local guidelines.  Both 
institutions have nurse-led preassessment clinics, with consultant support available as 
required.  Surgery and anaesthesia were either delivered or immediately supervised by 
consultants.  Local protocols regarding antibiotic and thrombo-prophylaxis, oral intake and 
physiotherapy plus occupational therapy were followed.   
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Postoperative Morbidity and Oxygen 
(POMO) 
VISION-UK 
MREC 09/H0805/58 MREC 10/WNo03/25 
Collection timing: 
       February 2011 to March 2012 
Collection timing: 
      March 2012 to August 2014 
Inclusion criteria 
- Major elective surgery 
(abdominal/oesophageal/hepatic 
resection/gynaecological/urological 
reconstructive surgery and who meet 
following criteria: 
1. ASA 3-4 
2. Age >50 years 
3. >2 risk factors defined by Revised 
Cardiac Risk Index 
 
Inclusion criteria 
- Non-cardiac surgery and received 
general anaesthetic 
- At least overnight admission to 
hospital 
- >45 years of age 
 
Exclusion Criteria 
- Refusal of consent 
- Concurrent lithium therapy 
- Acute myocardial ischaemia 
- Acute arrhythmias 
- Pregnancy 
- Palliative treatment only 
Exclusion Criteria 
- Refusal of consent 
Laboratory sampling time points 
Preoperative (Preassessment clinic),  
POD 3, POD 5. 
 
Immune assay sampling time points 
Preoperative (day of surgery), POD 1, POD 
3, POD 5. 
 
 
 
 
Immune assay sampling time points 
Preoperative (day of surgery), POD1, 
POD2, POD3. 
Table 2.1 Patient sampling criteria / protocol. 
POD=Postoperative day 
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2.1.2 Data collection 
Clinical and demographic data were collected prospectively as part of the POMO study 
protocol by trained research staff through analysis of written notes, electronic patient 
records and visits.  Perioperative risk scores were calculated using the American Society of 
Anaesthesiology Physical Status Score (ASA, 2014), Physiological and Operative Severity 
Score for the enumeration of Morbidity and Mortality (POSSUM) (Copeland et al., 1991), 
Duke Activity Status Index (Hlatky et al., 1989) and Veterans Specific Activity Questionnaire 
Metabolic Equivalents (Myers et al., 2001).  Full blood count samples were analysed by the 
hospital haematology laboratory using a Sysmex XE2100 analyser (Sysmex, Milton Keynes 
UK).  The VISION patient database is currently locked to analysis, therefore only age, sex 
and operation type are presented for these patients. 
2.1.3 Statistics 
Continuous data are presented as mean with 95% confidence intervals for normally 
distributed data, otherwise median with interquartile range.  For clarity, graphical data for all 
paired preoperative and postoperative are presented as paired line charts where n<10, and 
as box and whisker plots (median/IQR/min-max) where n>10.  Where n<6 statistics are not 
provided.  If n≥6 Wilcoxon matched pairs test was used, unless n>10 and box whisker plots 
suggested data was normally distributed, in which case Student’s paired t-test was used.    
Categorical data are presented as absolute plus percentage values, and compared using 
Pearson’s Chi2 or Fisher’s exact test as appropriate.   All statistics were analysed using Prism 
5.00 (Graphpad, USA). 
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2.2 Laboratory materials 
 
2.2.1 Equipment 
Equipment Supplier Address 
Biological safety cabinet (Class II): Holten LaminAir 
Model 1,2 
Thermo Scientific Waltham, USA 
Centrifuge: ALC PK120 ALC Cologno Monzese, 
Italy 
Centrifuge: Haraeus Megafuge 1.0R Kendro Laboratory 
products 
Langenselbold, 
Germany 
Cryogenic vials: 2ml Corning 
International 
NY, USA 
Falcon polypropylene tubes: 15ml, 50ml, 250ml BD Biosciences Oxford, UK 
Filter unit: Nalgene 90mm (0.2µm filter) Nalge Nunc 
International 
NY, USA 
Flow Cytometer off-line analysis: Kaluza 1.3 Beckman Coulter Inc High Wycombe, UK 
Flow Cytometer: Cyan ADP 9 colour (Summit 
4.3.1) 
Beckman Coulter Inc High Wycombe, UK 
Flow cytometry tubes: 5ml polystyrene round 
bottomed 
  
Haemocytometer (Neubauer) Assistent Germany 
Heated water bath: Grant JB4 Grant Instruments Cambridge, UK 
Incubator for cell culture Galaxy R 170litre RS Biotech 
Laboratory Ltd 
Irving, UK 
Microcentrifuge tubes: 1.5ml StarLab GmbH Ahrensburg, 
Germany 
Microcentrifuge: Eppendorf 5415 C Eppendorf Hamburg, Germany 
Microplate reader: Synergy Mx monochromator-
based multi-mode 
BioTek Winooski, USA 
Microscope: Zeiss Axiovert 25 Zeiss Oberkochen, 
Germany 
Pasteur pipettes (sterile): 3ml Ramboldi Ltd Limassol, Cyprus 
Pipette tips (Diamond, sterilised) tips:  
10, 200 and 1000uL 
Gilson Inc Middleton, USA 
Radiometer ABL800 Flex blood gas analyser Radiometer Bronshoj, Denmark. 
Real Time PCR: Rotor-Gene 6000 Corbett Life Sciences Cambridgeshire, UK 
Respirometer: Seahorse XF System Seahorse Copenhagen, 
Denmark 
Serological pipettes (Costar, disposable): 10, 25, 
50ml 
Corning 
International 
NY, USA 
 
Table 2.2 Laboratory equipment 
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2.2.2 Chemicals and reagents 
Reagent 
(Batch number) 
Supplier* 
(Product number) 
2-NBDG-FITC 
(Lot 1204217) 
Working solution 10mg/ml DMSO, stored at -20oC 
Life technologies 
N13195 
Annexin Buffer, made from: 
100mM HEPES,140mM NaCl, 25mM CaCl2, in distilled water 
Sterile filtered as above, stored at 4ºC. 
 
Sigma Aldrich 
Antimycin A from Streptomyces 
(lot 061M4063V) 
Stock solution 10mM in ethanol, stored at -20ºC 
Sigma Aldrich 
(A8674) 
Blood Lysis Buffer, made from: 
0.84g NaHCO3 
7.7g NH4CL 
1000ml distilled water 
Sterilized by passing through 0.22µm filter, stored at 4ºC 
Sigma Aldrich 
Bovine Serum Albumin 
(lot 099K1447) 
Stock solution 2% (w/v) in PBS, sterile filtered and stored at 4ºC 
Sigma Aldrich 
(B4287) 
Carbonyl cyanide -4(trifluoromethoxy)phenyldydrazone (FCCP) 
Stock solution 10mM in ethanol, stored at -20ºC 
Sigma Aldrich 
Cell Tak 
Stored at 4oC 
Corning 
D-Glucose 
(Lot K29908114) 
CTL Scientific Supply Corp 
(101174Y) 
Diarylsulfonamide (DASA) 
(Lot d00138745) 
Working solution 50mg/ml in DMSO, stored at -20oC 
Calbiochem 
(550602) 
Dihydroethidium (DHE) 
(1446356v) 
Working solution 10mM in DMSO, stored at -20oC 
Sigma Aldrich 
(37291) 
Dimethyl Sulphoxide (DMSO)# 
Stored at room temperature 
Sigma Aldrich 
(154938) 
Dulbecco’s Modified Eagle Medium Glutamax, 1g glc + pyruvate. 
Stored at 4oC 
Invitrogen 
(21885-025) 
Dulbeccos’s Phosphate-Buffered Saline, Calcium and Magnesium-
free. (PBS) 
Stored at 4oC 
Invitrogen Ltd 
(14190-094) 
E. coli-fitc (k-12 strain) 
(lot 929563) 
Invitrogen 
(e2861) 
E. coli LPS 0111:b4 l2630 – 25mg Invitrogen 
Ethanol 
(09/479 a10) 
Prolab diagnostics 
(L947907) 
Ficoll-Paque PLUS (Ficoll sodium diatrizoate) 
Stored at room temperature. 
GE Healthcare 
(17-1440-03) 
Hanks Balanced Salt Solution (HBSS) + CaCl2 +MgCl2 
Stored at 4oC 
Invitrogen 
(14025-050) 
Heparin sodium 1000iu.ml-1 (sterile) Leo Laboratories Ltd 
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Table 2.3 Chemicals and reagents. 
* Abcam PLC, Cambridge UK, GE Healthcare, Buckinghamshire UK; Corning, Bedford, MA; CTL Scientific 
Supply Corp, NY, USA; Sigma Aldrich, Dorset UK Glycotope biotechnology – Heidelberg Germany, Leo 
Stored at 4ºC 
HEPES buffer(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
2% gluteraldehyde 
Sigma Aldrich 
JC-1 
Stock solution 200x in DMSO, stored at -20OC 
(lot #505) 
Immunochemistry 
(#6260) 
Intracellular staining kit 
Stored at -4oC 
Life Technologies. 
Lipopolysaccharide, from Salmonella Typhosa 
(lot 113K4087) 
Stock solution in PBS sterile filtered, stored at 4ºC 
Sigma Aldrich 
(L6386) 
MitoSOX Red 
(Lot 449012) 
Working solution 5µM in HBSS/Ca/Mg, stored at -20oC 
Invitrogen 
(M36008) 
MitoTEMPO 
(lot H2113) 
Working solution 10mg/ml DMSO, stored at -20oC 
Santa cruz 
(Sc-221945) 
Myxothiazol from Myxococcus 
Stock solution 10mM in Ethanol, stored at -20oC 
Sigma Aldrich 
(T55580) 
Oligomycin 
(lot 061M8613) 
Stock solution 8mg.ml-1 in ethanol, stored at -20ºC 
Sigma Aldrich 
(04876) 
Paraformaldehyde 
2% (v/v) working solution in PBS, stored at 4ºC 
Sigma Aldrich 
(P6148) 
Phagoburst kit 
(Lot no 1323313109) 
Glycotope biotechnology 
Phagotest kit 
(Lot no 13948) 
Glycotope biotechnology 
Phorbol 12-myristate 13-acetate (PMA) 
(108K1443) 
Stock solution 100µM in ethanol, stored at -20oC 
Sigma Aldrich 
(P1585) 
Propidium Iodide (PI) 
Stock solution 50µg.ml-1 in PBS, stored at 4˚C 
Abcam plc 
Rotenone 
(lot 046K1189) 
Stock solution 10mM in ethanol, stored at -20ºC 
Sigma Aldrich 
(R8875) 
RPMI medium 1640 + 0.3g/L L-glutamine + 20% heat inactivated 
fetal calf serum 
Stored at -4oC 
Invitrogen 
(21875-034) 
Seahorse assay medium 
DMEM without sodium bicarbonate or phenol red, + 5.6mM 
glucose, 5mM pyruvate, 2mM L-glutamine.  pH adjusted to 7.4 at 
37oC and sterile filtered. 
Sigma Aldrich 
Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM) 
Stock solution 10mM in DMSO, stored at -20oC 
Life technologies 
Trypan Blue solution (0.4%) 
Stored at room temperature 
Sigma Aldrich 
(T8154) 
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Laboratories, Berkshire, UK; Invitrogen Ltd, Paisley UK Life technologies Paisley UK, Immunochemistry 
Technologies, MN, USA; Prolab diagnostics, Wirral, UK. # The concentrations of DMSO were all less than  
0.02%, well below those documented to have direct effects upon mitochondrial membrane potential and 
apoptosis (1.5 – 2% v/v) (Lin et al. 1995; Liu et al. 2001). In addition, appropriate volumes of DMSO were 
added to all control wells. 
 
2.2.3 Monoclonal antibodies and microbeads 
 
Antibody-
fluorochrome 
Clone 
(product / 
batch) 
Isotype 
(product / 
batch) 
Source Role 
Annexin-V-FITC (120-002-
355/51309270
69) 
n/a Miltenyi 
Biotec 
Ltd 
Binds to externalised 
phosphatidylserine (in the 
presence of calcium). 
CD11-APC M1/70.15.11.5 
(130-091-241/ 
5110802100 
Rat IgG2b 
Santa Cruz 
Sc-2895/ lot 
H2709 
Miltenyi 
Biotec 
Ltd 
As above 
CD11b-FITC M1/70.15.11.5 
(1300x81201/5
110916041) 
Rat IgG2b 
Santa Cruz 
Sc-2895/ lot 
H2709 
Miltenyi 
Biotec 
Ltd 
Integrin receptor for C3bi, 
fibrinogen and factor X. 
Strongly expressed on myeloid 
cells, scanty expression on 
some lymphocytes 
CD14-APC TUK4 
(1300x91243/5
110929113) 
Mouse IgG2a 
(130-091-837/ 
5120614134 
Miltenyi 
Biotec 
Ltd 
As above 
CD14-FITC TUK4 
(130-080-701/ 
5110527016 
Mouse IgG2a 
(130-091-837/ 
5120614134 
Miltenyi 
Biotec 
Ltd 
Part of the LPS receptor 
complex.  Strongly expressed 
on monocytes / macrophages 
and weakly expressed on 
some neutrophils 
CD16-APC VEP13 
(130-091-246/ 
5130718150) 
Mouse IgM 
(130-093-176/ 
512102119) 
Miltenyi 
Biotec 
Ltd 
As above 
CD16-FITC VEP13 
(1300x91244/5
110308207) 
Mouse IgM 
(1300x93178/5
101208144) 
Miltenyi 
Biotec 
Ltd 
Low affinity IgG receptor.  
Present on neutrophils, 
macrophages and NK cells. 
CD62L-APC 145/15 
(130-091-755 
5110906351) 
 
Mouse IgG1 
(1300x92214/5
120706226) 
MACS Recruitment of leukocytes 
across endothelium to 
inflamed tissues.  Most 
haematopoietic cells express 
CD62L. 
CD95(Fas)-APC DX2 
(305612/B128
Mouse IgG1 
(1300x92214/5
Miltenyi 
Biotec 
Member of TNF receptor 
superfamily – mediates 
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820) 120706226) Ltd apoptosis.  Expressed upon 
granulocytes, monocytes and 
many lymphocytes.  
CXCR2 
(CD182) 
 
5E8/CXCR2 
320704/B1472
74 
Mouse IgG1 
(1300x92214/5
120706226) 
Biolegend IL-8 receptor, as homo or 
heterodimer with CXCR1. 
Expressed on granulocytes, 
and many other 
haematopoietic cells 
FcR blocker 120-000-442 
512128065 
 MACS  
Ly-6G 
MicroBeads 
130-092-332   Positive selection of mouse 
neutrophils 
TLR4-PE 
(CD284) 
HTA125 
(312805/B156
775) 
Mouse IgG2a 
(130-091-837/ 
5120614134 
Biolegend Pathogen recognition 
receptor. Expressed on 
monocytes/macrophages, 
endothelial cells and low levels 
on neutrophils and B cells. 
TREM-1-PE 
 
193015 
(FAB1278P/LC
10411011 
Mouse IgG1 
(1300x92214/5
120706226) 
RD 
Systems 
Amplification/transduction of 
pattern recognition receptor 
signals. Expressed on 
neutrophils, 
monocytes/macrophages and 
dendritic cells. 
 
Table 2.4 Monoclonal antibodies and beads. 
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2.2.4 Fluorescent cellular probes 
 
Probe* 
 
Conversion 
product 
(excitation/ 
Fluorescence 
nm) 
Marker Notes 
Dihydrorhodamine-123 
(Poot et al., 1996; Rothe 
et al., 1988; Rothe and 
Valet, 1990) 
Rhodamine123 
(511/534) 
H2O2, (Royall 
and 
Ischiropoulos, 
1993) HOCl 
Used for clinical tests of 
neutrophil burst. Accumulates in 
mitochondria.  
Dihydroethidium 
(Lehmann et al., 1998) 
Ethidium 
(520/610) 
O2- 
(Walrand et 
al., 2003) 
Hyper-fluoresce when bound to 
DNA. 
MitoSOX RED 
(Mukhopadhyay et al., 
2007) 
Ethidium 
(520/610) 
O2- 
(Cationic) 
Ethidium conjugated with cationic 
triphosphohenyllinium# to target 
mitochondria 
TMRM 
(Ehrenberg et al., 1988; 
Feng et al., 2009). 
TMRM 
(535/573) 
Mitochondrial 
membrane 
potential 
(Cationic) 
Accumulates unchanged within 
mitochondrial intermembrane 
space. 
JC-1 
(Minamikawa et al., 1999; 
Salvioli et al., 1997) 
 
Green 
monomers 
(514/529nm) 
Red J-aggregates 
(514/590nm) 
Mitochondrial 
membrane 
potential 
(Cationic) 
Accumulates unchanged within 
mitochondrial intermembrane 
space.  Density dependent 
aggregation and colour change. 
 
Table 2.5 Fluorescent cellular probes 
*Stock details listed under Table 2.3, Chemicals and Reagents. #The inner mitochondrial membrane is far 
more negative (-140mV) than other organelles within the cell, therefore lipophilic cations preferentially 
accumulate there, (Murphy and Smith, 2000) 
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2.2.5 Neutrophil activation agents 
 
Activator* Target Working 
concentration 
Application / notes 
Opsonised E. coli Phagocytosis: Fc, 
PRR, complement 
receptors. 
 
Typically, x109/ml FITC labelled bacteria to 
quantify phagocytosis, 
unlabelled bacteria to 
measure respiratory burst 
Lipopolysaccharide 
(LPS) 
LPS receptor 
(TLR4/CD14) 
Dependent upon 
bacterial strain 
and LPS subtype. 
(0.5 to 100ng/ml) 
Requires lipopolysaccharide 
binding protein. 
fMLP fMLP receptor 1 to 50 ng/ml A potent chemoattractant, 
also a weak stimulus of 
respiratory burst – 
commonly used to identify 
primed neutrophils. 
PMA Protein Kinase C 
(Higher 
concentrations 
may directly 
activate NF-kB). 
100ng/ml to 
1ug/ml. 
Potent and persistent 
activator of PKC – 
endogenous signals are 
more transient.  Bypasses 
cell surface signalling 
machinery. 
    
 
Table 2.6 Neutrophil activating agents 
*Stock details listed within Table 2.3, Chemicals and Reagents. 
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2.3. Blood work 
Laboratory isolation of neutrophils has been repeatedly demonstrated to alter neutrophil 
function (Kotz et al., 2010; Kuijpers et al., 1991; Pallister and Topley, 2004). However, 
assays within whole blood maybe affected by the presence of other cell types and variable 
concentrations of neutrophils (Wenisch et al., 2001).  Therefore, experiments were 
repeated within whole blood and isolated neutrophils where possible.  Some assays, such as 
JC-1, cannot be used in whole blood.  Heparin anticoagulation better preserves cell surface 
antigen expression (Elghetany and Davis, 2005), while citrate depletion of calcium may 
impair signalling processes necessary for neutrophil activation.   
20ml of heparinised whole blood (19ml blood plus 1ml [1000 units] heparin) were collected 
for immune study studies, along with full blood count and chemistry samples for hospital 
laboratory analysis.  Heparinised whole blood samples were immediately placed on ice and 
processed with 2 hours of collection.  
 
2.3.1 Granulocyte isolation from whole blood 
Neutrophil isolation was by density gradient centrifugation.  15ml whole blood was diluted 
1:1 with phosphate buffered saline, layered over 15ml Ficoll-Paque within a 50ml Falcon tube 
and centrifuged at 220x g for 30minutes with braking disabled.  After removal of all layers 
above the neutrophil/red cell fraction using Pasteur pipettes, 30ml lysis buffer was added and 
samples were placed on ice for 20 minutes and regularly vortexed.  These falcon tubes were 
then centrifuged at 220x g for 6 minutes and the supernatant discarded. A second lysis stage 
was performed, as described above.  Samples were then washed in PBS, and a 100µL aliquot 
mixed with 100μL trypan blue, counted with a haemocytometer and resuspended at 1x106 
cells per ml in PBS with 10mg/ml sterile filtered glucose and placed on ice.  Manual counting 
of leukocytes is considered a reference standard (Roussel et al., 2012).  Trypan blue 
revealed >98% viability of cells. 
The granulocyte population includes neutrophils, eosinophils and occasional basophils.  
Neutrophils typically outnumber eosinophils 300-fold, therefore large scale investigations 
have considered the granulocyte population to be equivalent to a pure neutrophil 
population (Kotz et al., 2010; Xiao et al., 2011).  Further isolation procedures may increase 
iatrogenic injury and activate neutrophils.  Eosinophil contamination rates of 3% are typically 
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considered to be acceptable (Kotz et al., 2010).  In addition to physical separation, during 
flow cytometry experiments neutrophils were specifically identified by co-labelling with a 
conjugated CD16 monoclonal antibody.  For the respiratory burst experiments ‘backgating’ 
was used to remove cells with very low burst responses (see 2.6.4).  
 
2.3.2 Neutrophil isolation from murine bone marrow 
The Miltenyi Biotec isolation kit was used to positively select murine neutrophils.  Ly-6G 
antibody is highly specific for murine neutrophils.  Mixed cellular preparations were 
incubated with Anti-Ly-6G Biotin labelled monoclonal antibodies, then subsequently with 
Anti-Biotin magnetic microbeads.  The cells were then passed through a magnetic field 
which retains the co-labelled cells, but allows other cells to pass through.   
The Separation Buffer stock was diluted 1:20 with PBS to create a working solution (pH 7.2, 
0.5% bovine serum albumin, 2mM EDTA).  Heparinised murine bone marrow was extracted 
as described below, passed through a 30µm nylon mesh to remove clumps, counted and re-
suspended in 200uL buffer per 108 cells.  50µL Anti-Ly-6G-Biotin was added per 108 cells, 
samples mixed and incubated at 4oC for 10 minutes.  A further 150µL of buffer was added 
per 108 cells, then 100uL Ani-Biotin Microbeads per 108 cells.  Samples were mixed and 
incubated for further 15 minutes at 4oC, then a further 5ml of buffer added per 108 cells and 
centrifuged at 300g for 10 minutes.  Supernatant was aspirated and cells re-suspended in 
500µL of buffer per 108 cells. 
The MACS MS separation column was rinsed with 500uL buffer and placed in the separator.  
500µL aliquots of cell suspension were then added to the reservoir, and repeated once 
reservoir was empty.  The column was then removed, placed over a collection tube and 
flushed with 1ml buffer. 
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2.4 Animal models 
An animal model was used for bone marrow experiments within Chapter 4.  8-12 week old 
male mice (weight 20-25g) were selected.  Animals were housed with food and water 
available ad libitum in the specific pathogen-free central animal facilities of University College 
London Medical School (London, UK).  Experimental protocols were approved by the UCL 
Institutional Animal Care and Use Committee, and performed per UK Animals (Scientific 
Procedures) Act, 1986. Experiments were conducted in accordance with the ARRIVE 
guidelines (Kilkenny et al., 2013).   
Experiments were performed within a laboratory, in a separate room from the home cages.  
Topical bupivacaine was used for analgesia.  During experiments body temperature was 
maintained using a warming mat regulated by a rectal temperature probe.  Animals were 
randomised through numbering and random (blinded) selection of numbers, with treatment 
and control animals selected in alternating manner.  Animal welfare was overseen by UCL 
biological services department. 
 
2.5 HL-60 cell line  
HL60 cells were obtained from ATCC (ATCC CCL-240).  Cultures were performed within 
RS Biotech Galaxy R 170litre incubator (37.0oC, pCO2 5.0kPa).  All instrumentation was 
performed within a cleaned culture hood with laminar air-flow.  Experiments were 
performed upon cells between passage 10 and 40.  The cell line was maintained and 
differentiated by Ana Gutierrez del Arroyo.  Cells were seeded at 2.5x105/ml in RPMI 1640 
(with 0.3g/L L-glutamine and 20% heat inactivated fetal calf serum).  Cells were differentiated 
into neutrophil-like cells by the addition of 1.25% DMSO for 6 days prior to 
experimentation (Collins et al., 1979). All cells were washed twice in plain RPMI before 
functional assays were performed. Cells were counted using trypan blue as described above, 
and resuspended at 0.5M/ml. 
 
2.6 Flow cytometry 
Flow cytometry uses lasers to describe the optical properties of individual cells.  The 
scattering of laser light provides gross information about cell size and shape.  The highly 
specific fluorescent properties of fluorochrome chemicals are used to provide more detailed 
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information about each cell.  Fluorescence describes the optical property whereby 
excitation of an electron with a specific wavelength of light leads to a change in electron 
energy levels and subsequent emission of a second photon of light at a different, but equally 
specific wavelength.  The flow cytometer contains a series of lasers that are used to excite 
these electrons, and a series of detectors, which consist of photomultiplier tube detectors 
covered by monochromatic filters.   
Fluorochromes may be conjugated to monoclonal antibodies to measure specific antigens 
either outside, or within cells.  A range of fluorescent probes is also available, whose 
emission spectra change during highly specific chemical reactions, and may therefore be used 
to measure the rates of these reactions and make inferences about the quantities of 
reactants and reaction rates.  It is possible to combine fluorochromes and probes, provided 
emission spectra are different – however, even if peak fluorescence’s are different, the 
spectra may still overlap.  To isolate each signal, individual control samples are run to 
measure relative contributions from each signal, and to also measure 
background/autofluorescence. The flow cytometry techniques used throughout this thesis 
follow International Society for Analytical Cytometry MIFlowCyt guidelines (Lee et al., 
2008), and recommendations by Tung et al (Tung et al., 2007). 
Measurements were performed using the Beckman Coulter CyAn ADP flow cytometer 
(Beckman Coulter, High Wycombe, UK), using Summit 4.3.1 software to gather flow 
cytometry files (.fcs).  Off-line analysis was performed using Beckman Coulter Cyan Kaluza 
v1.3 software.   
Laser alignment was checked every day using Multicheck beads (Moflo, Beckman Coulter) 
and every two weeks using SpectrAlign beads (CyAn) to a target fluorescence resolution 
coefficient of variation <3% of full peak for 488nm excitation and <4% for 633nm excitation 
by a formally trained support scientist.  Lasers were allowed to warm up for 30 minutes 
before sample acquisition.  A routine cleaning protocol was run by each user at the end of 
each session, and an extended protocol run at the end of each working day.  A maintenance 
contract with Beckman Coulter provided yearly servicing and on-request engineer visits.   
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CyAn ADP specifications: 
Laser source Emission Filter  Fluorochrome / probe 
488nm, 25mW  
 
FL1 (530/40nm) FITC, rhodamine-123, JC-1 
488nm, 25mW  
 
FL2 (575/25nm) PE, JC-1, TMRM, DHE, 
MitoSOX Red 
488nm, 25mW  
 
FL3 (613/20nm) PI 
642nm, 60mW  
 
FL8 (665/20nm) APC 
 
Table 2.7 Optical specifications of CyAn ADP flow cytometer. 
Taken from (Beckman-Coulter, 2009) 
 
Feature CyAn ADP 
Maximal processing speed Up to 70,000 events per second 
Sample flow rate Up to 150µL/min 
Quartz cuvette Fused silica, 250µM square sectioned 
internal channel 
Compensation 9x9 matrix, auto compensation 
Signal resolution 4096 channels on all parameters 
Sensitivity (Molecules of equivalent soluble 
fluorochrome) 
FITC <100; PE <50 
Beam geometry Elliptical / spherical 
Sheath management system Electronic fluidic control of sheath, waste 
and cleaning fluid with continuous 
adjustable flow rate 
Operating system Windows XP Professional 
 
Table 2.8 Operating features of CyAn ADP flow cytometer 
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2.6.1 General conduct 
 
Individual control samples were used for each patient sample.    Photomultiplier tube 
voltages (gain) were set using control samples, and the voltage was adjusted to ensure the 
control (background) population fell within the first log order of fluorescence.  These 
settings, along with gating strategies, were saved as acquisition protocols to ensure 
comparability between data collected on different days.  All .fcs files were anonymised and 
saved onto the local hard drive and backed up onto the local network server, onto a home 
computer, and are available on request.   
The choice of control sample depended upon the experimental assay.  In the case of 
monoclonal antibodies isotype controls were used (O’Gorman and Thomas, 1999).  Isotype 
controls are of the same subtype from the same animal (e.g. Mouse IgG1), but are polyclonal 
and therefore directed to many different epitopes.  They account for class or non-specific 
binding of antibodies, and are particularly important when investigating cells with Fc 
receptors, such as neutrophils.  They were used in the same concentration as test 
antibodies. For fluorescent cellular probes, such as Rhodamine-123, unstained or untreated 
control samples were used instead. 
 
2.6.2 Filter compensation and fluorescence-minus-one 
The emission spectra of fluorochromes may overlap, leading to detection by an unintended 
photomultiplier tube.  Therefore, when two overlapping probes are used simultaneously a 
compensation process must be applied to isolate individual fluorochrome responses.  
Compensation is the first part of any analysis procedure.  Compensation uses each of the 
two overlapping antibody/probes individually as single compensation control samples, 
allowing the proportion of light detected by the unintended detector to be measured.  This 
proportion is then subtracted from the combined test sample containing both probes.  
Within modern flow cytometry machines compensation is a post-recording mathematical 
transformation and does not affect the protocol voltage settings during primary sample 
acquisition (Roederer et al., 2004).  The effects of compensation are demonstrated within 
the Annexin section below, where Annexin-FITC antibody overlaps with the PI cellular 
probe.   
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Figure 2.1 Compensation of FITC/PI sample.  
(A)In uncompensated sample the FITC emission spectra overlaps with the detection filter (B) With 
compensation applied PI detection of FITC signal is eliminated. 
 
Fluorescence-minus-one is an alternative method of eliminating spectra overlap.  It is 
particularly useful for samples with low level probe/antibody fluorescence where the relative 
contribution of autofluorescence to probe/antibody fluorescence will be high, or when 
several overlapping fluorochromes are being used together.  Rather than running each 
fluorochrome separately, a control sample is created which contains every fluorochrome 
except the probe of interest.  This may then be used to set background fluorescence gates, 
before the actual test sample is run, containing every probe of interest. 
 
2.6.3 Reporting and presentation of flow cytometry data 
FACS data are presented as fluorescence, in dimensionless arbitrary units, typically on a 
logarithmic scale.  However, since logarithmic values are asymptotic to zero, they cannot 
represent fluorescence values that are close, or approximate to zero.  Here, a logicle – or 
bi-exponential – scale is used, where values around zero have a linear scale.  Transformed 
data from filter compensation often leads to values that fall to zero, necessitating the use of 
logicle scales. 
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Neutrophil death and apoptosis were assessed by specific assays, including measurement of 
mitochondrial membrane potential, early and late apoptosis and cell death.  The addition of 
specific markers of cell death to other assays (e.g. of neutrophil function) were not 
performed, as has been generally advised by authors commenting on lymphocyte flow 
cytometry (Tung et al., 2007).   
Where possible, co-labelling of conjugated CD16 antibody was used to identify neutrophils 
during whole blood and isolated neutrophil flow cytometry experiments. 
 
2.6.4 Gating and positive staining 
 
Light scattered by cells passing through the machines laser beam is determined by cellular 
morphology.  Larger cells scatter more light in a forward direction, facing the laser beam 
(narrow angle, forward scatter, FSC), and denser cells (due to more cytoplasmic granules or 
organelles) scatter more light sideways (wide angle, side scatter, SSC).  Scattering of light 
may therefore be used to identify granulocytes within isolated samples (Fig 2.2) and lysed 
whole blood (Fig 2.3) since granulocytes possess distinct morphological features. 
Light scattering may also be used to identify cell clumping with the sample stream, and was 
the first gate set for all analyses.  The ’pulse width’ contains size information which is 
independent of many of the factors which contribute to forward and side scattering 
(Hoffman, 2009), and may be used to exclude clumps and doublets. 
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Figure 2.2 Flow cytometric identification of neutrophils within an isolated 
granulocyte sample. 
(A)Isolated granulocyte selected from contaminating lymphocytes/monocytes/debris.  (B) CD16hi population 
selected.  (C) CD16hi backgated onto fs/ss plot to confirm purity of isolation procedure. 
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Figure 2.3 Flow cytometric identification of neutrophils within whole blood        
(A) Granulocytes identified on fs/ss plot. (B) The CD16 isotype sample was loaded, and a gate set beyond 
95% of the isotype population.  (C) The test sample was then loaded.  (D) Back gating of this population 
onto the original fs/ss plot confirms these cells are granulocytes.  (E) Here, the entire leukocyte population is 
gated, which shows (F) A population of cells with low expression of CD16 (G) When this population is gated 
back onto the fs/ss plot, these cells are shown to be lymphocytes/monocytes and a few ‘granulocytes’.  These 
CD16lo cells may be apoptosing neutrophils, eosinophils or possibly activated monocytes.  
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The technique used to describe positive staining was determined by the extent to which the 
test sample was separated from the relevant control sample.  Where there were discrete 
subpopulations of cells staining positive, the percentage of cells present in the subpopulation 
and the median fluorescent intensity of the subpopulation were recorded (Fig 2.4 A-E).  
Samples were considered positive if they fell outside the 95th percentile of the relevant 
control sample.   
Where these samples overlapped, the percentage of cells which fell outside the 95% 
percentile of the control sample were recorded (Fig 2.4 F-H), unless the population was not 
normally distributed, in which case median fluorescent intensity (MFI) was reported.  Where 
the test population was completely separated from the control population, MFI was 
recorded. 
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Figure 2.4  Gating strategies for Cluster of Differentiation (CD) antigens.  
A-E Measurement of CD14 on neutrophils.  Here CD14 expression overlaps the isotype control, and 
monocytes must be excluded from whole blood sample.  (A) Granulocyte population selected. (B) Monocyte 
subpopulations express variable amounts of CD14, therefore expression of CD16 was used to select the 
neutrophil population (C) This was backgated onto fs/ss plot to confirm neutrophil population correctly 
identified.  (D) CD14 isotype control run.  (E) Overlay plot created, 95% markers created using isotype, then 
proportion of neutrophils expressing CD14 recorded. F-I Measurement of CD16 on neutrophils. Here the 
CD16 population is completely separated from the isotype control.  (F) Granulocyte population selected. (G) 
CD16 cells selected (H) Isotype control run (I) MFI of CD16 population recorded. 
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2.6.5 Monoclonal antibodies   
2.6.5.1 Extracellular: Cluster of Differentiation markers (CD)   
CD markers used are detailed in table 2.4, and their function and significance described in 
more detail within chapters 1 and 4. For whole blood samples, 2µL of the relevant 
conjugated monoclonal antibody (or isotype) was suspended in 100uL 2% BSA then added 
to 100µL heparinized whole blood and thoroughly mixed.  Samples were incubated for 1 
hour at 4OC, then fixed with 100µL 2% paraformaldehyde (PFA) for 5 minutes prior to 
addition of 3mls of Blood Lysis Buffer for a further 10 minutes with regular agitation.  
Samples were then centrifuged at 300g for three minutes, supernatants discarded, agitated 
and washed in PBS before repeat centrifuge for 3 minutes at 300g.  Supernatants were 
discarded, then samples agitated plus resuspended in 500µL of PBS and stored in dark at 
4oC ready for analysis.  All samples were processed within 24 hours of preparation.  
Isolated neutrophils were treated similarly.  1x106 cells (1ml) were centrifuged at 300x g for 
3 minutes, supernatant was then discarded and the pellet agitated prior to addition of 2µL 
antibody suspended in 100µL 2% BSA.  Samples were incubated for 30 minutes, then fixed 
and processed as before. 
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2.6.7 Assays of neutrophil function 
 
2.6.7.1 Phagocytosis  
Neutrophil phagocytosis was assessed using PhagoTest (Orpegen Pharma, Heidelberg, 
Germany). 100µL heparinised whole blood was added to two (test and control) flow 
cytometry tubes, then cooled to 0oC for 10 minutes.  20µL of precooled, vortexed 
opsonised FITC-labelled E. coli suspension (2x109/ml=4000 bacteria) were added to both 
tubes then vortexed again.  The control tube was kept on ice and test tube incubated at 
37oC in a water bath for 10 minutes in the dark.  At the end of incubation, the test sample 
was returned to 0oC.  100µL quenching solution (Trypan Blue) was added to each sample, 
then vortexed. Two wash steps consisting of 3ml cooled wash solution, centrifugation at 
300g for 5 minutes at 4oC, and discarding of supernatant were then performed.  2 ml of 
fix/lysis solution were then added and samples incubated for 20 minutes at room 
temperature, with regular vortexing.  Samples were then washed as before, resuspended in 
PBS then immediately analysed. 
Figure 2.5  Neutrophil phagocytosis assay analysis. 
[A] Neutrophils were identified on fs/ss plot.  (B) 0oC control sample used to set 95% gate. (C) 37oC test 
sample run and (D) MFI of test population recorded. 
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2.6.7.2 Respiratory burst  
 
Neutrophil respiratory burst was assessed using the BurstTest assay (Orpegen Pharma, 
Heidelberg, Germany).  100µL heparinised whole blood was added to 4 flow cytometry 
tubes (control, E. coli, fMLP and PMA) and placed on ice.  20µL wash solution were added 
to the control tube, with 20µL opsonised E. coli bacteria suspension (1x109/ml), 20μL fMLP 
working solution (5µM) and 20µL PMA working solution (8.1μM) to respective test tubes. 
Samples were then vortexed and placed in a 37.0oC water bath for ten minutes.   Samples 
were then returned to ice before addition of 20µL dihydrorhodamine-123 solution, 
vortexed and incubated for a further 10 minutes at 37oC in a water bath.  Samples were 
then returned to ice and fixed with 100μL PFA for 3 minutes, before addition of 2ml lysing 
solution and kept at room temperature with regular vortexing.  Finally, samples were 
washed once with 3ml of wash solution, vortexed, centrifuged at 300g for 5 minutes before 
aspiration of supernatant and resuspension in 100μl wash solution.  Samples were then 
processed immediately on the flow cytometer. 
For isolated cells, 1x106/ml (1ml) isolated neutrophils suspended in PBS with 10mg/ml 
glucose was used in place of whole blood, and the lysis step was omitted.  Only PMA test 
samples were run for isolated cells, since neutrophils do not readily respond to E. coli 
bacteria in the absence of serum. 
84 
 
Figure 2.6.Neutrophil respiratory burst assay analysis. 
(A) Control sample loaded, and granulocytes identified by fs/ss.  (B) Control FITC fluorescence recorded.  
(C,D,E) Next, fMLP, E. coli and PMA test samples were sequentially loaded, identified on FS/SS (not shown) 
and FITC fluorescence MFI recorded.   (F) Demonstrates overlay plot of all test samples.  For fMLP stimulus 
the percentage of granulocytes positive was also recorded, using a 95% marker previously set on the control 
sample. 
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2.6.8 Assays of neutrophil mitochondria  
Neutrophils contain functional mitochondria that maintain a mitochondrial membrane 
potential independent of cytoplasmic ATP production (Fossati et al., 2003; Maianski et al., 
2004).  The loss of neutrophil mitochondrial membrane potential is believed to be a critical 
regulator of constitutive apoptosis.   
 
2.6.8.1 Mitochondrial membrane potential 
Cell permeable, fluorescent cationic probes may be used with flow cytometry to measure 
changes within the mitochondrial membrane potential of individual cells.   JC-1 is a 
carbocyanine dye that exists as a green monomer at low concentrations and forms red J-
aggregates at high concentrations (Minamikawa et al., 1999; Salvioli et al., 1997).  The loss of 
red fluorescence and gain of green fluorescence may therefore be used to monitor 
mitochondrial membrane potential.  TMRM possesses red-orange fluorescence and 
accumulates within the positively charged mitochondrial intermembrane space.  The 
magnitude of fluorescence is therefore an indicator of mitochondrial membrane potential.  
TMRM may be used within whole blood samples, unlike JC-1 which requires an isolated cell 
system.  The uncoupling agent FCCP dissipates the mitochondrial membrane potential 
independently of ATP production, by providing a route for H+ to re-enter mitochondrial 
matrix along a concentration gradient.  FCCP may therefore be used as a positive control. 
 
JC-1 
I used the MitoPT JC-1 assay kit (Serotec, Kidlington, Oxon, UK, which is only validated 
within isolated cell preparations (Bassøe et al., 2003).  The assay was performed within a 
darkened room. Working solutions were prepared as per manufacturer’s instructions: 1x 
assay buffer solution and 1x JC-1 solution.  Isolated neutrophils were prepared as described 
above, 1x106/ml in PBS with 10mg/ml glucose, then 1ml neutrophil preparation was added to 
three flow cytometry tubes (test, control, isotype).  These tubes were centrifuged at 300g 
for 5 minutes, supernatants discarded and re-suspended in 1ml 1x JC-1 buffer.  1µL f FCCP 
stock (50mM) was added to the control sample (equivalent to 50μM FCCP) and 1µL DMSO 
to the test sample, all tubes were then incubated at 37oC in water bath for 15 minutes.  
Then, 1ml 1x JC-1 solution was added to test and control tubes, 1ml JC-1 buffer to the 
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isotype and 2µL CD16 antibody (or isotype) plus 100µL BSA to test, control and isotype 
tubes as appropriate.  All samples were incubated for a further 15 minutes at 37oC, before 
being centrifuged at 300g for 5 minutes at room temperature.  Supernatants were discarded 
and all samples washed once with 2ml assay buffer, centrifuged at 300g for 5 minutes, 
Supernatants were then discarded and re-suspended in 0.5ml of JC-1 buffer and processed 
immediately on the flow cytometer. 
 
Figure 2.7  JC-1 assay analysis. 
(A) FCCP positive control sample loaded, and granulocyte population identified by fs/ss.  (B) Positive control 
neutrophil population identified by CD16hi (C) FITC/PE plot of positive control sample used to identify a gate 
containing 95% of the neutrophil population.   The test sample was loaded and population identified by 
FS/SS (D) Test neutrophil population identified by CD16hi. (E) The proportion of neutrophils present within 
the positive control gate, and therefore which had lost their membrane potential, was recorded. 
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TMRM 
TMRM stock solution (10mM) was diluted to form 200nM working solution in JC-1 buffer 
solution. 100µL heparinised whole blood was added to three tubes (test, control, isotype) 
and placed on ice.  1µL FCCP stock (50mM) to control sample and 1uL DMSO to the test 
sample, and incubate at 37oC in water bath for 15 minutes.  Next, 1ml of TMRM working 
solution, and 2µL CD16 antibody (or isotype) suspended in 100uL BSA was added to each 
tube.  Samples were returned to the water bath at 37oC in the dark for a further 15 
minutes, before returning to ice. Two wash steps were performed, with 2ml JC-1 buffer, 
centrifuged at 300g and the supernatant then discarded.  Samples were then lysed with 2ml 
blood lysis buffer before being washed a final time, re-suspended in JC-1 buffer and 
processed immediately on the flow cytometer. 
Figure 2.8 TMRM assay analysis. 
(A) Positive control sample loaded, and granulocyte population identified by FS/SS (B) Neutrophils then 
identified by CD16hi (not shown). Test sample loaded and granulocytes identified by FS/SS (C) Test neutrophil 
identified by CD16hi (D) An overlay plot of positive control and test samples was created.  Both the MFI of 
the test sample, and the % of neutrophils that lost their membrane potential were recorded. 
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2.6.8.2 Mitochondrial superoxide production 
Redox sensitive fluorescent probes may be targeted to mitochondria through conjugation 
with a negatively charged moiety.  MitoSOX Red consists of the hydroethidium probe, 
which undergoes 2-hydroxylation in the presence of superoxide, attaching to the cationic 
triphenylphosphonium which promotes electrophoretic uptake by respiring mitochondria 
(Mukhopadhyay et al., 2007).  When oxidised MitoSOX Red binds to cellular DNA it 
becomes hyper fluorescent (Robinson et al., 2006). This must be considered during flow 
cytometry analysis.  Dihydrorhodamine-123 is less specific, and measures H2O2 – including 
that generated by mitochondrial superoxide dismutase - throughout the cell (Henderson 
and Chappell, 1993). 
 
MitoSOX Red 
The MitoSOX Red assay kit (Invitrogen, Paisley UK) was used.  A 50µg vial of MitoSOX was 
added to 13µl of DMSO, to make 5mM stock solution.  2 µL stock solution and 1µL CD16 
antibody were added to100µl MitoSOX assay buffer to create a test solution.  2 µL of 
DMSO plus 1µL CD16 antibody was added to 100µL of MitoSOX assay buffer to create a 
control solution and 2 µL DMSO plus1µL CD16 isotype was added to 100µL of MitoSOX 
assay buffer to make an isotype solution.  100µL of isolated neutrophils (prepared as 
described above – 1x106 cells/ml in PBS with 10mg/ml glucose) were added to flow 
cytometry tubes labelled test, control and isotype, with 100µL of the test solution, control 
solution and isotype solutions added as appropriate.  These samples were vortexed, then 
incubated at 37oC for 15 minutes at 5kPa CO2.  These samples were placed on ice and 
washed once by adding 2ml of 4oC assay buffer, vortexed, centrifuged at 300g for 5 minutes 
and supernatants discarded.  Samples were resuspended in 100µL of 4oC assay buffer, placed 
on ice in the dark and processed immediately on the flow cytometer. 
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Figure 2.9 MitoSOX Red assay analysis. 
(A) Unstained, negative control sample loaded and granulocyte population identified by fs/ss.  (B) PE 
fluorescence of negative sample noted.  (C) Test sample loaded, granulocyte population identified and higher 
staining cells excluded.  (D) Overlay plot of negative and test sample. A 95% gate was created from test 
sample, and the proportion of test neutrophils beyond this recorded. 
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2.6.9 Apoptosis: Annexin-V-FITC / Propidium Iodide (PI)  
Phosphatidylserine is usually present on the cytoplasmic side of the cellular membrane, but 
becomes externalised early in apoptosis (Vermes et al., 1995).  Annexin-V avidly binds to 
negatively charged phosphatidylserine, and is commercially available in a FITC conjugated 
form to detect apoptosis.  Further progression of apoptosis leads to fragmentation of the 
cellular membrane, allowing the vital dye PI to enter and bind to DNA.  Therefore, 
combination Annexin/PI staining may be used to classify cellular viability.  Cells that have 
entered early apoptosis will only stain with Annexin-FITC, while those which have 
progressed to late apoptosis or secondary necrosis will stain for both Annexin-FITC and PI.  
Meanwhile cells which are primarily necrotic will only stain with PI, while healthy non-
apoptotic cells will stain with neither.  The Annexin-V assay is widely used, and correlates 
with other techniques such as TUNEL and the DNA ladder assay (Yasuhara et al., 2003). 
1x106 cells/ml of isolated neutrophils in PBS plus 10mg/ml glucose were prepared as 
described above, with 1ml added to four flow cytometry tubes labelled Negative, Annexin, 
PI and Annexin+PI.  These samples were centrifuged at 300g for five minutes, supernatants 
were discarded and re-suspended in 100µL of Annexin buffer that contained either no 
added agent (negative, PI) or 0.5µL of Annexin-FITC (Annexin, Annexin+PI).  These samples 
were incubated for 20 minutes in the dark at room temperature.  A further 500µL of 
Annexin buffer was added to each tube, and samples were again incubated in the dark for 20 
minutes at room temperature. Finally, samples were placed on ice and 5µL PI was added to 
the PI and Annexin-PI tubes, vortexed and run immediately on the flow cytometer. 
Negative control samples were used to identify granulocytes on a FS/SS plot.  PMT voltages 
were adjusted so that this granulocyte population fell within the first log decade on the 
FITC/PI dot plot and to set the location of quadrant gates.  Annexin and PI tubes were then 
used to set compensation boundaries, prior to processing the Annexin+PI test sample.  
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Figure 2.10  Annexin-V/PI apoptosis assay analysis. 
(A) Negative control sample loaded and isolated granulocytes identified by fs/ss (B) FITC/PI PMT voltage 
adjusted so that population falls within 1 log decade for each.  Quadrants plotted to encompass 90% of 
neutrophil population, with 5% FITC positive and 5% PI positive (C) PI control loaded and compensation 
applied as described above (D) Annexin-FITC control loaded and compensation applied as described above 
(E) The Annexin-FITC and PI test sample was loaded and proportion of neutrophils within each quadrant 
recorded. 
 
2.6.10 2-NBDG Glucose uptake assay 
The fluorescent glucose analog 2-NBDG [CAS 186689-07-6] may be used to monitor 
glucose uptake in living cells (Yamada et al., 2007; Yoshioka et al., 1996).  Stock 10mg/ml 
was made by dissolving crystalline solid in DMSO, and stored at -20oC.  Isolated neutrophils 
were prepared as described above (1x106 cells/ml, PBS both with, and without glucose 
10mmol/L), and incubated with 2NBDG at 1, 10 and 100μM for 15 minutes at 37oC in a 
water bath.  Samples were then placed on ice and washed with ice-cold PBS, centrifuged at 
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300g for 5 minutes, washes again then re-suspended in PBS, and then processed 
immediately. 
Figure 2.11 2-NBDG glucose uptake assay. 
 (A) Isolated granulocytes were identified on fs/ss plot (B) Negative control sample loaded and neutrophils 
identified by CD16hi – isotype control not shown.  (C) FITC PMT voltage adjusted so that negative population 
falls within first log decade.  (D) Test sample loaded and neutrophils identified by fs/ss then CD16hi. (E) 2-
NBDG FITC fluorescence noted (F) Overlay plot of negative control and 2-NBDG test sample.  A gate was 
created to encompass 95 % of the control population, the proportion of neutrophils falling beyond this gate 
were recorded as positive.  
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2.7 Pharmacological manipulation of neutrophil metabolism 
2.7.1 Mitochondrial respiratory complex inhibitor assays 
To assess whether mitochondrial dysfunction may be responsible for the postoperative 
neutrophil phenotype, preoperative neutrophils were incubated with respiratory complex 
inhibitors and the functional assays described above were repeated. Stock solutions of 
respiratory complex inhibitors rotenone 10mM, antimycin A 10mM and myxothiazol 10mM 
were prepared in 100% ethanol.   
Rotenone inhibits complex I by preventing transfer of electrons from the Fe-S site to 
ubiquinone.  Antimycin A and myoxthiazol both inhibit the Q cycle at complex III, by binding 
to the Qi and Qo sites of cytochrome c reductase, respectively (Thierbach and Reichenbach, 
1981).   
Isolated neutrophils.  1x106 cells/ml isolated neutrophils in PBS containing 10mg/dL of 
sterile glucose were incubated for 30 minutes at 37oC in a water bath with relevant 
respiratory chain inhibiting drugs.  Appropriate functional assays were then performed, as 
described above.  Identical volumes of ethanol were added to control samples.  
HL60 cells. 500x105 cells washed HL60 cells (6day DMSO differentiated and 
undifferentiated) were suspended in 1ml plain RPMI 1640 and incubated for 30 minutes at 
37oC and 5.0 kPa CO2 with respiratory chain inhibiting drugs.  Functional assays were then 
performed as described above.  Identical volumes of ethanol were added to control samples.  
 
2.7.2 Mitochondrial ROS scavenging: MitoTEMPO  
To assess how a reduction of mitochondrial ROS affects neutrophil immune function, 
neutrophils were preincubated with the mitochondrial ROS scavenger MitoTEMPO prior to 
performing functional immune assays.  MitoTEMPO is a commercially available mitochondrial 
ROS scavenger, which consists of the antioxidant piperidine nitroxide conjugated to the 
lipophilic, cationic moiety triphenylphosphonium.  This leads to a 1000-fold concentration 
within mitochondria (Skulachev, 2007).  It may be considered a mitochondrial superoxide 
dismutase mimetic (Dikalov et al., 1997). 
MitoTEMPO was dissolved in DMSO to create a stock solution of 10mM and stored at         
-20oC.  MitoTEMPO has been used at concentrations ranging from 1nM (Liang et al., 2010) 
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to 5μM (Liu et al., 2010), and demonstrated to reduce mitochondria ROS, measured using 
MitoSOX Red.  
Six-day DMSO differentiated and undifferentiated HL60 cells were washed and prepared at a 
concentration of 3x105/ml in RMPI 1640 + L glutamine without added fetal calf serum.  
HL60 cells were then incubated with MitoTEMPO 100nM or 500nM for 1 hour at 37oC in 
CO2 5.0 kPa, prior to performing functional assays described previously.  Control samples 
contained an equivalent amount of DMSO. 
 
2.7.3 Pyruvate kinase M2 activation: DASA 
A cell permeable substituted N,N’ diarylsulphonamide (NCGC00181061; DASA) was used 
to selectively activate the M2 isoform of pyruvate kinase (PKM2).  PKM2 is the only isoform 
of pyruvate kinase which demonstrates oxidative inhibition.  Briefly, oxidation of cysteine 
residues at the active site of PKM2 leads to a change in the macrocomplex structure, with 
active tetramers dissociating to inactive dimers.  Pre-treatment of lung cancer cells with 
20μM DASA prevents inhibition of PKM2 induced by hydrogen peroxide, diamide and 
hypoxia (Anastasiou et al., 2012; Boxer et al., 2010). 
50 mg/ml DASA stock solution was made by dissolving DMSO and aliquots stored at -20oC.  
Neutrophil function assays were then performed in the presence of DASA, with equivalent 
amount of DMSO added to control samples. 10μM and 100μM DASA was added both 
immediately before functional assays, and incubated with neutrophils for 30minutes at 37oC 
in water bath.  These experiments were repeated in isolated neutrophils and HL60 cells.   
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2.8 Reactive oxygen species time course experiments 
To assess the temporal impact of mitochondrial inhibitors upon neutrophil baseline function 
and respiratory burst, the experiments described in section 2.8.1 were repeated with the 
samples loaded onto a 96-well plate and recordings made at 10-minute intervals for 1 hour 
using a monochromatic plate reader (Synergy MX microplate reader).   
 
 
2.8.1 Synergy MX Monochromator-based Multi-Mode Microplate Reader 
Microplate readers allow experiments to be set up on a multi-well plate, with 96 conditions, 
and absorbance/fluorescence intensity or luminescence measured for each condition at 
specified time points. 
Features include: 
- Four slits on excitation and emission permit upto 16 bandpass combinations for each 
wavelength pair 
- Accurate temperature control (±0.5oC at 37oC) 
- Fluorescence (top and bottom), absorbance and luminescence detection systems. 
 
• Absorbance – sample illuminated by a specific wavelength of light, selected by placing a 
monochromator in front of a light source, and a light detector on the other side of the 
sample records how much light passes through the sample.  
• Fluorescence – a specific wavelength of light, selected by a monochromator, excites 
the sample, causing light to be emitted at a different that is detected by a 
photomultiplier tube.   
• Luminescence – produced through a chemical or biochemical reaction.  Unlike 
fluorescence no light source is required. 
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2.8.2 Neutrophil ROS time course protocol: dihydroethidium (DHE) 
Human neutrophils were isolated and prepared from a single preoperative patient as 
described before, at a concentration of 2x106 per ml in PBS with 10mg/dL glucose.  The 
ROS probe dihydroethidium (DHE) was selected to confirm and extend previous findings 
with the ROS probe DHR.  DHE crystalline solid was dissolved in DMSO to create 10mM 
stock. The same doses of myxothiazol were chosen as for the flow cytometry respiratory 
burst experiments.  A fluorescence protocol was created, with excitation 530/25 nm, 
fluorescence detection 620/15nm, sensitivity set to 65, temperature 37.0oC and reading 
every 10 minutes. 
A 96-well plate was placed on ice.  Experimental conditions were negative, control, 
myxothiazol 1μM, myxothiazol 10μM, these were repeated with 1μM PMA.  195µL 
neutrophil suspension were placed in each well.  All conditions except negative had DHE 
added to a final concentration of 5μM.  Appropriate volumes of DMSO and ethanol were 
added to unstimulated and control wells as appropriate.  All experimental conditions were 
repeated in triplicate. The 96-well plate was inserted into the platereader, and the 
protocol started.  
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2.9 Bone marrow response to surgery 
Having established the effects of major elective surgery upon circulating neutrophils, the 
effects of anaesthesia and surgery upon the respiratory burst of murine bone marrow 
neutrophils were assessed. Bone marrow samples were prepared by Gareth Ackland. Cells 
were processed by density centrifugation prior to seeding, providing >90% purity.  The 
Seahorse XF24 (Seahorse, North Billerica, MA, USA) measures cellular oxygen consumption 
and acid production, and in combination with specific metabolic inhibitors, may quantify the 
rate of oxidative phosphorylation and glycolysis.  The magnitude of the respiratory burst 
may also be estimated by recording oxygen consumption in the presence of an activator, 
such as PMA.  
 
2.9.1 The Seahorse XF24 microplate respirometer 
The Seahorse permits the interrogation of whole cell mitochondrial and glycolytic function, 
through measurement of oxygen consumption and extracellular H+ through 
timed/programmed administration of specific metabolic inhibitors.  
The Seahorse utilises a 24-well culture plate into which samples are loaded.  A separate 
disposable sensor cartridge mirrors the 24-well plate structure.  It contains oxygen and pH 
sensors and four injection ports for metabolic inhibitors/substrates on a moveable platform.  
The sensor cartridge is placed on top of the culture plate and loaded into the respirometer.  
Samples are warmed to 37.0oC, and a series of measurement cycles performed.  During 
each 2-minute measurement cycle the moveable platform lowers down, partially isolating 
each well below the measurement sensors and injection ports, thereby limiting, but not 
completely preventing, O2 and CO2 exchange.   Baseline data are obtained during 3 
measurement cycles, then the loaded metabolic inhibitors are hydraulically injected in a 
sequential manner and changes to the oxygen plus pH profile recorded over further 
measurement steps.   
The O2 and pH sensors are embedded within a polymeric substrate that selectively permits 
the diffusion of O2 and H
+ ions to the fluorescent material.  Monochromatic light emitting 
diode (LED) sources excite the sensor fluorochromes. The oxygen sensor is excited by a 
530nm LED source, and maximally emits at 650nm, while pH sensor is excited by a 470nm 
source and maximally emits at 530nm.  Fluorescence is affected by temperature, therefore 
98 
 
temperature control wells, which contain cell free medium, must be included within the 
plate.  A calibration protocol is run before each assay, using calibration solution provided by 
the manufacturer. 
Oxygen acts to quench the sensor fluorescence.  A mathematical model that relates 
fluorescence at 0mmHg O2 (maximal) to the recorded fluorescence is used to calculate the 
partial pressure of oxygen in the sample.  Oxygen readings are made every 12 seconds 
during the measurement cycles, permitting calculation of the oxygen consumption rate 
(OCR).  Several replicates are used for each experimental condition to create a mean OCR.  
OCR accuracy is typically <30pmole/min, therefore optimisation assays were performed 
with different concentrations of neutrophils and a concentration of 1.5x106 cells/600µL was 
chosen.  Acceptable inter-well variability was considered to be a coefficient of variation of 
<20%.  Measurement of extracellular pH works on a similar principle, only using a 
fluorescent probe which is quenched by H+.  The Seahorse medium is unbuffered, therefore 
seeded plates must be stored within an air incubator. 
Cells must remain adherent to the plate base so that they are not washed away with 
medium changes and mixing procedures.  Plates are therefore coated with Cell-Tak (BD 
Biosciences, Bedford, MA, USA), which is a non-immunogenic polyphenolic compound 
commonly used to immobilise tissues and cells.  It has been successfully used for 
lymphocytes (Edwards et al., 2015). Cell-Tak is reconstituted into a neutral pH solution that 
leads to precipitation and adsorption onto the polystyrene plastic well wall.  
 
2.9.2 Experimental protocol 
Murine bone marrow neutrophils were isolated by Gareth Ackland.  Male C57 black mice 
(age 8-12 week; weight 20-25g) were selected.  Animals were housed with food and water 
available ad libitum in the specific pathogen-free central animal facilities at University College 
London Medical School (London, UK).  All experimental protocols were reviewed and 
approved by the UCL Institutional Animal Care and Use Committee and carried out in 
accordance with UK Animals (Scientific Procedures) Act, 1986 and ARRIVE guidelines 
(Animal Research: Reporting of In Vivo Experiments) (Kilkenny et al., 2013) 
Six test mice underwent midline laparotomy under isoflurane anaesthesia (oxygen 
flowmeter 1L/min; isoflurane 3.5% for induction and1.5% for maintenance) for 30 minutes.  
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Topical bupivacaine was administered for analgesia, and a core temperature of 36.9oC 
maintained through a closed loop heating mat/rectal temperature probe system.  Six control 
non-operated animals were caged in the same surgical environment.    Twelve hours before 
the assay run the sensor cartridge was hydrated in Seahorse calibration medium at 37oC in 
the air incubator.  An assay plate was prepared with 5µL Cell-Tak /cm2, which was left for 
45 minutes then aspirated and the wells washed twice with sterile distilled water and left to 
dry in a sterile hood.  Mice were systemically heparinised then culled 1 day after surgery and 
bone marrow was extracted following cervical dislocation.  Bone marrow neutrophils were 
isolated using Ly-6G microbeads, as described above, counted with trypan blue then re-
suspended in Seahorse assay medium, with 1.5x106 cells per 100µL added to each Cell-Tak 
coated well.  All experiments were performed in triplicate.  Neutrophils were allowed to 
adhere to Cell-Tak in the air incubator at 37oC, after 30 minutes a further 500µL of assay 
medium was carefully added to each well and returned to the air incubator for 1 hour.  
PMA (final concentration 1μM) was added to the first channel of each sensor plate well, 
then the sensor plate was inserted in the Seahorse XF and the calibration protocol started.  
Next, assay medium was changed to remove any residual buffer and metabolites from 
extracellular medium.  The protocol was run so that baseline oxygen consumption was 
measured for 20 minutes prior to addition of PMA.   
For these data to be accurate it is vital that the correct number of cells is placed, and 
remains, within each well.  Therefore, at the start of the experiment seeded wells were 
examined under the microscope to ensure neutrophils were evenly distributed.  At the end 
of the assay the cell plate was examined under a light microscope to check whether 
neutrophils had become detached.  Automated fluorescence microscopy was used to 
confirm cell counts at the end of the experiment.  A selection of plates were stained with 
Hoeschst 3342, images acquired with the Zeiss Cell Observer imaging system and counted 
using Velocity 5.0 software.    
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2.10 Extracellular lactate and glucose measurement. 
The effect of mitochondrial respiratory complex inhibitors and stimulation of pyruvate 
kinase M2 upon extracellular lactate and glucose was measured the Radiometer ABL 800 
Flex blood gas analyser. using a blood gas analyser. 
 
2.10.1 The Radiometer ABL 800 Flex   
Provides measurement of pH, blood gas tensions, electrolytes, metabolites and oximetry.   
- Automated sample processing reduces likelihood of measurement errors.   
- A three-layer membrane over the glucose and lactate sensors provides protection 
against interference.   
- Measurement of capillary tube samples up to 35µL volume. 
- 128 wavelengths f(478-672nm) for Co-Oximetry 
 
2.10.2 Experimental protocol 
Heparinised whole blood was obtained from five preoperative patients as described above.  
Samples were prepared in 4x4 plates that were placed on ice.  The same drug 
concentrations were used as in previous whole blood experiments.  Experimental 
conditions were control, DASA 100μM and Myxothiazol 10μM, with each repeated in the 
presence of PMA 1μM.  Appropriate volumes of DMSO, ethanol and PBS were added to 
necessary conditions to ensure volumes and conditions were equal throughout.   
Incubations were performed for 30 minutes at 37oC, pCO2 5.0.  Samples were then placed 
on ice, and processed in the blood gas analyser. 
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Chapter 3 – Establishing a clinical translational model for 
sepsis 
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3.1 Introduction 
The study of human sepsis presents fundamental challenges to the design of translational 
immunological investigations.  These begin with the very definition of sepsis, which 
incorporates a number of non-specific bed side parameters and the clinical suspicion of  
probable infection (Dellinger et al., 2013).   The results from microbiological investigations 
may not be available for several days, are often negative and even when positive do not 
confirm causation nor permit quantitative extrapolation of the infective dose.   
The identification of a suitable control population presents the second key challenge.  The 
outcome of case control studies may be affected by a range of confounding factors, which 
include age (Henriksen et al., 2015, Montecino-Rodriguez et al., 2013; Valente et al., 2009), 
gender (McGowan et al., 1975; Offner et al., 1999), comorbid disease (Henriksen et al., 
2015; Snyder and Greenberg, 2010, Fildes et al., 2009) and therapeutic interventions 
(Kalghatgi et al., 2013 Mikawa et al., 1998; Kanoh and Rubin, 2010, (Clarke et al., 1993 )  
Cohort study designs are methodologically superior to case-control studies because study 
samples maybe compared to individualised pre-illness controls, rather than a separate 
control population.  However, the technologies used are expensive and time consuming, 
therefore it is not practical for small laboratories to follow healthy patients and await the 
development of sepsis.    
The precise time at which sepsis begins cannot be known, which makes temporal 
descriptions of the subsequent dynamic inflammatory processes difficult.  While healthy 
volunteer endotoxin/cytokine models do permit cohort design, they cannot reproduce the 
severity of critical illness present within the ICU (Andreasen et al., 2008).   
The use of major elective surgery as a translational model of human sepsis may overcome 
many of these methodological challenges.  Cohort investigations are feasible because surgery 
happens at a planned time, permitting the acquisition of individualised pre-insult controls 
samples at specific post-insult time points.  Surgical patients are subject to standardised 
preoperative assessment protocols (Stringer, 2010), which defines the study group with 
superior accuracy and facilitates the investigation of specific immunologically relevant 
preoperative disease.   
While microbiological investigations permit the identification of possible infections, they 
provide little information about the quantity or severity of infection – it remains unclear to 
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what extent sepsis is a product of infective burden and/or an inappropriate host response.  
By contrast, the ‘dose’ of surgery is more homogenous, and maybe controlled further by 
recruiting patients who have similar procedures performed by the same operative teams.  
This surgical model of sepsis is biologically relevant because – as explored within chapter 1 - 
human responses to infection and trauma are highly conserved at molecular (Matzinger, 
1994; Nathan, 2006), genomic (Haimovich et al., 2014; Xiao et al., 2011) and clinical 
(Matzinger, 1994; Seong and Matzinger, 2004) levels. 
This chapter will establish whether the theoretical methodological advantages of studying 
surgical patients are realised within the translational immunological literature.  A preliminary 
PubMed search determined that the most frequently investigated functional assay for the 
principal circulating immune cells was neutrophil respiratory burst, monocyte endotoxin 
tolerance and lymphocyte apoptosis.  The experimental design of these three topics was 
then compared across sepsis, trauma and elective surgery patients.   
 
3.1.1 Hypothesis 
Translational immunological investigations in elective surgery patients are methodologically 
superior to those in septic and trauma patients, since they facilitate the use of cohort study 
design and carefully timed sampling from a precisely defined study population. 
 
3.1.2 Aims 
To survey the sepsis, trauma and surgical  
human immune literature to establish:  
i. Use of cohort or case control study design 
ii. Differences between study and control group age, ethnicity, sex, comorbid disease 
and therapeutic interventions 
iii. The timing of patient sampling in relation to the inflammatory insult 
iv. Variations in the criteria used to define sepsis. 
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3.2 Methods 
PubMed, PubMed Central and Embase databases were searched for the terms “Neutrophil 
respiratory burst” OR “Monocyte endotoxin tolerance” OR “Lymphocyte apoptosis” AND 
“Sepsis” OR “Trauma” OR “Surgery”, restricted to adult human studies published between 
01/03/1998 and 01/03/2013.  The abstract of each paper was manually assessed for 
suitability. Healthy volunteer in-vitro investigations were excluded.  Clinical and laboratory 
data collected are detailed below 
 
Category Data collected 
Demographics Age, gender, ethnicity, severity, control population, number 
of patients, a priori power analysis. 
Control population Source (Healthy volunteer/cohort/other patient 
population), number. 
Purpose of study Experimental context (Clinical outcome, experimental, 
pathophysiological, biomarker comparison) 
Timing of sampling Sample trigger (hospital admission, ICU admission, onset 
sepsis, onset of organ failure), time window for sampling, 
number and timing of subsequent samples. 
Clinical severity Scoring system used, average score and range. 
Microbiology Microbiology results reported, independent adjudication of 
sepsis diagnosis, definition of sepsis used. 
Exclusion criteria Malignancy, immunosuppressive illness. 
Drug therapy Sedation, antibiotics, steroids. 
Primary conclusion  
of study 
Summary of study findings. 
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3.2.1 Statistics 
Data are presented as mean±SD, or median (interquartile range), as appropriate.   95% 
confidence intervals were constructed from age data, and used to compare control and 
study population age.  
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3.3 Results 
57 eligible studies were identified and are summarized in Figure 3.1.  
3.3.1 Literature search and study selection  
 
Figure 3.1 Flow diagram of study selection process for literature review.    
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3.3.2 Data tables 
Author (Year) 
 
Study population Subjects  
(n) 
Control 
population 
Control 
(n) 
Experimental context Outcome 
measure 
correlated with 
immune 
readout 
(Santos et al., 
2012) 
Sepsis 49 Healthy 
volunteer 
19 Clinical outcome Yes 
(Paunel-Görgülü 
et al., 2011) 
Trauma 7 Healthy 
volunteer 
6 Experimental No 
(Bruns et al., 
2011) 
Sepsis (cirrhotics) 45 Healthy 
volunteer and 
cohort 
9 and 39 Pathophysiological No 
(Shih et al., 
2010) 
Trauma 32 Healthy 
volunteer 
Not 
provided 
Biomarker comparison Yes 
(Kasten et al., 
2010) 
Trauma 3 Healthy 
volunteer 
3 Pathophysiological No 
(Valente et al., 
2009) 
Trauma 24 Healthy 
volunteer 
11 Pathophysiological No 
(Kawasaki et al., 
2007) 
Elective surgery 20 (10,10) Cohort 20 Pathophysiological No 
(Fröhlich et al., 
2006) 
Elective surgery 20 Cohort 20 Experimental No 
(Martins et al., 
2003) 
Sepsis 16 Healthy 
volunteer 
16 Pathophysiological Yes 
(Barth et al., 
2002) 
Sepsis 27 Healthy 
volunteer 
11 Biomarker comparison No 
(Mariano et al., 
2001) 
Sepsis (renal 
replacement 
therapy) 
7 Haemodialysis 
patients. 
10 Pathophysiological No 
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(Quaid et al., 
2001) 
Trauma 7 Healthy 
volunteer 
Not 
provided 
Pathophysiological No 
(Wiezer et al., 
2000) 
Elective surgery 22 (6,6,10) Cohort 22 Pathophysiological / 
experimental 
Yes 
(Ahmed et al., 
1999) 
Sepsis 32 Healthy 
volunteer 
17 Pathophysiological No 
(Shih et al., 
1999) 
Trauma / Surgery 18 Cohort and 
healthy 
volunteer 
18 Pathophysiological No 
(Ertel et al., 
1999) 
Trauma 10 (5,5) Elective Surgery 10 Pathophysiological No 
(Ogura et al., 
1999) 
Trauma 24 (7 
infected) 
Cohort and 
healthy 
volunteer 
24 and 15 Pathophysiological Yes 
(Pascual et al., 
1998) 
Sepsis 23 Elective surgery 23 Pathophysiological / 
experimental 
No 
 
Table 3.1 Principal features of neutrophil respiratory burst studies 
Subjects: Values within brackets refer to number of sub-populations of study patients (e.g. different anaesthetic technique, presence of infection etc), used within the 
study 
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Authors 
(Year) 
Age Gender (%male) 
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 d
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Severity of subject disease 
 
Subject drug 
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documentation 
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N
o
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G
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S
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A
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S
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s 
(Santos et 
al., 2012) 
60 
±17 
55.3 
±18 
N 57 53 N N APACHE II 17 (4-30) 3 N N N 
(Paunel-
Görgülü 
et al., 
2011) 
46 
±4 
33±
2 
N* 
(p<0.001) 
74 59 N N Mortality 9% 1 N N N 
(Bruns et 
al., 2011) 
58 
(40
-
80) 
45 
(37-
82); 
58 
(?) 
0.437 82 73/ 48 0.341 N - 
 
1 N N N 
(Shih et 
al., 2010) 
33 
±14 
? N 66 ? N N ISS 23 2 N N N 
(Kasten et 
al., 2010) 
36 
±2 
38 
±2 
p>0.05 100 100 p>0.05 N ISS 23 1 N N N 
(Valente 
et al., 
2009) 
75 >65 N 46 ? N N ISS 15.00 1 N N N 
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(Kawasaki 
et al., 
2007) 
52 
±4 
54±
4 
N/A N 70 70 p>0.05 N ASA I - II 2 Y N N 
(Fröhlich 
et al., 
2006) 
66 
±10 
69 
±6 
N/A N 40 20 N N ASA I 2 Y 
t 
Y 
t 
Y 
t 
(Martins 
et al., 
2003) 
50±
21 
31 
±6 
N* 
(p=0.0011) 
? ? N N Mortality 38% 2 N N N 
(Barth et 
al., 2002) 
N/S 
(36
-
82) 
24 
(22-
50) 
N 60 36 N N Mortality 37% 1 N N N 
(Mariano 
et al., 
2001) 
67 
±4 
? N ? ? N N - 
 
1 N N N 
(Quaid et 
al., 2001) 
37 
(20
-
71) 
? N ? ? N N ISS 24 
(17-34) 
 N N N 
(Wiezer 
et al., 
2000) 
57±
3 
62±
2 
58±
5 
? N 83, 
66, 70 
 
N N APACHE III Graphs 
(No 
difference) 
3 N N N 
(Ahmed et 
al., 1999) 
55 
±6 
36 
±16 
N* 
(p<0.0001) 
46 ? N N APACHE II 20 ±1 1 N N N 
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(Shih et 
al., 1999) 
42±
19 
N/S N 55 ? N N ISS 26 ±7.2 3 N N N 
(Ertel et 
al., 1999) 
N/S ? N ? ? N N AIS Head 4.5 
±0.2, 
Chest  4.1 
±0.1 
1 N N N 
(Ogura et 
al., 1999) 
40±
19 
35 
±6 
N 75 ? N N ISS 31 ±10 2 N N N 
(Pascual et 
al., 1998) 
59 
(27
-
81) 
45 
(27-
81) 
p>0.05 51 43 N N Mortality 21% 1 N N Y 
t 
Table 3.2 Demographic information of neutrophil respiratory burst studies.     
Age – N/S – not summarised (tabulated data for every patient provided), ?-not provided within the manuscript, N/A – not applicable Statistical test result – N=not 
reported. N*=not reported but significant p value identified from the original manuscript data.  Severity of subject disease. The average clinical severity score of subjects 
with an index of listed in brackets. The number of severity groups which subjects were divided into is listed.  ISS/AIS= Injury Severity Score/Abbreviated Injury Severity 
Score (Baker et al. 1974); ASA = American Society of Anesthesiologists Physical Status Classification System (ASA 2014); APACHE II= Acute Physiology and Chronic 
Health Evaluation II (Knaus et al. 1985), APACHE III = Acute Physiology and Chronic Health Evaluation III (Knaus et al. 1991).  Subject drug use detailed – whether 
patient exposure to known immunomodulating drugs was documented.  A ‘t’ signifies that the timing of the drug administration in relation to blood sampling was clear 
from the study methodology. 
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(Santos et 
al., 2012) 
Sepsis 72hrs (Dx sepsis); 
48hrs (organ 
failure); onset of 
septic shock 
2  
(7days) 
1 A,B,C N N Y Y 
(Paunel-
Görgülü 
et al., 
2011) 
Trauma  24hrs (Hosp 
Adm) 
1 2 A,B,C N N Y N 
(Bruns et 
al., 2011) 
Sepsis 
(cirrhotics)  
24hrs (Hosp 
Adm) 
1 5 Y N Y N 
(Shih et 
al., 2010)  
Trauma  24hrs (Hosp 
Adm) 
2  
(3 days) 
N N N Y Y 
(Kasten et 
al., 2010)  
Trauma  48-72hrs (Post-
trauma) 
1 N N N Y N 
(Valente 
et al., 
2009) 
Trauma  48hrs (Hosp adm) 3  
(5 days) 
N N N Y N 
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(Kawasaki 
et al., 
2007) 
Elective 
surgery  
Pre-insult 5  
(4 days) 
N N N Y N 
(Fröhlich 
et al., 
2006) 
Elective 
surgery  
Pre-insult 2 (end of 
anaesth) 
N n/a n/a Y Y 
(Martins 
et al., 
2003) 
Sepsis  48hrs (ICU adm) 1 1 B,C Y N Y Y 
(Barth et 
al., 2002) 
Sepsis  ? 6  
(5 days) 
1 C 
(>4d) 
Y N N N 
(Mariano 
et al., 
2001) 
Sepsis 
(renal 
replacemen
t therapy) 
? 4  
(1 day) 
1 B,D N N N N 
(Quaid et 
al., 2001) 
Trauma  24hrs (Hosp adm) 1 N N N N N 
(Wiezer 
et al., 
2000) 
Elective 
surgery 
Pre-insult 5 
(7 days) 
“clinical 
criteria
” 
N N Y N 
(Ahmed et 
al., 1999) 
Sepsis 72hrs (Proof of 
infection) 
1 1 A,B Y Y Y Y 
(Shih et 
al., 1999) 
Trauma / 
Surgery 
24hrs (Hosp adm) 3+  
(7 days) 
1 A,B,C N N Y Y 
(Ertel et 
al., 1999) 
Trauma  24hrs (Hosp adm)  2  
(3 days) 
N N N Y N 
(Ogura et 
al., 1999) 
Trauma  24hrs (Post 
trauma) 
4+1 (21 
days) 
2 
A B C 
Y N N N 
(Pascual et 
al., 1998) 
Sepsis 24hrs 
(ICU adm) 
1 1 
A C 
Y N N N 
Table 3.3 Experimental conduct and exclusion criteria of neutrophil respiratory burst studies. 
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Sample Timing. Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the 
subject? How many samples were taken for each subject in total and over what time span? 
Sepsis criteria. The criteria used to enrol subjects into the study.  Where subgroups of these criteria were used (e.g. septic shock) these are detailed.  0=not stated 1= 
ACCP/SCCM 1992 Consensus Conference(Bone et al., 1992), 2=ACCP/SCCM Consensus Conference 2001(Levy et al., 2003), 3=SSC Consensus Conference 
2008(Dellinger et al., 2008), 4=CDC NNIC(“CDC definitions for nosocomial infections, 1988.,” 1989), 5=Microbiology and clinical assessment, 6=Postmortem 
identification of infection, N=infection not considered, ?=criteria not described.  Sepsis severity groups enrolled:  A=sepsis, B=severe sepsis, C=septic shock, D=acute 
renal failure E=SIRS 
Microbiology documentation - Were causative organisms isolated and identified?  Were additional steps taken to define whether subject had sepsis beyond the initial 
clinical diagnosis i.e. retrospective review of case considering subsequent information?   
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
Author/Year Study 
population 
Subjec
ts (n) 
Control 
population 
Control
s (n) 
Experimental context Outcome measure 
correlated with 
immune readout 
(Liu et al., 2011) Sepsis 2 Healthy volunteer 2 Experimental No 
(Buttenschoen et al., 
2009) 
Elective surgery 20 Cohort 20 Pathophysiological No 
(Pachot et al., 2008) Sepsis 47 Healthy volunteer 21 Pathophysiological Yes 
(West et al., 2007) Sepsis 7 Healthy 
volunteer, elective 
surgery and SIRS 
16, 5 and 
4 
Pathophysiological No 
(Härter et al., 2004) Sepsis 21 Healthy volunteer 12 Pathophysiological No 
(Flohé et al., 2004) Surgery in 
trauma patients 
16 Healthy volunteer 12 Pathophysiological No 
(Arnalich et al., 2003) Sepsis 3(5) Healthy volunteer 3 Pathophysiological No 
(Heagy et al., 2003) ICU patients 
(sepsis) 
62 Healthy volunteer 15 Clinical outcome Yes 
(Calvano et al., 2003) Sepsis 18 (10) Healthy volunteer 15 (6) Pathophysiological No 
(Sfeir et al., 2001) Sepsis 10 Healthy volunteer 10 Pathophysiological No 
(Kawasaki et al., 2001) Elective surgery 20 Cohort 20 Pathophysiological No 
(Heagy et al., 2000) Sepsis 58 Healthy volunteer 14 Clinical outcome Yes 
(Bergmann et al., 
1999) 
Sepsis 30 (2) Healthy volunteer 12 Pathophysiological No 
Table 3.4 Principal features of monocyte tolerance studies    
Subjects: Values within brackets refer to number of sub-populations of study patients (e.g. different anaesthetic technique, presence of infection etc), used within the 
study 
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Authors 
(Year) 
Age Gender 
(%male) 
S
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t 
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y
 
Severity of subject 
disease 
 
Subject drug 
exposure 
documentation 
 
S
u
b
je
c
ts
 
 
C
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n
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o
ls
 
S
ta
ti
st
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a
l 
te
st
 r
e
su
lt
 
S
u
b
je
c
ts
 
C
o
n
tr
o
ls
 
S
ta
ti
st
ic
a
l 
te
st
 
re
su
lt
 
In
d
e
x
 
S
c
o
re
 
N
o
. 
G
ro
u
p
s 
S
e
d
a
ti
v
e
s 
A
n
ti
b
io
ti
c
s 
S
te
ro
id
s 
(Liu et 
al., 2011) 
? ? N ? ? N N ? ? 1 N N N 
(Buttensc
hoen et 
al., 2009) 
56 (33-88) N/A N 70 N/A N N ? ? n/a N N N 
(Pachot 
et al., 
2008) 
68 (54-76) 51 (42-65) N 62 52 N N SAPS II 51 
(±5) 
2 N N N 
(West et 
al., 2007) 
N/S N/S N 42 100; 20; 
56 
N N ? ? 2 N N N 
(Härter 
et al., 
2004) 
48 ±20 "comparable" N 71 12 N N APACHE 
II 
13±6 1 N N N 
(Flohé et 
al., 2004) 
47±18 37±14 N 68 50 N N ISS 39±9 1 N N N 
(Arnalich 
et al., 
2003) 
51±12 49±12 N ? ? N N ? ? 1 N 
 
 
N N 
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(Heagy et 
al., 2003) 
49±3; 44±8 ? N ? ? N N Mortality 20%, 
9.6% 
2 N N N 
(Calvano 
et al., 
2003) 
60; 61 58 N 66; 66 66 N N ? ? 2 N N Y 
t 
(Sfeir et 
al., 2001) 
63±3 50±7 N*(p<0
.0001) 
80 50 N N APACHE 
II 
27±5 1 N N N 
(Kawasak
i et al., 
2001) 
? N/A N ? N/A N N ASA I-II 1 N N N 
(Heagy et 
al., 2000) 
49±21 ? N 66 ? N N ? ? 4 N N N 
(Bergman
n et al., 
1999) 
60; 51 32 N ? ? N N MODS 15±1, 
7±1 
2 N N N 
Table 3.5 Demographic information of monocyte tolerance studies  
Age – N/S – not summarised (tabulated data for every patient provided), ?-not provided within the manuscript, N/A – not applicable Statistical test result – N=not 
reported. N*=not reported but significant p value identified from the original manuscript data. Severity of subject disease. The average clinical severity score of subjects 
with an index of listed in brackets. The number of severity groups which subjects were divided into is listed.  ISS/AIS= Injury Severity Score/Abbreviated Injury Severity 
Score(Baker et al., 1974); ASA = American Society of Anesthesiologists Physical Status Classification System (ASA, 2014);  APACHE II= Acute Physiology and Chronic 
Health Evaluation II (Knaus et al., 1985), APACHE III = Acute Physiology and Chronic Health Evaluation III (Knaus et al., 1991)(REF). 
Subject drug use detailed – whether patient exposure to known immunomodulating drugs was documented.  A ‘t’ signifies that the timing of the drug administration in 
relation to blood sampling was clear from the study methodology. 
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populatio
n 
Sample timing 
D
e
fi
n
it
io
n
 o
f 
se
p
si
s 
M
ic
ro
b
io
lo
g
y
 r
e
su
lt
s 
p
ro
v
id
e
d
. 
In
d
e
p
e
n
d
e
n
t 
a
d
ju
d
ic
a
ti
o
n
 o
f 
se
p
si
s 
d
ia
g
n
o
si
s 
E
x
c
lu
si
o
n
 c
ri
te
ri
a
 
im
m
u
n
o
su
p
p
re
ss
iv
e
 
d
is
e
a
se
 
E
x
c
lu
si
o
n
 c
ri
te
ri
a
 
m
a
li
g
n
a
n
c
y
 
 
T
im
e
 o
f 
fi
rs
t 
sa
m
p
le
 
N
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S
a
m
p
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s 
(t
im
e
sp
a
n
) 
(Liu et 
al., 2011) 
Sepsis ? 1 ? 
B C 
N N N N 
(Buttensc
hoen et 
al., 2009) 
Elective 
surgery 
Pre-insult 4 
(2days) 
N N N Y N 
(Pachot 
et al., 
2008) 
Sepsis 72hrs (onset 
sep shock) 
2 1 C Y Y N N 
(West et 
al., 2007) 
Sepsis 24hrs (ICU 
adm) 
1 1 A, E Y N N N 
(Härter 
et al., 
2004) 
Sepsis ? 1 1 A B C Y Y N N 
(Flohé et 
al., 2004) 
Surgery in 
trauma 
patients 
48hrs (ICU 
adm) 
Mon, 
Thu. 
1 A B C Y N Y Y 
(Arnalich 
et al., 
2003) 
Sepsis 48hrs (onset 
sepsis) 
1 1 A Y Y Y Y 
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(Heagy et 
al., 2003) 
ICU 
patients 
(sepsis) 
72hrs (ICU 
adm) 
1 5 N Y N N 
(Calvano 
et al., 
2003) 
Sepsis ? 1 1 E A Y N N N 
(Sfeir et 
al., 2001) 
Sepsis 24 
(Sep Shock) 
1 1 C Y Y Y N 
(Kawasak
i et al., 
2001) 
Elective 
surgery 
Pre-ins 7 
(7days) 
N N N Y N 
(Heagy et 
al., 2000) 
Sepsis 72hrs 
(ICU adm) 
1 5 Y Y N N 
(Bergman
n et al., 
1999) 
Sepsis ? 
 
1 B C N N N N 
Table 3.6 Experimental conduct and exclusion criteria of monocyte tolerance studies 
Sample Timing. Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the 
subject? How many samples were taken for each subject in total and over what time span?     Sepsis criteria. The criteria used to enrol subjects into the study.  Where 
subgroups of these criteria were used (e.g. septic shock) these are detailed.  0=not stated 1= ACCP/SCCM 1992 Consensus Conference(Bone et al., 1992), 
2=ACCP/SCCM Consensus Conference 2001(Levy et al., 2003), 3=SSC Consensus Conference 2008(Dellinger et al., 2008), 4=CDC NNIC(“CDC definitions for 
nosocomial infections, 1988.,” 1989), 5=Microbiology and clinical assessment, 6=Postmortem identification of infection, N=infection not considered, ?=criteria not 
described.  Sepsis severity groups enrolled:  A=sepsis, B=severe sepsis, C=septic shock, D=acute renal failure E=SIRS.     Microbiology documentation - Were causative 
organisms isolated and identified?  Were additional steps taken to define whether subject had sepsis beyond the initial clinical diagnosis i.e. retrospective review of case 
considering subsequent information?   
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Author 
(Year) 
Study population Subjects 
(n) 
Control population Controls 
(n) 
Experimental 
context 
Outcome 
measure 
correlated with 
immune readout 
(Roger et al., 
2012) 
Sepsis 48 Healthy volunteer 15 Pathophysiological No 
(Bandyopadhyay 
et al., 2012) 
Trauma 113 Healthy volunteer ? Pathophysiological No 
(White et al., 
2011) 
Sepsis 60 Gram negative infection 
and healthy volunteer 
15 and 20 Pathophysiological Yes 
(White et al., 
2011) 
Elective surgery 
(infective 
complications) 
19 Cohort 41 “ “ 
(Zhang et al., 
2011) 
Sepsis 19 Healthy volunteer 22 Pathophysiological No 
(Guignant et al., 
2011) 
Sepsis 64 Healthy volunteer 49 Pathophysiological No 
(Vaki et al., 
2011) 
Sepsis 
 
48 (68) Healthy volunteer 20 Pathophysiological No 
(Słotwiński et 
al., 2011) 
Elective surgery 50 (26, 24) Cohort 50 Experimental / 
clinical outcome 
No 
(Gogos et al., 
2010) 
Sepsis PN 183, 
CAP 97, IA 
100, PB 61, 
HAP 64 
N/A  Pathophysiological Yes 
(Hoogerwerf et 
al., 2010) 
Sepsis 16 Healthy volunteer 24 Pathophysiological No 
(Yousef et al., 
2010) 
Sepsis 32 SIRS and 
w/o SIRS 
35 / 33 Patient outcome Yes 
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(Turrel-Davin 
et al., 2010) 
Sepsis 13 Healthy volunteer 15 Biomarker 
comparison 
No 
(Pelekanou et 
al., 2009) 
Sepsis VAP 36 Other infections 32 Pathophysiology No 
(Resident et al., 
2009) 
Elective surgery 40 (21, 19) Cohort 40 Pathophysiological No 
(Delogu et al., 
2008) 
Sepsis 16 ? ‘individuals’  Pathophysiological No 
(Weber et al., 
2008) 
Sepsis 16 Non-infected ICU and 
healthy volunteer 
10 and 11 Pathophysiological No 
(Roth et al., 
2003) 
Sepsis 15 Healthy volunteer 20 Pathophysiological No 
(Le Tulzo et al., 
2002) 
Sepsis 47 (25, 23) SIRS and healthy 
volunteer 
7 and 25 Pathophysiological 
/ clinical outcome 
Yes 
(Hotchkiss et 
al., 2001) 
Sepsis 27 (FC 5) 
(3 intraop, 
24 autopsy) 
Critically ill non-septic 
and trauma 
16 and 25 
(FC 6) - 3 
prospective, 
13 
retrospective 
Pathophysiological No 
(Delogu et al., 
2001)  
Elective surgery 18 Cohort 18 Pathophysiological No 
(Pellegrini et al., 
2000) 
Trauma 17 (+13 
burns) 
Healthy volunteer 17 Clinical outcome / 
pathophysiological 
(Correlate to 
MODS) 
(Delogu et al., 
2000) 
Surgical 15 Healthy volunteer 10 Pathophysiological 
/ patient outcome 
Yes 
(Hotchkiss et 
al., 2000) 
Trauma 10 Elective surgery 6 (all 
prospective) 
Pathophysiological No 
(Hotchkiss et 
al., 1999) 
Sepsis 20 Non-septic prospective 
/ non-septic 
retrospective / 
1 / 9 / 6 / 2 / 
8 
Pathophysiological No 
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prospective trauma 
splenectomy / 
prospective colectomy 
/ retrospective 
colectomy. 
(Sasajima et al., 
1999) 
Elective surgery 16 (11, 5) Cohort 16 Pathophysiological No 
(Sugimoto et al., 
1998) 
Elective surgery 10 (5, 5) Cohort 10 Pathophysiological No 
Table 3.7 Principal features of lymphocyte apoptosis studies 
Subjects: Values within brackets refer to number of sub-populations of study patients (e.g. different anaesthetic technique, presence of infection etc), used within the 
study 
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Authors 
(Year) 
Age Gender  
(%male) 
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c
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N
o
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G
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u
p
s 
S
e
d
a
ti
v
e
s 
A
n
ti
b
io
ti
c
s 
S
te
ro
id
s 
(Roger et 
al., 2012) 
63 
(37-
82) 
55 
(37-5) 
0.04 50 43 0.76 N SAPS II 55 (12-92) 2 N Y 
t 
Y 
t 
(Bandyopa
dhyay et 
al., 2012) 
? "matched" N ? "matched" N N APACHE >21 1 N N N 
(White et 
al., 2011) 
54 
(72-
80) 
Bacteraemia: 
73 (70-82) 
>0.05 52 Bacteraemia 
40 
>0.05 Y APACHE 25 (21-28) 2 N N N 
(White et 
al., 2011) 
64±
2 
65±1 0.74 68 70 0.86 N 
  
2 N N N 
(Zhang et 
al., 2011) 
58±
4 
59±4 N 52 50 N N APACHE 
II 
26±3 1 N Y 
t 
Y 
t 
 63 
(54-
73) 
? N 68 N N  SAPS II 53(39-64) 1 N N Y 
t 
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(Guignant 
et al., 
2011) 
(Vaki et al., 
2011) 
71±
2 
? N 54 ? N N APACHE 
II 
20±9 1 
(3) 
N N N 
(Słotwiński 
et al., 
2011) 
62±
9  
63±
9 
- N 5, 50 - N N TNM ? 1 N Y 
t 
N 
(Gogos et 
al., 2010) 
67±
17, 
68±
20, 
54±
25, 
64±
16 
 P<0.00
01 
52, 62, 
57, 67, 
64 
 P=0.01
1 
N APACHE 
II 
12±7, 
16±9, 
13±8, 
18±8, 
20±5 
3 N N N 
(Hoogerw
erf et al., 
2010) 
57±
5, 
66±5 N* 
(p<0.00
01) 
63 50 N N APACHE 
II 
19±2 1 N N N 
(Yousef et 
al., 2010) 
44±
9 
45±9, 44±10 N 59 60, 57 N N SOFA 12 (7-14) 3 
(5) 
N N N 
(Turrel-
Davin et 
al., 2010) 
60±
4 
‘Age matched’ N 63 ‘Sex 
matched’ 
N N SAPS II 51±3 1 N N Y 
(Pelekanou 
et al., 
2009) 
69±
16 
64±20 0.099 64 43 0.300 N APACHE 
II 
18±4, 
15±5 
1 N N Y 
(Resident 
et al., 
2009) 
66±
7,  
 0.8 85, 47 
 
0.54 N ASA I-II 1 Y 
t 
Y 
t 
Y 
t 
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67±
10 
(Delogu et 
al., 2008) 
? ? N ? ? N N ? ? 1 N N N 
(Weber et 
al., 2008) 
 
56±
4 
61±5,? >0.05 68, 80 ? N N SAPS II 26± 2 1 N N Y 
(Roth et 
al., 2003) 
56±
6 
52±14 N 66 "matched" N N APACHE N/S 1 N N N 
(Le Tulzo 
et al., 
2002) 
55±
4, 
64± 
4 
72 ±4, 55± 4 N* 
(p<0.00
01) 
? ? N N SAPS II 33±3, 
58±4 
2 N N N 
(Hotchkiss 
et al., 
2001) 
N/S N/S N 59 56, ? N N - 
 
1 N N Y 
(Delogu et 
al., 2001) 
47±
17 
"matched" N ? "matched" N N ASA I-II 1 Y 
 
N Y 
t 
(Pellegrini 
et al., 
2000) 
44 
(20-
83) 
(18-60) N ? ? N N ISS 25 (9-59) 1 N N N 
(Delogu et 
al., 2000) 
? "matched" N ? "matched" N N ASA I-II 1 N N Y 
t 
(Hotchkiss 
et al., 
2000) 
18-
46 
? N 90 ? N N ISS N/S (9-50) 1 N N N 
(Hotchkiss 
et al., 
1999) 
N/S N/S N 65 ? N N - 
 
1 N N Y 
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(Sasajima 
et al., 
1999) 
62 
(55-
74), 
49(3
7-
58) 
 N  ? N N ? ? 1 N N N 
(Sugimoto 
et al., 
1998) 
N/S 
 
N 50 
 
N N ? ? 1 N N Y 
t 
Table 3.8 Demographic information of lymphocyte apoptosis studies. 
Age – N/S – not summarised (tabulated data for every patient provided), ?-not provided within the manuscript, N/A – not applicable 
Statistical test result – N=not reported. N*=not reported but significant p value identified from the original manuscript data. 
Severity of subject disease. The average clinical severity score of subjects with an index of listed in brackets. The number of severity groups which subjects were divided 
into is listed.  ISS/AIS= Injury Severity Score/Abbreviated Injury Severity Score(Baker et al., 1974); ASA = American Society of Anesthesiologists Physical Status 
Classification System(ASA, 2014);  APACHE II= Acute Physiology and Chronic Health Evaluation II (Knaus et al., 1985), APACHE III = Acute Physiology and Chronic 
Health Evaluation III (Knaus et al., 1991)(REF). 
Subject drug use detailed – whether patient exposure to known immunomodulating drugs was documented.  A ‘t’ signifies that the timing of the drug administration in 
relation to blood sampling was clear from the study methodology. 
 “matched” – paper provided no details but stated the control population was matched to the study population. 
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e
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n
) 
(Roger et al., 
2012) 
Sepsis Before 1st abs 1 3 
B C 
Y Y Y Y 
(Bandyopadhyay 
et al., 2012) 
Trauma ? Every 
4 days (28 days) 
N N N Y N 
(White et al., 
2011) 
Sepsis 24hrs (ICU 
adm/positive 
BC) 
2 
(7 days) 
1 
B C 
N Y Y N 
(White et al., 
2011) 
Elective 
surgery 
(infective 
complica
tions) 
Pre-insult 3 
(5 days) 
4 N Y Y N 
(Zhang et al., 
2011) 
Sepsis 24hrs (sep 
shock) 
1 1 
C 
N N Y N 
(Guignant et al., 
2011) 
Sepsis 48hrs (sep 
shock) 
3 
(10 days) 
1 
C 
Y Y N Y 
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(Vaki et al., 
2011) 
Sepsis 
 
12hrs (organ 
failure) 
 2 
B C 
Y Y Y N 
(Słotwiński et 
al., 2011) 
Elective 
surgery 
Pre-insult 4 
(7 days) 
N N N Y N 
(Gogos et al., 
2010) 
Sepsis 24hrs (signs of 
sepsis) 
1 2 
B C 
Y Y Y N 
(Hoogerwerf et 
al., 2010) 
Sepsis 24hrs (dx sepsis) 1 2 
A 
Y Y Y N 
(Yousef et al., 
2010) 
Sepsis ? 1 1 
A B C 
N N Y N 
(Turrel-Davin 
et al., 2010) 
Sepsis 48hrs (sep 
shock) 
2 
(5 days) 
1 C Y Y N N 
(Pelekanou et 
al., 2009) 
Sepsis 24hrs (signs of 
sepsis) 
1 1 2 
A B C 
Y Y Y N 
(Resident et al., 
2009) 
Elective 
surgery 
Pre-insult 2 
(1 day) 
N -  Y Y 
(Delogu et al., 
2008) 
Sepsis 24hrs (septic 
shock) 
1 ? 
C 
Y N N N 
(Weber et al., 
2008) 
 
Sepsis 4hrs (severe 
sepsis) 
1 1 
B 
N N Y Y 
(Roth et al., 
2003) 
Sepsis ? 1 1 
A B C 
N N N N 
(Le Tulzo et al., 
2002) 
Sepsis +ve microbio-
logy ±3days 
2 
(6 days) 
1 
B C E 
Y N N N 
(Hotchkiss et 
al., 2001) 
Sepsis 6hrs (death) 1 6 Y N Y N 
(Delogu et al., 
2001) 
Elective 
surgery 
Pre-insult 3 
(4 days) 
N N N Y Y 
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(Pellegrini et al., 
2000) 
Trauma ? 2/wk 
(until death/ 
discharge) 
N N N N N 
(Delogu et al., 
2000) 
Surgical Pre-insult 3 
(4 days) 
N N N Y Y 
(Hotchkiss et 
al., 2000) 
Trauma 10hrs (injury to 
surgery) 
1 N N N N N 
(Hotchkiss et 
al., 1999) 
 
Sepsis 6hrs (death) 1 6 Y Y N N 
(Sasajima et al., 
1999) 
Elective 
surgery 
Pre-insult 5 
(7 days) 
N N N N N 
(Sugimoto et al., 
1998) 
Elective 
surgery 
Pre-insult 4 
(4 days) 
N N N N N 
Table 3.9 Experimental conduct and exclusion criteria of lymphocyte apoptosis studies.  
Sample Timing. Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the 
subject? How many samples were taken for each subject in total and over what time span? 
Sepsis criteria. The criteria used to enrol subjects into the study.  Where subgroups of these criteria were used (e.g. septic shock) these are detailed.  0=not stated 1= 
ACCP/SCCM 1992 Consensus Conference (Bone et al. 1992), 2=ACCP/SCCM Consensus Conference 2001(Levy et al. 2003), 3=SSC Consensus Conference 
2008(Dellinger et al. 2008), 4=CDC NNIC(Anon 1989), 5=Microbiology and clinical assessment, 6=Postmortem identification of infection, N=infection not considered, 
?=criteria not described.  Sepsis severity groups enrolled:  A=sepsis, B=severe sepsis, C=septic shock, D=acute renal failure E=SIRS 
Microbiology documentation - Were causative organisms isolated and identified?  Were additional steps taken to define whether subject had sepsis beyond the initial 
clinical diagnosis i.e. retrospective review of case considering subsequent information?   
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Investigator Source Control 
group 
Duration 
follow up 
(days) 
Duration 
burst 
increased 
Duration 
burst 
decreased 
(Hughes et 
al., 2010) 
Surgical Preop 5 days 1 day 0 
(Kawasaki 
et al., 2007) 
Surgical Preop 4 days 0 0 
(Fröhlich et 
al., 2006) 
Surgical Preop 2hrs 0 2 hrs 
(Wiezer et 
al., 2000) 
Surgical Preop 7 days 2 hrs 0 
(Paunel-
Görgülü et 
al., 2011) 
Trauma HV 1 day 1 day - 
(Shih et al., 
2010) 
Trauma HV 3 days 3 days - 
(Kasten et 
al., 2010) 
Trauma HV 4 days 3 days ? 
(Valente et 
al., 2009) 
Trauma HV 5 days 3 days. 0 
(Quaid et 
al., 2001) 
Trauma HV 1 day 1 day - 
(Oehler et 
al. 2000) 
Trauma HV 5 days 5 days - 
(Ertel et al., 
1999) 
Trauma Surgery 3 days 3 days - 
(Ogura et 
al., 1999) 
Trauma HV 21 days 21 days - 
(Shih et al., 
1999) 
Trauma HV 7 days 3 days 0 
(Botha et 
al., 1995) 
Trauma HV 3 days 1 day 0 
(Tanaka et 
al., 1991) 
Trauma HV 7 days 3 days 0 
(Santos et 
al., 2012) 
Sepsis HV 7 days 7 days - 
(Bruns et 
al., 2011) 
Sepsis HV/patients Single 
measurement 
Reduced 
(Martins et 
al., 2003) 
Sepsis HV Single 
measurement 
Increased 
(Barth et 
al., 2002) 
Sepsis HV Daily 
assessment 
Increased throughout 
(Mariano et 
al., 2001) 
Sepsis Patients Single 
measurement 
Increased 
(Ahmed et 
al., 1999) 
Sepsis HV Single 
measurement 
- - 
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(Pascual et 
al., 1998) 
Sepsis HV Single 
measurement 
Increased 
(Kaufmann 
et al., 2006) 
Sepsis HV Single 
measurement 
Increased fMLP 
(Wenisch 
and 
Graninger, 
1995) 
Sepsis HV Single 
measurement 
Reduced 
(Bass et al., 
1986) 
Sepsis HV Single 
measurement 
Increased 
Table 3.10 Respiratory burst assay results. 
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3.3.3 Study power and source of experimental control subjects 
Sample size calculations utilising existing laboratory or clinical data were not performed by 
any study.  Cohort methodology was only employed by 25% (14/57) studies, of which 86% 
(12/14) were performed in elective surgery patients, meaning only one elective surgery 
study did not use this method.  Case-control study design was used by 74% (42/57) of 
studies, of which 83% (35/42) recruited healthy volunteers and the rest utilised variously and 
loosely described clinical samples (Figure 3.2, Tables 3.1, 3.4, 3.7).  The remaining 25% 
(14/57) studies used cohort methodology  
Figure 3.2 Identity of control groups used by for different study populations 
 
3.3.4 Age, gender and ethnicity 
Only 48% (20/42) of case control studies included age data for both study and control 
populations. Of the 35 healthy volunteer studies, 27 reported age data for both study and 
control populations.  Within these 27 studies the average age of study populations was 
higher than control populations on 17 occasions, but this difference was only significantly 
different on one occasion (Roger et al., 2012), due to the wide range of ages recruited.  
Gender distribution was reported by 62% (26/42) of studies and ethnicity by only one.  
Collectively these data demonstrate frequent underreporting, and within reported data 
widespread heterogeneity between and within case control study groups, of immunologically 
relevant parameters. 
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3.3.5 Comorbid disease 
60% (34/57) of studies excluded patients with confirmed immune suppression, and 14% 
(8/57) excluded those with malignancy (Fig 3.3)  
Figure 3.3 Proportion of studies which excluded, or documented the presence of  
major immunological comorbidities. 
3.3.6 Definitions of sepsis 
Most studies (79%; 26/33) used established consensus conference criteria to define sepsis 
syndrome (ACCP/SCCM or Surviving Sepsis Campaign) (Bone et al., 1992; Dellinger et al., 
2008; Levy et al., 2003).  58% (15/26) of these studies enrolled patients with ‘sepsis’, 77% 
(20/26) those with ‘severe sepsis’ and 92% (24/26) those with septic shock.  These 
subcategories were combined for analysis by 42% (11/26).  One study only included patients 
with septic shock of 4 days duration (Barth et al., 2002).  Of the studies within trauma and 
surgery patients, only 25% (6/24) reported whether infection developed during the study 
course, with 5/6 using consensus conference criteria. 
 
3.3.7 Microbiology 
Although 44% (25/57) studies provided microbiological data, only 30% (17/57) of studies 
described independent post hoc evaluation of this data and the sepsis diagnosis.  Two 
studies by Hotchkiss provided autopsy evidence of infection (Hotchkiss et al., 2001, 1999)   
134 
 
3.3.8 Organ dysfunction and illness severity  
Indices of organ dysfunction, such as SAPS-II or APACHE-II were reported by 33% (19/57) 
of studies, which in turn reported a wide range of illness severity.  Only 7% (4/57) reported 
whether patients died and none of these described the severity of illness in survivors. 
3.3.9 Sample timing 
While the majority (72%; 24/33) of sepsis studies reported the timing of the index blood 
sample, sampling triggers varied widely (Figure 3.4).  These included the onset of septic 
shock (7/24), diagnosis of sepsis (5/24), ICU admission (5/24), onset of organ failure (3/24) 
evidence of infection (2/24), death with autopsy sampling (2/24), onset of sepsis (1/24) and 
hospital admission (1/24) (Fig 3.4).  Several studies combined the above triggers to create 
composite inclusion criteria.   
The index patient sample was acquired within 24 hours of hospital admission within 58% 
(14/24) of sepsis studies.  One study restricted inclusion to patients identified within 24hrs 
of the onset of sepsis symptoms, which included accident and emergency patients, plus 
followed them up for 28 days (Gogos et al., 2010).  Overall, serial sampling was frequently 
undertaken, but over variable time intervals which were not defined a priori.  Similar 
patterns of sample timing were described for trauma patients.  Conversely all 12 elective 
surgery studies collected preoperative control samples and further samples on 
predetermined postoperative days.  Two studies investigated whether the time delay 
between patient sampling and laboratory processing affected the results (Gogos et al., 2010; 
Hotchkiss et al., 1999).  
Figure 3.4 Septic patient sample timing  
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3.3.10 Confounding impact of therapeutic interventions 
The concurrent administration of drugs with widely recognised immune modulating 
properties was reported by 25% (14/57) studies, and of these sedative agents were reported 
by 7% (4/57), antibiotics by 11% (6/57) and steroids by 26% (15/57) (Fig 3.5).  In one study 
of trauma patients the range for administration of blood products was 0-49 units, with data 
reported from blood sampled after transfusion (Quaid et al., 2001).  
Figure 3.5 Documentation of administered drugs which affect immune function. 
 
3.3.11 Relationship between study population, experimental context outcomes 
and experimental assay results. 
Neutrophil respiratory burst studies conducted in septic patients repeatedly revealed an 
increased burst response within the septic patient groups (Table 3.10).  However, these 
studies invariably employed a healthy volunteer control group, therefore it is uncertain 
whether this is attributable to the presence of sepsis, other differences between the groups 
or perhaps even predisposes to sepsis.  None of the three surgical studies investigating the 
neutrophil burst identified any perioperative change.  Monocyte and lymphocyte studies 
described similar patterns.  An index of clinical outcome was related to immune cell 
function by 23% (13/57) of clinical studies. 
Simultaneous sampling of blood and tissue neutrophils from live patients was employed by 
only one study (Ahmed et al., 1999), which reported that tissue neutrophils had diminished 
functionality when compared to blood derived neutrophils.   
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3.3.12 Response of respiratory burst to surgery, trauma and sepsis 
Table 3.10 summarises respiratory burst assay results for septic, trauma and surgical 
patients.  All trauma studies identified an increase in respiratory burst when compared to 
healthy volunteers, or in one case surgical patients, which persisted for between 1 and 21 
days.  Conversely investigations of surgical and septic patients yielded more variable results, 
with both increased and decreased respiratory burst commonly described.  The 
experimental assay methodology for these studies is summarised in Appendix A, and 
demonstrates a wide variation in experimental protocols. 
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3.4 Discussion 
 
3.4.1 Key findings 
1. Translational investigations of surgical patients use individualised pre-insult 
control samples for each patient, unlike equivalent studies within septic and 
trauma patients.  Every study of surgical patients used cohort study design, with each 
patient serving as their own control sample.  In addition, surgical studies described the study 
population with more detail and used accurately timed sampling in relation to the primary 
insult.   
2. Some patients enrolled into sepsis studies may not have an infection.  Many 
studies of septic patients failed to report microbiological data and few utilised post-
admission clinical/microbiological information to confirm the initial diagnosis.   
3. Sepsis studies employ control populations that are not age, race or gender 
matched. Therefore, studies of septic patients cannot determine whether observed 
differences within experimental readouts are due to sepsis, predispose to sepsis or are a 
consequence of the many other differences between the study and control groups.   
4. There is a wide variation in enrolment criteria between studies of sepsis 
patients, with immunologically relevant patient information often not reported.  
This is partly generated by subtle differences in sepsis diagnosis between various iterations 
of sepsis guidelines, and may limit inter-study comparisons.  Several studies combined 
different subcategories of sepsis to create composite study groups, e.g. severe sepsis and 
septic shock.  Since these are essentially clinical syndromes that require institution of 
specific therapeutic interventions with known immunological effects – such as septic shock 
and noradrenaline - it is not possible to determine whether the observed differences are 
due to sepsis.  It follows that combining these different subpopulations into composite 
groups may diminish or distort sepsis experimental signals.  
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3.4.2 Interpretation of results  
Experimental conclusions from translational sepsis investigations are limited by intrinsic 
challenges of study design and a failure to consider or report potentially controllable factors 
which may impact upon immune function.  By contrast, translational investigations within 
major elective surgery overcame many of these limitations.   As described, observations 
from surgical patients are relevant to those with sepsis because of the established molecular, 
genomic and clinical similarities between these groups.  Therefore, the study of surgical 
patients may provide a translational model of human critical illness, which overcomes the 
methodological challenges of human sepsis, and the biological limitations of model organism 
investigations.    
3.4.2.1Intrinsic limitations presented by the unpredictable and indeterminate 
onset of human sepsis.   
This prevents pre-insult control samples from being taken, meaning alternative control 
populations must be chosen that differ from the study population in many immunologically 
relevant ways, aside from the presence of infection.  Such uncertainty also precludes the 
accurate timing of patient sampling and consequently the description of putative dynamic 
immune processes.  The importance of accurately timed patient samples is supported by 
genomic data describing differences in inflammatory markers at 24 hours of intensive care 
admission which predict survival (Xiao et al., 2011). 
3.4.2.2 The diagnostic challenge of sepsis 
The most important controllable factor which was ignored by sepsis investigations was 
confirmation of the sepsis diagnosis i.e. review of latterly returned microbiological results.  
Some patients enrolled into sepsis studies may not have an infection, since most sepsis 
studies did not make full use of available information to confirm the sepsis diagnosis, such as 
post-hoc microbiology results.  Critically ill patients are colonised with potentially 
pathogenic organisms.  Failure to demonstrate infection is important, since recent 
laboratory investigations have revealed that the clinical signs/symptoms of sepsis are 
frequently mimicked by non-pathogenic molecules (Menu and Vince, 2011).   Even then, the 
binary presence of infection may be insufficiently accurate, since the location and type of 
micro-organisms may generate specific immune responses (Menu and Vince, 2011; 
Vandenesch et al., 2012) - only one study of the 57 described above specified infection site 
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or pathogen type.  This criticism is also true of many surgical and trauma studies, which 
failed to record whether infections developed in the study population.   
3.4.2.3 Underexplored, but potentially controllable variables 
Other under explored controllable factors included the selection of an appropriate control 
population, enrolment criteria and reporting of therapeutic interventions.   Therefore, 
although the finding of almost universally increased respiratory burst within septic patients is 
interesting (table 3.10), deeper consideration of the many limitations within these studies 
questions their validity.  
The variation of assays used to measure specific immune processes is fundamental problem 
of translational studies.  There are no agreed standards, with both major and subtle 
differences between assay protocols (Table 3.11-3.12) that may impact upon the assay 
result.  For example, heparin has been shown to affect lipopolysaccharide priming of the 
respiratory burst (Bortolussi et al., 1997).  This underscores the importance of using 
multiple assays of same process within studies, to improve the internal validity.   
3.4.2.4 Experimental and clinical implications of findings 
Incorporation of the surgical model into the translational investigative process does not 
mean identical studies must first be performed in surgical patients.  What it allows is robust 
characterisation of standardised immune processes which can be used as readouts for other 
patient types, for example the use of immune modulating agents may be trialled in septic 
patients with appropriate immunological readouts.  A study of vasoactive medications would 
never be performed without measuring blood pressure, therefore it is remarkable that so 
many immunological studies have been performed without the appropriate immune 
readouts. 
Findings from studies of immune function cannot be extrapolated to describe clinical 
outcome unless they are adequately powered, since the up-regulation of immune function 
may improve bacterial killing but at expense of increased host cell injury, ultimately causing 
more harm.  Power calculations were not described by any studies for immune function or 
clinical outcome.   
Beyond directly modelling inflammation with the surgical insult, the incidence of sepsis is 
sufficiently high in surgical patients to permit cohort investigations of postoperative sepsis.  
Depending upon health care system and database chose, the incidence of clinically defined 
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sepsis varies between 6.98% and 12.25% (Lawson et al., 2012).  Since approximately 240 
million surgical procedures are performed worldwide each year, large numbers of well 
characterised patients may be followed. 
 
 
3.4.3 Strengths and weaknesses 
The studies chosen are representative of the current translational literature, spanning the 
three most popular areas of translational immunological research over the past fifteen years.  
Despite this, the number of studies included in this investigation is relatively small.  
Therefore, it was only possible to perform descriptive rather than quantitative comparisons 
between the different study types.  
These findings support the use of the surgical model as a bridge between model organism 
and septic patient research, where understanding of immune processes may be refined prior 
to definitive evaluation in carefully selected and characterised septic patients, which may 
then be subject to pragmatic real-world testing.  They do not imply this model is a 
replacement for animal model or septic patient research. 
This study has only examined the methodological advantages of studying surgical patients 
over septic patients.  While the many similarities between human responses to infection and 
trauma have already been described, no studies have reported how functional immune 
assays, such as those described within this study, vary between these two patient groups.  
For example, there are clinical scenarios where clear differences exist. The fulminant septic 
responses of patients with meningococcal septicaemia are never encountered following 
major surgery.  Whilst presenting a limitation, studies which directly compare surgical and 
sepsis patients may identify the key molecular switches which define the differences 
between the two groups.  Although original papers were retrieved for each study, these 
only contained summary data, therefore the raw data for each investigation was not 
examined. 
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3.4.4 Conclusions 
The translational investigation of septic patients presents potentially controllable but often 
ignored methodological limitations.  The study of major elective surgery overcomes many of 
these.  The molecular, genomic and clinical similarities that exist between surgical and septic 
patients provide biological plausibility to this model.  The study of major elective surgery 
may therefore provide an additional translational model between model organism research, 
healthy volunteer studies and clinical evaluation.  Within other areas of translational 
research, such as cancer cell biology, experimental protocols have been standardised to 
facilitate comparisons between different studies.  Translational sepsis research would benefit 
from similar standardisation.  In addition, the incidence of post-operative sepsis is sufficiently 
common to permit cohort investigations of septic patients that include individualised pre-
sepsis control data. 
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Chapter 4.  The perioperative neutrophil phenotype. 
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4.1 Introduction 
 
Neutrophils may have an important role in determining the human response to surgery, 
because they are the predominant cell type of the early inflammatory response (J. C. 
Marshall, 2005).  Although neutrophil function is critical to the timely resolution of 
infection/inflammation (Almyroudis et al., 2013; Morgenstern et al., 1997) these effector 
processes may also cause collateral tissue injury (Chollet-Martin et al., 1996; Miller et al., 
1992; Steinberg et al., 1994). Therefore, excessive and diminished neutrophil function may 
both be associated with harm, depending upon the context within which they are operating. 
Within laboratory models of neutrophil impairment, using both neutrophil depletion or 
chemical inhibition, the timing of neutrophil impairment in relation to the index 
inflammatory insult and further inflammatory stimuli (‘second hits’)  alters experimental 
outcome (Deitch et al., 1990; Hoesel et al., 2005, Chen et al., 2015, Liu et al., 2006).  The 
coordination of these various immune activities during systemic inflammatory responses 
remains poorly understood.  
Sampling from major elective surgical patients may allow an accurate temporal description of 
the putative dynamic changes in neutrophil immune function which follow a major 
inflammatory insult, where individualised human subjects are directly compared to their own 
pre-insult control samples, thereby accounting for pre-existing comorbidity.  Within 
previous studies the baseline variability in neutrophil respiratory burst assays overlaps with 
post insult samples, suggesting important experimental signals may be missed unless paired 
statistical analysis is used (Fröhlich et al., 2006; Kawasaki et al., 2007; Shih et al., 1999; 
Wiezer et al., 2000).   
Key neutrophil immune processes include the respiratory burst and phagocytosis.   These 
effector processes rely upon common cellular mechanisms such as energy generation, 
cellular remodelling and the fusion of cellular plus vesicular membranes.  Two investigations 
have identified diminished neutrophil phagocytosis following major surgery (Jones et al., 
2014; Kawasaki et al., 2007) and three investigations have failed to show any change in 
perioperative neutrophil respiratory burst function (Fröhlich et al., 2006; Kawasaki et al., 
2007; Wiezer et al., 2000).  In addition to these effector processes, a range of cell surface 
proteins are necessary for coordinated activity of neutrophil within experimental 
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investigations.  These include adhesion receptors, cytokine receptors, pattern recognition 
receptors and immunoglobulin heavy chain receptors, and are described below.   
Previous investigations have described how individual cell surface proteins and effector 
processes change within patients undergoing specific surgical procedures (e.g. liver 
resection, cataract surgery).  None of these studies have documented a wide range of 
markers/processes within a highly phenotyped general surgical cohort patients undergoing 
major elective surgery, who are likely to acquire postoperative sepsis.  
 
 
4.1.1 Hypothesis 
Major elective surgery is associated with impaired neutrophil immune function.  
 
4.1.2 Aims 
To describe how major elective surgery alters:  
1. Circulating numbers of major immune blood cells, 
2. Effector processes: the respiratory burst and phagocytosis (including CD16 
expression). 
3. Cell surface expression of key ligands necessary for the entry of neutrophils into 
inflamed tissues (CD62L, CD11b, CXCR2) and the detection of tissue injury and 
infection (TLR-4, TREM-1) 
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4.2 Methods 
Patients were recruited from the Post-Operative Morbidity Oxygen study (POMO, MREC 
09/H0805/58) and VISION-UK (MREC 10/WNo03/25) studies.  All samples were compared 
to preoperative controls.  POMO was a randomised study of goal directed therapy.  I 
examined patient responses independently of their treatment/control group allocation, and 
remained blinded to group allocation during the experimental part my investigation - table 
4.4 describes the relative contribution of treatment/control patients within each 
experimental assay.  VISION-UK was an observational study.  Patient selection, blood 
sampling, clinical data collection and further details of these studies are described in General 
Methods.    
Blood samples was collected on the morning before surgery, postoperative day two and on 
postoperative day five.   A five-day follow-up period was chosen because this is the time 
frame in which major elective surgery patients have frequently clinically recovered 
(mobilising freely, switched to oral medications, urinary catheter out etc).  For tests where 
significant differences were identified on postoperative day two, further patients were 
recruited for analysis of blood samples after surgery was complete and anaesthesia reversed, 
within the theatre recovery areas.    
Whole blood assays were performed to minimise iatrogenic impact of cell isolation upon 
results.  To validate the isolated neutrophil model used in subsequent chapters, key findings 
were retested in isolated cells, and described at the end of this chapter.  Flow cytometric 
assays are described with General Methods.   
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4.3 Results 
 
4.3.1 Patient details 
The total study population characteristics are described within tables 4.1 and 4.2, 
perioperative care details within table 4.3.  Due to the large number of experimental assays 
used, each assay was not performed within all patients.  The characteristics of patients used 
for each assay are compared within chapter 4.4.   
 
Clinical and demographic details 
Demographics 
Number of patients studied 59 
Age (median, [IQR]) (years) 64 [55-72] 
Male (n, [%]) 36 [61.0] 
Surgery Type 
Hepatobiliary (n, [%]) 42 [71.2] 
Upper gastrointenstinal (n, [%]) 9 [15.3] 
Colorectal (n, [%]) 2 [3.3] 
Urology (n, [%]) 2 [3.3] 
Gynaecological oncology (n, [%]) 2 [3.3] 
Perioperative risk evaluation 
Body Mass Index (median, [IQR]) kg/m2 27.4 [24.5-30.3] 
Current smoking (n, [%]) 16 [27.1] 
POSSUM predicted morbidity (%, [IQR]) 53.9 [41.1-72.5] 
POSSUM predicted mortality (%, [IQR]) 5.24 [1.8-6.3] 
Duke Activity Status Index (median, [IQR]) 35.0 [21.1-50.7] 
VSAQ METS (median, [IQR]) 8 [5-8] 
 
Table 4.1 Demographic and clinical features of study patients.   
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Co-morbidities and preoperative medications 
Co-morbidities 
Malignancy  38 [64.4] 
Estimated glomerular filtration rate (GFR) 
mls/min/1.73m2 
72.8 [16.2] 
Abnormal electrocardiogram/ECG 26 [44.1] 
Hypertension  25 [42.3] 
Diabetes Mellitus  14 [23.7] 
Asthma / Chronic obstructive pulmonary disease 10 [17.5] 
Ischaemic heart disease 9 [15.3] 
Arrhythmia  6 [10.2] 
Rheumatoid arthritis 4 [6.8] 
Cerebrovascular disease 2 [3.4] 
Thyroid disease 2 [3.4] 
Chronic congestive heart failure 2 [3.3] 
Renal impairment (GFR <50 mls/min/1.73m2)  1 [1.7] 
Crohns 0 [0.0] 
Ulcerative colitis 0 [0.0] 
Cirrhosis 0 [0.0] 
Medications 
ACE inhibitor / angiotensin receptor blocker  24 [40.7] 
Statin 23 [39.0] 
Aspirin 14 [23.7] 
Beta-blocker 12 [20.3] 
Calcium channel blocker 11 [18.6] 
Diuretic 11 [18.6] 
Clopidogrel 3 [5.1] 
Warfarin 2 [3.4] 
Proton pump inhibitor / H2 antagonist 19[32.2] 
Chemotherapy (past 3 months) 7 [11.9] 
Paracetamol  5 [8.5] 
Oral opiates 4 [6.8] 
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Non-steroidal anti-inflammatory agents 2 [3.4] 
Sulfasalazine 1 [1.7] 
Antibiotics 1 [1.7] 
Steroids 0 [0.0] 
Azathioprine 0 [0.0] 
Anti-Tumour necrosis factor drugs 0 [0.0] 
Intravenous opiates 0 [0] 
Table 4.2 Comorbidities and preoperative medication use of study patients. 
 All values refer to (number of patients, [%]) unless otherwise stated.  *Abnormal ECG defined by any of left 
ventricular hypertrophy, left bundle branch block, ST/T-wave abnormalities. 
 
Perioperative care 
                                                  Perioperative day 
 Intraoperative POD 2 POD 5 
Duration of operation hrs: mins 
(mean, [sd]) 
4:25 [1:57]   
Fluid mls/kg (median, [IQR]) 22.3 [13.1-27.2]   
Patients received blood products 6 [10.2]   
Vasopressor / inotropic infusion 9 [15.3] - - 
Sedation 10 [17.0] - - 
Epidural  37 [62.7] 29 [49.2] 24 [40.7] 
Intravenous opiates 18 [30.5] 26 [44.1] 25 [42.4] 
Low molecular weight heparin - 39 [66.1] 46 [78.0] 
Positive microbiology* 1 [1.7] 0 [0] 2 [3.3] 
Location within postoperative 
care / intensive care unit  
59 [100] 9 [15.3] 7 [11.9] 
Table 4.3 Perioperative care of study patients. 
All values refer to (number of patients, [%]). * Microbiology cultures from blood/sputum/urine/wound/bile of 
potentially pathogenic organisms. Management of patients with suspected sepsis was left to discretion of 
bedside clinicians. 
149 
 
Individual assay patient demographics, co-morbidity and medication data 
Assay Total 
number# 
Age 
(median, 
[IQR]) (years) 
Male 
(n, [%]) 
Malignancy 
(n, [%]) 
Immune 
medications 
(n, [%]) 
POMS 
morbidity 
(median, [IQR]) 
(%) 
Hepatobiliary 
surgery 
(n, [%]) 
POMO 
Goal 
Directed 
Therapy* 
(n, [%]) 
Respiratory 
burst  
(preop-pod2) 
18 63 
(58-73) 
12 [67] 6 [33] 2 [11] 49.2 [23.1-67.1] 12 [67] 10 [55] 
Respiratory 
burst  
(preop-postop) 
4 73.5 
(68.5-77.25) 
1 [25] 4 [100] 0 [0] 58.54 [53.9-62.3] 2 [50] 1 [25] 
Respiratory 
burst  
(preop-POD2-POD5) 
6 64 
(63-73) 
3 [50] 1 [17] 0 [0] 54.3 [47.6-63.1] 4 [67] 4 [67] 
Phagocytosis 
(preop-POD2) 
9 59 
(48-66) 
4 [44] - - - 2 [22] VISION 
CD16  
(preop-POD2) 
19 69 
(61-74) 
10 [52] 11 [58] 1 [5] 51.2 [45.5-62.3] 11 [58] 7 [37] 
CD16  4 73.5 1 [25] 4 [100] 0 [0] 58.54 [53.9-62.3] 2 [50] 1 [25] 
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(preop-postop) (68.5-77.25) 
CD16 
(preop-POD2-POD5) 
11 66.5 
(60-73.75) 
5 [45] 7 [64] 1 [9] 56.3 [50.6-62.3] 5 [45] 5 [45] 
CXCR2 
(preop-POD2) 
4 61 
(58.5-66.25) 
3 [75] - - - 1 [25] VISION 
TREM1 
(preop-POD2) 
6 58.5 
(54.75-61.5) 
3 [50] - - - 1 [17] VISION 
TLR4 
(preop-POD2) 
6 61 
(59.25-71) 
4 [67] - - - 2 [33] VISION 
CD62  
(preop-POD2) 
4 67 
(61-76.5) 
3 [75] 2 [50] 0 [0] 61.8 [47.2-71.1] 1 [25] 2 [50] 
CD11b  
(preop-POD2) 
15 73 
(67-74) 
6 [40] 7 [47] 0 [0] 49.8 [44.0-69.8] 8 [53] 8 [53] 
 
Table 4.4 Key demographic, co-morbidity and medication data for individual experimental assays. 
Each assay was not performed on every patient, therefore data from tables 4.1-4.3 is summarised here so that patients within each assay group maybe compared.  
#Only complete data sets for each time point are included within study analysis, therefore there are more preop-POD2 than preop-POD2-POD5, owing to missing patient 
samples.  *Within POMO studied patients were randomised to receive standardised goal directed therapy or standard, anaesthetist directed, care (Ackland et al., 
2015), “VISION” denotes patients were recruited through the VISION study.  The inclusion criteria for these two studies are detailed within Table 2.1
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4.3.2 Perioperative change in blood leukocyte numbers  
Figure 4.1 describes perioperative changes in leukocyte subsets.  The absolute neutrophil 
count was elevated, and the absolute lymphocyte reduced throughout the recorded 
perioperative period.  Monocyte counts increased from postoperative day two. The 
biological significance of these changes in cell number is uncertain. 
Figure 4.1 Perioperative change in blood leukocyte counts. 
Box and whisker plots represent median and IQR.  Postoperative (D0) samples were taken on arrival of 
patient within intensive care / postoperative care unit, D2=postoperative day 2, D5=postoperative day 5.  
Friedman’s ANOVA with Dunn’s post-test comparing preoperative with each postoperative value. * p<0.05.  
Only complete data sets represented, therefore total patient numbers described are less than total studied.  
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4.3.3 Perioperative neutrophil respiratory burst 
The E. coli and PMA stimulated respiratory burst capacity were reduced on postoperative 
day 2 (Fig 4.2, 4.3), and began to return to baseline by postoperative day 5.  No differences 
were identified with fMLP (Fig 4.4).  fMLP is a gentler stimulant than E.coli and PMA, and has 
been used by other investigators to identify small differences in neutrophil priming.  The 
distribution of burst responses within individuals was normally distributed - FACS plots did 
not identify any evidence for distinct subpopulations / multi-modal distributions.  (Fig 4.2, 
4.3, 4.4). 
Next, using a murine model, I sought to establish whether the postoperative decrease in 
respiratory burst was also evident in bone marrow derived neutrophils which have not 
egressed into the systemic circulation.   Mice were randomised to either 30 minutes of 
isoflurane anaesthesia plus midline laparotomy, or sham groups and bone marrow harvested 
24hr later.  The isoflurane/laparotomy group demonstrated reduced PMA stimulated oxygen 
consumption when compared to the sham group (Fig 4.5). The apparent increase in control 
sample (resting cell) ROS production on postoperative day two when compared to 
preoperative samples (Fig 4.2C, 4.3C) is explored further in Chapter 5. 
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Figure 4.2 Perioperative change in whole blood granulocyte PMA stimulated 
respiratory burst 
All data are paired preoperative and postoperative samples.  Only complete data sets for each time point 
are presented, therefore total numbers within each graph vary. A Preop-POD 2 population data. Box-whisker 
plot is median-IQR-max/min; Wilcoxon matched pairs test used.   B Population data for other time points.    
C Overlay plot showing typical paired preop-POD 2-POD 5 data. 
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Figure 4.3 Perioperative change in whole blood granulocyte E. coli stimulated 
respiratory burst 
All data are paired preoperative and postoperative samples.  Only complete data sets for each graph are 
presented, therefore total numbers within each graph vary.  A Population data for preop-POD2 time points. 
Box-whisker plot is median-IQR-max/min with Wilcoxon matched pairs test used.   B Preop-post surgery and 
preop-POD2-POD5 time points.  C Overlay plot showing typical paired preop-POD 2-POD 5 data.  
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Figure 4.4 Perioperative change in whole blood granulocyte fMLP stimulated 
respiratory burst 
All data are paired preoperative and postoperative samples.  Only complete data sets for each graph are 
presented, therefore total numbers within each graph vary.  A. Population data for rhodamine 123 MFI at 
specified time points, box-whisker plots are mean-IQR-max/min with Wilcoxon matched pairs for preop-
POD2.  B Population data for % granulocytes with rhodamine123 fluorescence, median-IQR-max/min.   
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Figure 4.5 PMA stimulated oxygen consumption of murine bone marrow 
neutrophils 24hrs after surgery. 
Two groups were compared: 30 minutes of isoflurane anaesthesia plus midline laparotomy or sham 
(anaesthesia without surgery) groups.  N=3 per group and each experiment performed in triplicate. Bone 
marrow neutrophils were plated 24hrs later.  Animals were randomised through number identification and 
blinded selection of numbers.  Further experimental details are provided within section 2.4.  Oxygen 
consumption rates following PMA stimulation were measured with the Seahorse Bioscience XF respirometer.  
Error bars represent mean +/- sd.  
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4.3.4 Perioperative neutrophil phagocytosis. 
Neutrophil phagocytosis of E. coli bacteria on postoperative day 2 were unchanged when 
compared to preoperative values (p=0.084) (Fig 4.6).  However, cell surface expression of 
the Fc receptor CD16 was significantly reduced on postoperative day two, with no apparent 
relationship between postoperative day two and five levels (Fig 4.7). 
Figure 4.6 Perioperative change in whole blood granulocyte phagocytosis of  
heat-inactivated FITC-labelled E. coli bacteria. 
All data are paired preoperative and postoperative samples.  Only complete data sets for each graph are 
presented, therefore total numbers within each graph vary.  A Population data at defined time points.  Post-
surgery samples taken within two hours of the end of surgery.  Paired line charts are presented and Wilcoxon 
matched pairs test used for Preop-POD2 data. B Overlay plot of typical preoperative – postoperative day 2 
sample, showing 0oC control and 37oC test samples. 
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Figure 4.7 Perioperative change in granulocyte cell surface expression of CD16.  
All data are paired preoperative and postoperative samples.  A Population data at specified time points.  
Post-surgery samples taken within two hours of the end of surgery.  Paired t-test used for Preop-POD2 data, 
and Friedman matched pairs analysis used for Preop-POD2-POD5 data.  B Overlay plot demonstrating 
typical paired patient samples. 
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4.3.5 Perioperative change in neutrophil adhesion and chemotaxis 
receptors 
No significant differences in cell surface expression of CD62L, CD11b or CXCR2 were 
identified on postoperative day two (Fig 4.8).  
 
Figure 4.8 Perioperative expression of neutrophil cell surface receptors 
facilitating transmigration and chemotaxis.   
All data are paired preoperative and postoperative samples.  Where n>10 box-whisker plots are provided 
(median-IQR-max/min) and Wilcoxon matched pairs test used, if n<10 paired line plots are provided alone.  
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4.3.6 Perioperative expression of neutrophil pattern recognition 
receptors. 
Neutrophil expression of TREM-I was significantly increased on postoperative day 2, 
although no difference in TLR4 expression was identified (Fig 4.9).  
 
 
 
 
 
 
 
Figure 4.9 Perioperative change in neutrophil cell surface expression of TREM1.  
All data are paired preoperative and postoperative samples. A Typical overlay plot B Population data.  Paired 
line plot and Wilcoxon matched pairs test used. 
Figure 4.10 Perioperative change in neutrophil cell surface expression of TLR4.  
All data are paired preoperative and postoperative samples.                                                           
Paired line plot and Wilcoxon matched pairs test. 
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4.3.7 Isolated granulocyte experiments. 
There are many assays of neutrophil functions which have only been validated within 
isolated, rather than whole blood cells.  Therefore, I repeated positive experimental findings 
from whole blood cells within isolated granulocytes.  Isolated postoperative neutrophil 
displayed diminished CD16 and PMA simulated respiratory burst (Fig 4.11) – the same 
pattern as previous whole blood data.  E.coli respiratory burst does not work within an 
isolated cell system. 
Figure 4.11 Perioperative change in isolated neutrophil respiratory burst  
and CD16 expression. 
Granulocytes were isolated and prepared as described in general methods.  All data are paired preoperative 
and postoperative samples.  Overlay plots detail typical paired patient samples. A Perioperative change in 
isolated granulocyte CD16 expression. Wilcoxon matched pairs tests used. B Perioperative change in isolated 
granulocyte PMA stimulated respiratory burst. Wilcoxon matched paired test used. 
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4.4 Discussion 
 
4.4.1 Key findings 
1. Patients on postoperative day two have a reduced respiratory burst and 
cell surface CD16 expression. The PMA (p<0.001; n=18) and E. coli (p=0.01; 
n=18) respiratory burst and cell surface CD16 (p=0.042; n=19) were both reduced 
on postoperative day two when compared to individualised preoperative control 
samples. The fMLP respiratory burst, a marker of more subtle changes in neutrophil 
function (priming), was unchanged.  The PMA and E.coli respiratory burst samples 
were typically increased on postoperative day five.  The baseline / resting variation in 
these data which is evident in every assay used suggests that subtle experimental 
signals may be missed if case control study design were used, with unpaired statistical 
tests. These findings are compatible with impaired Fc receptor mediated 
phagocytosis and bacterial killing/activation of neutrophil granular contents on 
postoperative day two.  The postoperative expression of neutrophil surface TREM-1 
was increased (p=0.03; n=6), which may reflect TREM-1 amplifying inflammatory 
responses following the detection of endogenous PAMPs. 
 
2. The neutrophil count was increased on postoperative day two.  The 
absolute and relative neutrophil counts were increased on postoperative day two 
and five (p<0.001; n=37).  Therefore, my data reveal a difference between a widely 
used index of inflammation (neutrophil count) and  laboratory assays of circulating 
neutrophil immune function (PMA/E.coli respiratory burst).  The activity of egressed 
tissue neutrophils was not recorded.   
 
3. Isolated neutrophils demonstrate diminished cell surface CD16 and PMA 
stimulated respiratory burst, similar to whole blood assays 
The respiratory burst (p=0.016; n=7) and cell surface CD16 (p=0.032; n=11) were 
similarly reduced within an isolated system. These observations are mechanistically 
relevant, since they suggest that the postoperative functional impairment is not due 
to the tonic effects of circulating neurohumoral mediators or drugs.  Additionally, 
they broaden the range of available assays which may be used in subsequent 
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chapters, since many experimental assays are not validated for use with whole blood 
samples.  
 
4.4.2 Interpretation of key findings 
The data provide experimental evidence of reduced postoperative neutrophil immune 
function, and demonstrate how the inter-individual variation in baseline function may lead to 
missed experimental signals unless an individual’s postoperative responses are compared to 
their own preoperative control samples.  Whether this functional extends between 
postoperative days one to four is unknown, because samples were not recorded at these 
time points.  This baseline variation is evident within other perioperative investigations of 
neutrophil immune function (Fröhlich et al., 2006; Takashi Kawasaki et al., 2001; Wiezer et 
al., 2000).  It is possible that this variation is due to differences in patient’s baseline health, 
such as comorbid disease, presence of malignancy or administration of immune altering 
medications. Such accurate timing and access to baseline data are not possible during the 
study of established critical illness, such as trauma and sepsis.  It is therefore possible that 
studies within these patient groups may therefore miss subtle experimental signals. 
This period of impaired neutrophil functionality – with reduced PMA and E. coli stimulated 
respiratory burst – may be plausibly related to the development of postoperative 
complications.  The respiratory burst is not only responsible for direct bacterial killing but 
also optimises activity of phagocytic granules (Segal, 2005), while observations from patients 
with chronic granulomatous disease suggest a diminished respiratory burst may generate 
states of chronic non-resolving sterile inflammation (Morgenstern et al., 1997).  The 
magnitude of postoperative respiratory burst depression is comparable with that found in 
alcoholic hepatitis superimposed upon cirrhosis (Mookerjee et al., 2007) and in established 
sepsis (Pascual et al., 1998).   
Greater depression of postoperative PMA burst responses than E. coli burst responses may 
have mechanistic implications.  PMA mediates a persistent, maximal activation of the 
respiratory burst through direct binding to protein kinase c.   Therefore, the postoperative 
functional impairment is not simply due to reduction in DAMP receptor signalling pathways, 
for example through reduced CD14 expression.  Confirmation of the PMA data within the 
isolated cell system further excludes the possibility of tonic effects of circulating neuro-
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humoral mediators.  At a molecular level, the diminished respiratory burst may therefore be 
mediated through impaired PHOX assembly, subunit activity or substrate availability.   
At a cellular level, the decreased quantity of neutrophil surface CD16 is compatible with 
previous descriptions of immature neutrophil release (Brown et al., 1989; Orr et al., 2005), 
implying postoperative day two neutrophils will be functionally immature also.  CD16 
expression is acquired at the metamyelocyte stage, and increases progressively with 
neutrophil maturation in bone marrow (Terstappen et al., 1990).  Alternatively, exposure of 
bone marrow cells to neuro-humoral mediators, or drug exposure, may result in mature 
but functionally impaired cells.   
Measurement of circulating neutrophil lifespan in humans is difficult to perform.  Studies 
using ex vivo transplant of modified neutrophils suggest circulating lifespan is less than 1 day 
in health (Dancey et al., 1976).  Since the changes I recorded were evident at postoperative 
day two, the presence of functionally impaired mature cells may be more likely than 
circulating immature cells.  The murine bone marrow data provided is compatible with both 
explanations.  On average postoperative CD16 MFI was reduced by 20% of preoperative 
levels, far less than the 90% downregulation that is observed during early apoptosis 
(Dransfield et al., 1994).  Therefore, the postoperative reduction in CD16 is unlikely to 
signify the presence of neutrophil apoptosis.    
Together, these data suggest that established tests of systemic inflammation - white cell 
count and CRP – do not correlate with a functional assay of circulating neutrophil immune 
function.   The clinical significance of these changes warrants further investigation. If 
immunomodulatory therapies are to be delivered to clinical benefit, then they must be 
administered according to reliable assays of immunological function.  Therefore, the surgical 
model provides an opportunity to investigate and define the role of immunomodulatory 
therapy. 
None of the three previous investigations into perioperative neutrophil respiratory burst 
identified any significant postoperative changes (Fröhlich et al., 2006; Kawasaki et al., 2007; 
Wiezer et al., 2000).  There are several key differences between these studies and mine.  
One study was conducted in patients undergoing cataract surgery (Fröhlich et al., 2006) and 
only sampled neutrophils on the operative day.  Here, the minor surgical insult coupled with 
short follow up time may be insufficient to promote a change in global immune function. 
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The other two studies were conducted in comparable patient populations, partial 
gastrectomy and major liver surgery, and used identical reagents E. coli/PMA stimulated 
Dihydrorhodamine-123 assays (Kawasaki et al., 2007; Wiezer et al., 2000).  However, 
Kawasaki et al analysed patient responses on postoperative days 1 and 4, and will have 
missed the day 2 effect this investigation has revealed.  Wiezer’s data sampled blood on 
postoperative day two, however the assay methodology was different, using only isolated 
neutrophils, a different isolation technique, lower doses of PMA (10ng/ml) and the addition 
of calcium which will alter calcium dependent respiratory burst response. The number of 
patients studied with this investigation is comparable to the other respiratory burst 
investigations (table 3.1).   
Respiratory burst studies in trauma and septic patients have typically demonstrated an 
increased burst response when compared to healthy volunteer control group populations 
(Table 3.10).  Given the fundamental similarities of human innate immune responses to 
disparate stimuli revealed by genomic investigations (Xiao et al., 2011), the data presented in 
this chapter initially appears counterintuitive.  However, chapter 3 identified several intrinsic 
limitations within studies of trauma and sepsis patients which may explain this apparent 
difference.   Although these methodological limitations provide sufficient explanation for 
differences between these populations, it is possible that specific differences mediated by 
PAMP c.f. DAMP signalling, or perhaps the prior/simultaneous administration of 
anaesthetic/analgesic agents at the time of inflammatory insult significantly modifies 
functional responses.   
In contrast, diminished CD16 expression has been described  following surgery and 
traumatic injury (Fung et al. 2008; Holzer et al. 2010, Wakefield et al. 1995). Reduced 
postoperative expression of CD16 is compatible with impaired opsonin mediated 
phagocytosis, but may only be confirmed with further investigation.  This investigation did 
not reproduce the commonly described neutrophil cell surface CD11b increase and CD62L 
decrease.  Several of the studies reporting the CD11b/CD62L relationship recorded data 
from the immediate perioperative period, and reported a return to pre-surgery values by 
postoperative day two.  Therefore, these changes may have occurred too early to be 
identified within this study.    
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4.4.3 Strengths and limitations 
This study describes a reduction in PMA and E.coli neutrophil respiratory burst, and 
reduction in neutrophil surface CD16, on postoperative day two.  These changes may be 
mechanistically relevant to the development of both infectious and non-infectious 
complications, however this would require further clinical correlation.  The breadth of 
assays performed is larger, and the number of patients studied broadly comparable with 
other investigations of innate immune cell function (Table 3.1).   
Patients were part of a controlled, protocolised clinical trial and therefore received highly 
standardised care and underwent extensive preoperative assessment.  Whole blood assays 
were used with significant findings subsequently confirmed within an isolated model.  
Confirmation within the isolated system provides mechanistic insight since it removes the 
tonic effects of circulating neurohumoral mediators and validates the use of isolated cellular 
assays for the mechanistic experiments within chapters 5 and 6.  The ROS probe 
dihydrorhodamine is generally agreed to be the most reliable cellular probe with which to 
measure the respiratory burst (van Pelt et al., 1996). 
However, the in vitro measurement of a specific aspect of cellular function does not 
necessarily equate to in vivo changes.  True assays of human bacterial killing are difficult to 
perform.  Even then, such killing assays will not identify the impact of dysregulated chronic 
inflammation.  Neutrophils are highly susceptible to injury and activation during isolation 
procedures, and it is not ethical to invoke direct infection.    Diminished neutrophil immune 
functionality may lead to both protection and harm, however this was a pilot study, and not 
powered to explore relationships with clinical outcome.   
This study examined circulating neutrophil immune function.  The activity of tissue 
neutrophil function is unknown.  Crucially, differences in endothelial activation at different 
time points may lead to more activated neutrophils being pulled from circulation.  It is 
therefore possible that tissue neutrophils would behave differently to circulating cells. 
The results I have provided do not describe a universal postoperative phenotype, because all 
assays were not performed within the same patients.  Specifically, patients were recruited 
from two other clinical studies (POMO and VISION), with the POMO group being split into 
treatment (goal directed therapy) and control (standard care) populations.  The overall 
patient features are described within tables 4.1-4.3, and the patient features for each assay 
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described within table 4.4. For example, less patients from the respiratory burst preop-
POD2 group had malignancy than within the respiratory burst preop-POD2-POD5.  
Patients were not sampled upon postoperative days one and three, therefore it is uncertain 
how long the respiratory burst is depressed for.   
 
4.4.4 Conclusions and further work 
This study has identified an impairment of the neutrophil respiratory burst at postoperative 
day two, as well as a reduction in the Fc receptor CD16.  This impairment is compatible 
with diminished bacterial killing and possible prolongation of inflammation which may both 
predispose to postoperative complications. The data support a functional cellular defect 
within the burst machinery itself, which is present within bone marrow as well as circulating 
cells following elective surgery.  Microscopy examination of blood samples maybe 
performed to identify the proportion of neutrophil precursors at different time points.  
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Chapter 5 – Postoperative neutrophil mitochondrial 
dysfunction and regulation of the respiratory burst 
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5.1 Introduction 
Oxidative stress is a feature of the human response to surgical injury (Biglioli et al., 2003; 
Lefer and Lefer, 1996; Stipancic et al., 2005).  This chapter will investigate the role of 
reactive oxygen species (ROS) within postoperative neutrophils, focussing upon the 
mechanistic relationship between resting cellular ROS levels and activated functional activity.   
Mitochondria are a common source of ROS within cells which synthesise bioenergetic ATP 
through oxidative phosphorylation (Fig 1.4). While neutrophils are considered to be solely 
glycolytic (Borregaard and Herlin, 1982; Karnovsky, 1968; Segal and Abo, 1993) they do 
contain mitochondria which maintain a membrane potential independent of cytoplasmic ATP 
production (Fossati et al., 2003; Maianski et al., 2003; Pryde et al., 2000), and regulate 
neutrophil life span through constitutive apoptosis. 
In patients with established sepsis, monocytes and platelet mitochondrial function is 
impaired (Japiassú et al., 2011; Protti et al., 2014; Weiss et al., 2015).  Similar impairment of 
neutrophil mitochondria is supported by genomic investigations of healthy volunteer 
endotoxin exposure, which reveal a dramatic reduction in the expression of genes 
associated with mitochondrial function (Calvano et al., 2005).  Within a monocyte cell line, 
mitochondrial ROS production at complex III has been shown to transduce hypoxic and 
outside inflammatory stimuli (Brunelle et al., 2005) through stabilisation of HIF and the 
integration of inflammatory signals that promote inflammasome assembly (Menu and Vince, 
2011).   
Since the majority of priming agents simultaneously augment neutrophil effector function 
and prolong lifespan (El Kebir et al., 2009; Lee et al., 1993;  a C. Lee et al., 1999), it is 
plausible that neutrophil mitochondria may be involved in inflammatory/immune effector 
signalling in addition to apoptotic signalling.  Specifically, the generation of mitochondrial 
ROS within inflamed neutrophils may be responsible for the diminished postoperative 
respiratory burst response. 
The regulation of neutrophil PHOX by mitochondrial ROS has not been directly addressed 
within the literature before.  However, several investigations have addressed roles for 
(mitochondrial) ROS during activation of PHOX, and other immune processes within a 
range of immune cells.   The direct addition of H2O2 to human neutrophils increases PHOX 
derived superoxide (El Jamali et al., 2010).  Within human lymphoblasts, which contain 
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functional PHOX, the addition of the complex I inhibitor rotenone 10μM and complex III 
inhibitor antimycin A 10μM increases NADPH oxidase derived extracellular ROS (Dikalov 
et al., 2012).   Within human neutrophils the inhibition of complex I and III increases resting 
neutrophil cellular ROS,  impairs cytoskeletal rearrangement (Fossati et al., 2003) and 
inhibits LPS induced NF-kB activation and proinflammatory cytokine production (Zmijewski 
et al., 2008).   
 
5.1.1 Hypothesis 
Postoperative neutrophils exhibit mitochondrial dysfunction, which may inhibit the 
respiratory burst. 
 
5.1.2 Aims 
 
1. To describe postoperative changes in resting neutrophil mitochondrial function.  
2. To determine whether postoperative neutrophil mitochondrial oxidative stress is 
mechanistically responsible for the impaired respiratory burst response.  
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5.2 Methods 
Patient samples were collected from POMO (ISRCTN76894700) and VISION-UK 
(10/WNo03/25) studies, and the patient characteristics for each experimental assay are 
detailed in table 5.1.  Laboratory methods, including HL-60 cell line and differentiation, are 
detailed in General Methods.  Neutrophil isolation and assays in sections 5.2.1 and 5.2.2 are 
more completely described in General Methods.  
5.2.1 Perioperative human mitochondrial function 
The measurement of cellular and mitochondrial ROS and neutrophil apoptosis are described 
in General Methods.  
5.2.2 Model 1: Respiratory complex inhibition within human 
neutrophils  
Respiratory complex inhibitor experiments were performed within a standardised, isolated 
cell system consisting of 1x106/ml neutrophils suspended within PBS plus glucose 10mM. 
The complex I inhibitor rotenone and complex III inhibitors Myxothiazol and Antimycin A 
were added to preoperative and postoperative samples initially at 10µM doses, as described 
previously (Zmijewski 2008, Dikalov 2012).  30 minute incubation times were chosen to 
minimise the impact of ex-vivo incubation upon neutrophil function (Wenisch et al., 2001).  
Time course assays were performed with a plate reader and the ROS probe 
dihydroethidium. 
5.2.3 Model 2: ROS manipulation within cell line model 
Undifferentiated and DMSO-differentiated HL-60 cells were prepared as described within 
general methods.  The resting and PMA stimulated ROS profiles of undifferentiated and 
DMSO differentiated HL-60 cells were characterised using probes MitoSOX-Red, 
dihydroethidium, rhodamine-123, and TMRM.     
The redox status of resting HL60 cells was manipulated using ROS generating myxothiazol, 
and the ROS scavenger MitoTEMPO.  Dose response experiments with MitoTEMPO, within 
an isolated system using cytochrome c, identified MitoTEMPO 500μM to provide the 
greatest antioxidant protection within an isolated system (Trnka et al., 2009).  Similarly, my 
own dose response / time course experiments with undifferentiated (‘postoperative’) HL-60 
cells supported the 500μM dose, with an incubation time of 240 minutes. 
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5.3 Results 
5.3.1 Patient characteristics 
 
Assay 
 
Total 
number 
 
Age 
(median, 
[IQR])  
(years) 
 
Male 
(n, [%]) 
 
Surgical speciality 
(n, [%]) 
  
Patient  
study  
source 
    Hepato- 
biliary 
Gynae- 
cology 
Urology Maxillo- 
facial 
Gastro- 
intestinal 
Ortho- 
paediacs 
Breast  
Whole blood 
granulocytes DHR  
(preop-pod2) Fig 5.1AB 
18 63 
(58-73) 
12 [67] 12 [67] 1 2 - 1 -  POMO 
Isolated granulocytes 
Mitosox.  
(preop-POD2) Fig 5.1CD 
8 61 
(51-69) 
4 [50] 1 [13] 1 [13] 3 [13] - 2 [25] -  VISION 
Whole blood TMRM 
(preop-POD2) Fig 5.2 AB 
15 61 
[54-65] 
8 [53] 3 [20] 1 [7] 7 [47] 2 [13] 1 [7] 1 [7]  VISION 
Isolated granulocytes 
TMRM 
(preop-POD2) Fig 5.2C 
4 66.5 
[61-72] 
2 [50] 1 [25] 1 [25] 2 [50] - - -  VISION 
Isolated granulocytes 
JC-1 
8 69.5  
(60-75) 
3 [38] 6 [80] 1 - - 1 -  POMO 
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(preop-POD2) Fig 5.3AB 
Isolated granulocytes 
Annexin 
(preop-POD2) Fig 5.4AB 
9 68 
(64-79) 
3 [33] 1 [11] 3 [33] - - 1 [11] 4 [44]  VISION 
Fas (CD95) 
(preop-POD2) Fig 5.5 AB 
17 71 
(65-75) 
7 [41] 12 [71] 2 2 - 1 -  VISION 
Rotenone 10µM + DHR 
Fig 5.6 A 
16 60 
(53-72) 
6 [38] 2 [13] 4 [25] 6 [38] -  2 [13] 2 [13] VISION 
Rotenone 10µM 
 + Mitosox 
Fig 5.6 BC 
7 55 
(51-69) 
4 [57] 1 [14] 0 3 [43] - 2 [29] - 1 [14] VISION 
Rotenone 10µM 
 + PMA + DHR 
Fig 5.6 DE 
18 61.5 
(53-74) 
8 [44] 3 [17] 5 [28] 6 [33] - - 2 [11] 2 [11] VISION 
Rotenone 10µM  
+ PMA + DHR 
(preop-POD2) Fig 5.7 
6 57 
(54– 59) 
3 [50] 1 [17] 1 [17] 2 [33] - - 1 [17] 1 [17] VISION 
Myxothiazol 10µM  
+ Rhodamine 
Fig 5.8 AB 
7 65 
(61-77) 
4 [57] - 1 [14] 4 [57] - 2 [29] - - VISION 
Myxothiazol 10µM   
+ Mitosox  
7 55 
(51-69) 
4 [57] 1 [14] - 3 [43] - 2 [29] - 1 [14] VISION 
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Fig 5.8 CD 
Myxothiazol 10µM  
+ PMA + DHR 
Fig 5.8 EF 
5 63 
(59-90) 
2 [40] - 1 [20] 2 [40] - 2 [40] - - VISION 
Myxothiazol 10µM  
+ CD16 
Fig 5.9 AB 
6 60 
(55-69) 
3 [50] 1 [17] - 3 [50] - - 2 [33] - VISION 
Myxothiazol 10µM  
+ Annexin 
Fig 5.9 CDE 
3 54 
(54-68) 
2 [67] - - 3 [100] - - - - VISION 
Antimycin A 10µM 
 + DHR 
Fig 5.10 AB 
11 62 
(58-74) 
6 [55] 2 [18] 1 [9] 2 [18] 1 [9] 3 [27] 2 [18] - VISION 
Antimycin A 10µM 
 + PMA + DHR 
Fig 5.10 CD 
11 62 
(58-74) 
6 [55] 2 [18] 1 [9] 2 [18] 1 [9] 3 [27] 2 [18] - VISION 
Antimycin A 10µM 
 + CD16 
Fig 5.11 AB 
7 61 
(58-65) 
3 [43] 2 [29] - - 1 [14] 2 [29] 2 [29] - VISION 
Antimycin A 10µM 
 + Annexin 
Fig 5.11 CDE 
6 62 
(60-67) 
3 [50] 2 [33] - - 1 [17] 1 [17] 2 [33] - VISION 
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Myxothiazol 1µM 
 + DHR 
Fig 5.12 AB 
14 65 
(59-72) 
8 [57] 1 [7] 1 [7] 4 [29] - 1 [7] 7 [50] - VISION 
Myxothiazol 1µM 
 + PMA + DHR 
Fig 5.12 CD 
12 66 
(61-75) 
6 [50] - 1 [8] 3 [25] - 1 [8] 7 [58] - VISION 
Myxothiazol 1µM 
 + CD16 
Fig 5.12 E 
10 65 
(59-67) 
6 [60] 1 [10] 1 [10] 3 [30] - - 5 [50] - VISION 
Myxothiazol 1µM 
 + Annexin 
Fig 5.12 F 
6 69 
(61-76) 
3 [50] - 1 [17] - - 1 [17] 4 [67] - VISION 
Myxothiazol ± PMA + 
DHE  
2 55, 65 1 [50] - 1 [50] - - 1 [50] - - VISION 
Table 5.1 Characteristics of the patients for Chapter 5 experimental assays.  
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5.3.2 Perioperative neutrophil mitochondrial phenotype 
Rhodamine-123 (Fig 5.1 A,B) and MitoSOX Red fluorescence (Fig 5.1 C,D) were increased 
in postoperative resting whole blood and isolated neutrophils respectively, when compared 
to matched preoperative control samples, which supports the presence of increased cellular 
and mitochondrial ROS within postoperative neutrophils.   
Figure 5.1 Perioperative resting neutrophil reactive oxygen species production. 
All data are paired preoperative and postoperative samples.  A Overlay plot demonstrating typical change in 
perioperative Rhodamine-123 fluorescence. B Box whisker plots (median-IQR) demonstrating population 
change in perioperative Rhodamine-123 production. Paired t-test.  C Overlay plot demonstrating typical 
change in perioperative Mitosox-Red fluorescence, D Paired line plot demonstrating population change in 
perioperative Mitosox-Red fluorescence, Wilcoxon matched pairs test 
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Within whole blood neutrophils TMRM staining was increased postoperatively (Fig 5.2 A,B), 
suggesting hyperpolarisation of the mitochondrial membrane potential within postoperative 
neutrophils.   
 
 
Figure 5.2 Perioperative resting neutrophil mitochondrial membrane potential: 
TMRM assay (whole blood and isolated granulocytes) 
All data are paired preoperative and postoperative samples.  A Overlay plot demonstrating typical patients 
perioperative change in whole blood neutrophil TMRM fluorescence.  10μM FCCP used as positive control. B 
Population box-whisker plots for perioperative change in whole blood neutrophils TMRM fluorescence.  
Wilcoxon matched pairs test used. C Perioperative change in isolated neutrophil TMRM fluorescence. 
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By contrast, isolated neutrophil TMRM fluorescence (Fig 5.2C) and JC-1 fluorescence (Fig 
5.3 A,B) was diminished within postoperative neutrophils. 
Figure 5.3 Perioperative resting isolated                                                                  
neutrophil mitochondrial membrane potential: JC-1 assay. 
A Density plots demonstrating perioperative change in isolated neutrophil JC-1 fluorescence.  FCCP 10μm 
used as positive control to generate 95% threshold for loss of mitochondrial membrane potential B Paired 
line diagram demonstrating population change in proportion of isolated neutrophils which have lost 
mitochondrial membrane potential, as determined by JC-1 fluorescence and comparison to individualised 
FCCP positive controls, Wilcoxon matched pairs test used. 
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There was no difference between matched preoperative and postoperative neutrophil 
Annexin-V and PI expression/uptake (Fig 5.4 A,B).  These assays were performed 
immediately following neutrophil isolation.   Neutrophil apoptosis is accompanied by a 
specific, and dramatic (80%+) downregulation of cell surface CD16 (Dransfield et al., 1994).  
Therefore, although chapter 4 identified an approximate 20% reduction in cell surface 
CD16, this is not a sufficient decrease to support the presence of apoptosis.  Together 
these data suggest that there are no differences in the rate of neutrophil apoptosis on 
postoperative day two as preoperatively,  
Figure 5.4 Perioperative isolated neutrophil apoptosis: Annexin-V assay. 
All data are paired preoperative and postoperative samples.  A Density plots demonstrating isolated 
neutrophil perioperative combined annexinV-FITC/PI staining.  B Box whisker plots (median-IQR-max/min) 
demonstrating perioperative change in isolated neutrophil annexin V/PI expression, overall p-value for one 
way ANOVA reported.   
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However, expression of the extrinsic apoptosis regulator protein Fas (CD95) was higher 
upon postoperative neutrophils (Fig 5.5 A,B).  Engagement of Fas activates the extrinsic 
apoptotic pathway, and may also have synergistic effects in promotion of intrinsic apoptosis 
(Brown and Savill, 1999; Liles et al., 1996; Renshaw et al., 2000).  Postoperative neutrophils 
may be more susceptible to extrinsic apoptotic signalling. 
Figure 5.5 Perioperative neutrophil apoptosis: cell surface Fas (CD95). 
A Population data demonstrating whole blood granulocyte cell surface CD95 expression, paired t-test used.   
B overlay plot demonstrating typical patient sample.   
 
Collectively these data support the presence of postoperative neutrophil mitochondrial 
dysfunction, characterized by increased mitochondrial ROS and relatively hyperpolarised 
mitochondrial membrane potential within whole blood samples.  By contrast isolated 
postoperative neutrophils display a loss of mitochondrial membrane potential, possibly 
because of an increased sensitivity to the isolation process.  This study found no evidence to 
support the presence of increased neutrophil apoptosis on postoperative day two, however 
increased Fas receptor expression suggests these cells may be more sensitive to in-vivo FasL 
death receptor pathway signalling. 
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5.3.3 Model 1: Respiratory complex inhibition within human 
neutrophils 
The data presented above supports the presence of mitochondrial oxidative stress within 
resting postoperative neutrophils.  Within chapter 4, I demonstrated that activated 
postoperative neutrophils possess a diminished respiratory burst.  Here, I test the 
hypothesis that resting oxidative stress is mechanistically responsible for the diminished 
respiratory burst within postoperative cells, using two different models of oxidative stress. 
The principal sites of mitochondrial ROS production are believed to be respiratory 
complexes I and III (Chen et al., 2003; Lenaz et al., 2006).  Previous investigators have 
demonstrated that the addition of low doses of inhibitors to respiratory complex I and III to 
neurones promotes mitochondrial hyperpolarisation and ROS generation (Forkink et al., 
2014) - the same phenotype I identified within postoperative cells.  Therefore, for the first 
model I incubated granulocytes with respiratory complex inhibitors and measured 
respiratory burst responses.  An isolated neutrophil system was chosen for these 
experiments to ensure the ratio of cells to inhibitor was constant.   
 
5.3.2.1 Respiratory complex I inhibition: Rotenone. 
Incubation of isolated preoperative neutrophils with rotenone 10μM for thirty minutes did 
not increase resting cell rhodamine-123 fluorescence (Fig 5.6 A) but there was a trend for 
increased resting MitoSOX-Red fluorescence (Fig 5.6 B,C).  Rotenone increased the PMA 
activated respiratory burst (Fig 5.6 D,E).  Rotenone 10μM did not alter expression of 
Annexin-V or CD16 in isolated preoperative neutrophils (data not shown).   
182 
 
 
Figure 5.6 The effect of respiratory complex I inhibition with Rotenone 10µM 
upon isolated neutrophil PMA respiratory burst. 
All rotenone incubations performed with rotenone 10μM, at 37oC for 30minutes. Negative samples are 
unstained, without MitoSOX Red.  Vehicle and rotenone samples are with MitoSOX Red.  Wilcoxon matched 
pairs test used throughout.  A Paired line diagram demonstrating change in proportion of resting neutrophils 
generating Rhodamine-123 following addition of Rotenone.  B C Overlay plot / paired line diagram 
demonstrating typical sample / population response of MitoSOX-Red fluorescence following addition of 
Rotenone D E Overlay plot / Box-whisker (median-IQR-max/min) demonstrating typical response / population 
response in PMA-activated respiratory burst (Rhodamine-123 fluorescence) after preincubation with 
Rotenone.   
183 
 
Pre-incubation with rotenone increased the preoperative PMA respiratory burst in every 
patient, however it was reduced for one patient postoperatively (Fig 5.7)  
Figure 5.7 Perioperative change in isolated neutrophil PMA stimulated 
respiratory burst following incubation with rotenone 10µM. 
Isolated neutrophils were incubated with rotenone 10µM for 30 minutes prior to respiratory burst assay. 
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5.3.2.2 Respiratory complex III inhibition: Myxothiazol and Antimycin A 
Incubation of isolated resting neutrophils with Myxothiazol 10µM for 30mins increased 
Rhodamine (Fig 5.8 A,B) and MitoSOX-Red (Fig 5.8 C,D) derived fluorescence and was 
accompanied by a trend for reduced PMA stimulated Rhodamine fluorescence (Fig 5.8 E,F).   
Figure 5.8 The effect of myxothiazol 10µM upon isolated neutrophil ROS. 
All Myxothiazol incubations performed at 37oC for 30minutes.  Wilcoxon matched pairs test used 
throughout. A B Overlay plot / paired line diagram demonstrating typical sample / population response of 
resting neutrophils Rhodamine-123 fluorescence following incubation with Myxothiazol. C D Overlay plot / 
paired line diagram demonstrating typical sample population response of resting neutrophils Mitosox-Red 
fluorescence following incubation with Myxothiazol. E F Overlay plot / paired line diagram demonstrating 
typical sample / population response of PMA stimulated neutrophil burst. 
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However, the addition of Myxothiazol 10µM to isolated neutrophils also promoted an 
approximately 80% down-regulation of cell surface CD16 (Fig 5.9 A,B) and a trend for 
increased Annexin binding (Fig 5.9 C-E).  These data suggest that incubation of isolated 
neutrophils with Myxothiazol 10µM for 30 minutes induces apoptosis. 
Figure 5.9 The effect of Myxothiazol 10µM upon isolated neutrophil apoptosis. 
All Myxothiazol incubations performed at 37oC for 30 minutes. A B Overlay plot / Paired line diagram 
demonstrating typical sample / population change in neutrophil surface CD16 expression following incubation 
with Myxothiazol, Wilcoxon matched pairs test used C D E Density plots / paired line diagram demonstrating 
effect of Myxothiazol upon neutrophil apoptosis (Annexin-V positivity).  Quadrant numbers represent 
percentage of gated population within each quadrant. F Paired line diagram demonstrating change in isolated 
neutrophil TMRM fluorescence following incubation with Myxothiazol. 
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Incubation of isolated neutrophils with a second respiratory complex III inhibitor - 
Antimycin-A 10µM - produced similar effects upon resting and PMA activated neutrophil 
ROS levels to Myxothiazol 10µM, with an increase in resting Rhodamine fluorescence (Fig 
5.10 A,B), reduction in PMA stimulated Rhodamine fluorescence (Fig 5.10 C,D). 
 
Figure 5.10 The effect of Antimycin A 10µM upon isolated neutrophil ROS.         
All Antimycin A incubations performed at 37oC for 30minutes. Wilcoxon matched pairs test used throughout. 
A B Overlay plot / paired line diagram demonstrating typical sample / population response of resting 
neutrophils Rhodamine-123 fluorescence following incubation with Antimycin A. C D Overlay plot / paired line 
diagram demonstrating typical sample / population response of PMA stimulated neutrophil following 
preincubation with Antimycin A  
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Incubation of isolated neutrophils with Antimycin A consistently downregulated neutrophil 
cell surface CD16 (Fig 5.11 A,B), and tended to increase Annexin V binding (Fig5.11 C-E), 
suggesting than incubation with Antimycin A promotes resting isolated neutrophil apoptosis.  
However, the magnitude of CD16 downregulation and of annexin binding was less than 
previously with Myxothiazol (Fig 5.9). 
Figure 5.11 The effect of Antimycin A 10µM upon isolated neutrophil apoptosis. 
All Antimycin A incubations performed at 37oC for 30minutes.  A B Overlay plot / paired line diagram 
demonstrating typical sample / population change in neutrophil surface CD16 expression following incubation 
with antimycin A, Wilcoxon matched pairs test used. C D E Density plots / paired line diagram demonstrating 
effect of antimycin A upon neutrophil apoptosis (Annexin-V positivity). 
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Within other cell types, respiratory complex III inhibitors demonstrate a dose dependent 
effect upon mitochondria, with high doses causing lipid peroxidation with complex 
disaggregation and lower doses increasing the mitochondrial membrane potential while 
maintaining mitochondrial viability (Lenaz et al., 2006).  Therefore, I repeated these 
experiments using Myxothiazol 1µM.  Myxothiazol 1µM did not cause a measurable change 
in resting neutrophil Rhodamine fluorescence (Fig 5.12 A,B), however PMA stimulated 
Rhodamine fluorescence was increased (Fig 5.12 C,D), without any change in cell surface 
CD16 (Fig 5.12 E) or Annexin (Fig 5.12 F).  
Figure 5.12 The effect of Myxothiazol 1µM upon                                          
isolated neutrophil ROS and apoptosis 
All myxothiazol incubations performed at 37oC for 30 minutes. Wilcoxon matched pairs test used 
throughout.  A B Overlay plot / paired line diagram demonstrating typical sample / population response of 
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resting neutrophils Rhodamine-123 fluorescence following incubation with Myxothiazol 1µM. C D Overlay 
plot / paired line diagram demonstrating typical sample / population response of PMA stimulated neutrophils 
following preincubation with myxothiazol 1µM. E Paired line diagram demonstrating population change in 
neutrophil surface CD16 expression following incubation with Myxothiazol. F Paired line diagram 
demonstrating effect of myxothiazol upon neutrophil apoptosis (Annexin-V positivity).  
 
Having demonstrated differences between Myoxthiazol 1µM and 10µM upon resting and 
activated isolated neutrophil ROS levels following 30-minute incubation, I next tested the 
effect of incubation time for these Myxothiazol concentrations using a platereader (Fig 5.13) 
to permit sequential fluorescence measurements.  At 1µM Myxothiazol did not increase 
resting cell DHE fluorescence, and did not affect PMA stimulated burst.  At 10µM 
Myxothiazol tended to increase resting neutrophil dihydroethidium fluorescence, but 
reduced PMA stimulated respiratory burst fluorescence (Fig 5.8).   
Therefore, myxothiazol may have different effects upon resting DHR and DHE fluorescence.  
10µM myxothiazol may increase resting DHR and DHE fluorescence, however 1µM only 
increases resting DHE fluorescence.   
 
Figure 5.13 The effect of Myxothiazol 1uM and 10uM upon isolated resting and 
PMA stimulated neutrophil DHE fluorescence.    
Two patient samples were used.  Each condition was performed in triplicate at each time point.  Graph 
represents mean +/- standard deviation. 
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5.3.4 Model 2: HL-60 cell line model  
The data from model 1 describes how respiratory complex III inhibitors may increase 
resting neutrophil ROS and impair the PMA stimulated respiratory burst within healthy 
volunteer/preoperative cells – mimicking the postoperative neutrophil phenotype.  Now, I 
again tested the hypothesis that mitochondrial ROS may impair the neutrophil respiratory 
burst within a new model, using the HL-60 promyelocyte cell line.  DMSO-differentiated 
HL-60 cells have been widely employed as a model to explore neutrophil biology (Birnie, 
1988). The addition of DMSO to undifferentiated promyelocyte precursors promotes their 
differentiation into neutrophil like cells over a 5-7 day period (Collins et al., 1979; 
Newburger et al., 1979).  DMSO differentiated cells display diminished ATP turnover and an 
increased respiratory burst when compared to undifferentiated cells (Muranaka et al., 2005; 
Newburger et al., 1979).  Therefore, correlation of HL-60 oxidative stress/respiratory burst 
profile permits further interrogation of the primary hypothesis that mitochondrial 
dysfunction (ROS) may regulate the neutrophil respiratory burst. 
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5.3.3.1 DMSO differentiated and undifferentiated HL-60 cells mimic the 
oxidative characteristics of preoperative and postoperative neutrophils 
respectively. 
Resting undifferentiated HL60 cells displayed increased MitoSOX Red (Fig 5.14 A,B), 
Rhodamine-123 (Fig 5.14 C,D) and TMRM (Fig5.15 E,F) fluorescence.  These data suggest 
the resting undifferentiated HL-60 cells contain more mitochondrial and cellular ROS than 
DMSO differentiated cells.  
 
Figure 5.14 Resting HL-60 cell ROS characteristics. 
Overlay plots demonstrate typical samples, dot plots population responses.  A B MitoSOX Red fluorescence 
of resting HL-60 cells.  C D Rhodamine fluorescence of resting HL-60 cells. E F TMRM fluorescence in 
resting HL-60 cells, with FCCP 10uM positive control samples.  
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PMA activation caused a reduction in DMSO differentiated MitoSOX Red fluorescence 
(Fig5.15 A,B), and an increase in cellular ROS production (Fig 5.15 C,D), that were not 
evident within undifferentiated cells.    DMSO differentiated HL-60 cells and undifferentiated 
HL-60 cells mimic the resting ROS characteristics I identified within preoperative and 
postoperative neutrophils. 
 
Figure 5.15 PMA activated HL-60 cell ROS characteristics 
Overlay plots demonstrate typical samples, dot plots population responses.  A B MitoSOX Red fluorescence 
of PMA stimulated HL-60 cells C D Rhodamine-123 fluorescence of PMA stimulated HL-60 cells 
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5.3.3.2 The addition of Myxothiazol 10µM to DMSO differentiated HL-60 cells 
increases resting cell ROS, but not the PMA stimulated respiratory burst. 
Next, I sought to determine whether I could recreate the postoperative ROS phenotype 
within ‘preoperative’ DMSO differentiated cells by increasing resting ROS levels through the 
addition of Myxothiazol 10µM and promoting a decrease in activated DMSO differentiated 
respiratory burst. 
Myxothiazol 10µM did not increase resting cellular ROS, but did increase PMA stimulated 
ROS (Fig 5.13 A,B) - similar to the addition of Myxothiazol 1uM to isolated human 
neutrophils (Fig 5.12).  Therefore, I tested a higher dose of Myxothiazol, and found that the 
addition of 100µM Myxothiazol to DMSO differentiated HL-60 cells increased baseline ROS, 
but had no significant effect upon PMA activated cell ROS production (Fig 5.16 A,B).  The 
addition of Myxothiazol to DMSO differentiated HL60 cells did not reproduce the 
postoperative neutrophil phenotype. 
 
Figure 5.16 The effect of Myxothiazol upon resting and PMA stimulated DMSO 
differentiated (‘preoperative’) HL-60 cell ROS production. 
Myxothiazol incubations were performed for 20mins, prior dihydrorhodamine assay as described above. A 
Resting DMSO differentiated HL60 cells. B PMA simulated DMSO differentiated HL60 cells.   
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5.3.3.3 Addition of the mitochondrial antioxidant MitoTEMPO to 
undifferentiated HL-60 cells does not increase the PMA stimulated respiratory 
burst 
Next, I attempted to induce the preoperative ROS phenotype (low resting ROS, high 
activated ROS) within undifferentiated HL-60 cells (analogous to postoperative neutrophils), 
through the addition of the mitochondrial antioxidant MitoTEMPO.   
Previous investigators have published MitoTEMPO incubation data at doses ranging from 
25µM to 500µM and times ranging from 30mins to 240mins (Dikalov et al., 2014; Trnka et 
al., 2009).  At lower dose range and incubation times I observed no effects upon 
undifferentiated HL-60 cell ROS production.  Incubation of undifferentiated HL-60 cells with 
MitoTEMPO 500µM for 240 minutes tended to increase resting cell MitoSOX Red 
fluorescence (Fig 5.17 A,B), but there was no clear effect upon either resting cell Rhodamine 
fluorescence (Fig 5.17 C,D) or PMA activated Rhodamine fluorescence (Fig 5.17 E,F).   
    
Figure 5.17 The effect of mitochondrial antioxidant mitoTEMPO upon resting 
and PMA stimulated undifferentiated (‘postoperative’) HL-60 cells. 
Undifferentiated HL-60 cells were incubated with MitoTEMPO 500µM for 240minutes prior to addition of 
ROS probes or PMA activation for 10mins then subsequent addition of ROS probes.  Overlay plots 
demonstrate typical samples, dot plots population responses.  Mann-Whitney test where statistics used.  A B 
MitoSOX Red fluorescence, resting cells. C D Rhodamine fluorescence, resting cells.  E F Rhodamine 
fluorescence, PMA activated cells. 
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5.4 Discussion 
 
5.4.1 Key findings 
This study has made several findings which support the presence of dysfunctional 
mitochondria within postoperative neutrophils.  Mitochondria within postoperative 
neutrophils display a raised mitochondrial membrane potential and produce increased 
amount of mitochondrial ROS.  Two models were presented which each support a 
mechanistic association between elevated postoperative mitochondrial ROS and the 
impaired activated cell respiratory burst.  
 
1. Mitochondrial dysfunction is acquired within postoperative neutrophils.  
Postoperative neutrophil mitochondria produce more ROS and have a 
hyperpolarised membrane potential when compared to preoperative cells.  
Together, these observations suggest that damaged mitochondria persist within 
postoperative cells, and that a distal impairment of oxidative phosphorylation may be 
preventing the return of hydrogen ions to the matrix.  These findings are consistent 
with dysfunctional mitochondria that release ROS, impair cellular function and may 
ultimately promote apoptosis and/or inflammation. 
 
An association between raised membrane potential and increased ROS production 
has been previously identified within neurones.  Although an increase in 
mitochondrial membrane potential maybe plausibly associated with an increase in 
ROS production, there are other possible sources of ROS production within 
postoperative neutrophils, such as endoplasmic reticulum or PHOX activity within 
partially activated cells (Balaban et al., 2005; Landmesser et al., 2003; Sevier and 
Kaiser, 2008).   
 
2. The proportion of neutrophils undergoing (Annexin-V positive) apoptosis 
is similar in isolated preoperative and postoperative preparations.  Total 
apoptosis and overt necrosis were unchanged within postoperative samples when 
compared to paired preoperative controls.  Reported rates of in vitro neutrophil 
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apoptosis widely between different laboratories (Luo and Loison, 2008), e.g. 10 to 
75% at 6hours (Blomgran et al., 2007; Cowburn et al., 2005).  A previous 
perioperative study identified an increased rate of neutrophil apoptosis at 12hrs       
(Delogu et al., 2001a) and decreased at 24hrs (Fanning et al., 1999b), but neither 
reported on postoperative day two.  FasL was upregulated on postoperative cells.  
As well as mediating extrinsic apoptosis, there is evidence for cross talk between 
FasL and neutrophil constitutive apoptosis (Brown, 1999; Liles et al., 1996; Renshaw 
et al., 2000) and may directly promote mitochondrial dysfunction (Watson et al., 
1999).    
 
In contrast to whole blood samples, isolated neutrophils demonstrated a 
postoperative loss of mitochondrial membrane potential - an established measure of 
apoptosis - suggesting that postoperative cells may be more likely to enter apoptosis 
under physiologically stressful conditions. 
 
3. Two different models of neutrophil mitochondrial dysfunction support a 
mechanistic relationship between resting ROS levels and respiratory 
burst function: 
 
a.  Pharmacological inhibition of respiratory complex III.  Myxothiazol is a 
competitive inhibitor of ubiquinol, and blocks electron transfer to the Rieske 
protein of complex III (Thierbach and Reichenbach, 1981).  Antimycin binds to 
the Qi site of cytochrome reductase within complex III (Bolgunas et al., 2006).  
Both Myxothiazol and Antimycin increased resting neutrophil ROS and decreased 
the PMA activated respiratory burst.  The magnitude of respiratory burst 
depression and cell surface CD16 expression which followed incubation of 
preoperative neutrophils with Antimycin 10µM was similar to that found within 
freshly isolated postoperative neutrophils.  Myxothiazol 10µM produced greater 
depressions in PMA stimulated respiratory burst and CD16 expression than was 
seen in postoperative neutrophils.  Both Antimycin A 10µM and Myxothiazol 
10µM caused an increased rate of neutrophil apoptosis when compared to 
resting postoperative cells.   
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Conversely, lower doses of respiratory complex III inhibitors and complex I 
inhibition augmented/primed the neutrophil respiratory burst.   These findings 
are consistent with previously reported effects of rotenone 10µM and 
Myxothiazol 10µM upon lymphoblast respiratory burst (Dikalov et al., 2014) and 
Oligomycin 1ug/ml upon neutrophil burst (Fossati et al., 2003).   This observation 
supports the presence of decreased complex I responsiveness within 
postoperative cells, and may be mechanistically relevant to the decreased 
postoperative burst.  The priming effect of Rotenone was not apparent within 
postoperative neutrophils, which is compatible with inhibition of the respiratory 
burst within preoperative neutrophils by higher dose complex III inhibition. 
 
 
b. DMSO differentiated and undifferentiated HL-60 cells parallel the 
resting and PMA stimulated oxidative profiles of preoperative and 
postoperative neutrophils respectively.  DMSO differentiated HL60 cells 
demonstrate lower resting cellular ROS production with higher PMA stimulated 
ROS production.  Conversely, undifferentiated HL60 cells demonstrate higher 
resting cellular ROS production, but lower PMA stimulated ROS production. The 
addition of Myxothiazol to DMSO differentiated HL60 cells and MitoTEMPO to 
undifferentiated cells did not mimic the postoperative and preoperative 
neutrophil phenotypes respectively.     
 
5.4.2 Interpretation of key findings 
These data describe several related differences between preoperative and postoperative 
neutrophil mitochondrial function.  Together, these observations support the presence of 
dysfunctional mitochondria within postoperative neutrophils and furthermore, are 
consistent with a mechanistic relationship between resting neutrophil ROS and the 
respiratory burst.    
The methodological advantages presented by the study of surgical patients allowed carefully 
timed postoperative samples to be taken and compared to individualised control results.  
The only previous investigation of  postoperative neutrophil mitochondrial function used a 
single probe (DiOC6) within isolated cells, and reported an increased rate of apoptosis at 12 
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hours post insult (Delogu et al., 2001) which had fallen at 24 hours (Fanning et al., 1999), 
neither sampled at 48 hours post insult.   
Previously, the mechanistic impact of mitochondrial ROS upon neutrophil inflammatory 
function has only been described in terms of NF-kB stabilisation and cytokine expression, 
not actual immune effector mechanisms (Zmijewski et al., 2009, 2008).  The interrogation of 
effector mechanisms does not necessarily reflect changes observed in alternative markers of 
inflammation do not necessarily correlate with those of neutrophil effector function 
[Chapter 4].  
The production of mitochondrial ROS following hyperpolarisation of mitochondrial 
membrane potential has been described before within neurones, and was associated with 
diminished ATP production and H+ utilisation (Abramov et al., 2005, 2004).  Alternative 
explanations for the increase in mitochondrial ROS would be an increase in flux through 
oxidative phosphorylation or impaired ROS detoxification capacity, including reduced 
mitochondrial superoxide dismutase, cytoplasmic catalase or glutathione peroxidase 
(Hellmich et al., 2005)(Fosslien, 2003; Hellmich et al., 2005; Lebovitz et al., 1996).  However, 
none of these alternative explanations provides a unifying explanation for all the 
experimental observations I have made, which the presence of postoperative mitochondrial 
dysfunction does.  Glutathione peroxidase requires NADPH, therefore it is possible that 
impaired hexose monophosphate shunt may promote both an increase in resting ROS levels 
and an impaired respiratory burst within activated cells.  
The differences between whole blood and isolated data – where isolated data showed loss 
of postoperative mitochondrial membrane potential – may be explained by an increased 
sensitivity of postoperative cells to the isolation process.  This sensitivity may be a 
manifestation of limited postoperative bioenergetic reserve, thereby limiting effector 
function (explored further within chapter 6).  
The increase in PMA stimulated respiratory burst following addition of Rotenone 10µM or 
Myxothiazol 1µM is supported by previous work which revealed similar increases in PMA 
burst responses following the direct addition of H2O2 (El Jamali et al., 2010) or Oligomycin 
(Fossati et al., 2003) to neutrophils, and Rotenone or Myxothiazol to lymphoblasts (Dikalov 
et al., 2012).  However, other investigators have demonstrated that the incubation of 
neutrophils with complex I and III inhibitors causes diminished NF-kB signalling and cytokine 
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production (Zmijewski et al., 2009, 2008).  Hypoxia has been shown to inhibit the 
respiratory burst and killing of S. aureus in human neutrophils (McGovern et al., 2011).  The 
addition of rotenone 10µM delivered measurable increases in resting neutrophil 
mitochondrial superoxide production (MitoSOX Red), but not overall cellular ROS 
(Rhodamine-123), supporting a mechanistic role for mitochondrial ROS. 
The reduction in postoperative respiratory burst following the addition of the complex I 
inhibitor Rotenone suggests that complex I may act as a signal transducer during the 
respiratory burst, and toward a loss of complex I responsiveness postoperatively.  
Diminished mitochondrial complex I function has been previously described within septic 
peripheral blood mononuclear cells (Garrabou et al., 2012). 
Conversely, the reduction in preoperative respiratory burst following the addition of 
complex III inhibitors Antimycin A 10µM and Myxothiazol 10µM suggests that loss of 
complex III function may mediate the observed postoperative mitochondrial dysfunction.  
Since complex III is the principal source of mitochondrial ROS, distal inhibition of oxidative 
phosphorylation (e.g. absence of terminal electron recipient oxygen) will lead to liberation 
of electrons at complex III, and therefore ROS formation.   Beyond its role in oxidative 
phosphorylation, complex III is critical for wider range of cellular functions that effectively 
function independently of oxidative phosphorylation, such as oxygen tension sensing at  
complex III and initiation of HIF signalling (Brunelle et al., 2005; Klimova and Chandel, 2008).   
Although HIF was first identified as a mediator of hypoxic inflammatory signalling, it is now 
understood to be activated during many other inflammatory insults (Klimova and Chandel, 
2008), which may or may not be dependent upon mitochondrial ROS.  Within other cell 
types HIF signalling and AMPK regulate the interaction between mitophagy and glycolysis.  
Cellular AMP accumulates with bioenergetic stress and is detected by AMPK, which in 
synergy with growth signal integrating mTOR (Papandreou et al., 2006; Semenza et al., 1994; 
Zhang et al., 2007) regulates mitochondrial biogenesis (Jäger et al., 2007).  HIF-1 regulates 
cellular oxygen consumption, in part through the promotion of glycolysis and inhibition of 
mitochondrial biogenesis and function.  Healthy volunteer endotoxin experiments reveal a 
reduction in leukocyte ATP that is associated with simultaneous decline in AMPK and 
increase in  autophagy (Haimovich et al., 2014; Z. Zhang et al., 2010)) at very low doses of 
endotoxin that are insufficient to cause a SIRS response.  
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These two models support a mechanistic role for mitochondrial ROS in the regulation of 
the respiratory burst.  ROS are not only injurious, but at lower concentrations mediate 
signal transduction for a diverse range of cellular functions, where specific redox reactions 
within target proteins causes a change in shape and function (Dröge, 2002).   There are 
many possible targets which could impact upon the respiratory burst function beyond HIF 
signalling e.g. NADPH oxidase assembly and function, inflammatory cytokine binding 
(Davidson et al., 2013; Segal et al., 2010), or regulation of associated cellular processes such 
as NADPH production.  Alternatively, the increase in mitochondrial ROS may not be 
directly related and could be on feature of a wider mitochondrial impairment.  For example, 
maintenance of mitochondrial membrane potential is necessary for calcium/potassium 
transport and calcium homeostasis (Graier et al., 2007), and respiratory burst is a calcium 
dependent process.  Calcium flux through the VDAC family of mitochondrial membrane 
proteins is critical to ROS production, and inhibition of VDAC causes a reduction in 
mitochondrial ROS (Colombini, 2004). 
While human neutrophils are traditionally considered to be solely glycolytic, the 
experiments which determined this were all performed within healthy, non-inflamed, human 
subjects.  Perhaps the bioenergetic profiles of neutrophils during established inflammatory 
responses differ to healthy circulating counterparts.  Indeed, some of these studies have 
reported a change in neutrophil ATP balance following the addition of respiratory complex 
inhibitors (Minakami, 1968; Sbarra and Karnovsky, 1959).  Therefore, it is possible that 
mitochondrial dysfunction may impair postoperative neutrophil immune function through by 
limiting the supply of ATP.    
 
5.4.3 Strengths and weaknesses 
 
Comorbid disease, age and therapeutic interventions are associated with altered 
mitochondrial function, and may confound experimental observations without the selection 
of an appropriately matched control population.  This study used patients matched 
preoperative and postoperative samples, so that each test sample could be compared to its 
own, individualised preoperative control sample.  Theoretically this allows the effect of the 
experimental insult – surgery and anaesthesia – to be individually isolated from baseline 
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variations in immune function.  However, it remains possible that specific comorbidities or 
medications may interact with perioperative insult differently, therefore it is not possible to 
expand the results of individual assays to the wider surgical population.  Since different 
assays were performed in different patients, it is not possible to generalise observations into 
a universal postoperative phenotype.  Samples were taken within the same postoperative 
window that was associated with impairment of neutrophil function described in Chapter 4. 
Assays of mitochondrial function were performed in whole blood whenever possible to 
minimise processing artefacts.  The fluorescent probes used have been extensively 
characterised by other investigators, and are generally agreed to be the most specific 
available.  Visualisation with confocal microscopy would identify the specific subcellular 
location of fluorescent signals, and may help determine whether ROS signals were coming 
from mitochondria or other cytoplasmic sources, such as resting NOX/PHOX activity. 
The two in vitro models of oxidative stress both support the hypothesis for mitochondrial 
ROS regulating the postoperative neutrophil phenotype, with each demonstrating an 
increase in baseline ROS with a decrease in the respiratory burst/activated cell ROS 
production, through different mitochondrial insults.  Pharmacological inhibition of 
respiratory complex III within preoperative cells profoundly inhibits the respiratory burst.  
The redox characteristics of DMSO differentiated and undifferentiated HL-60 cells mirror 
those of postoperative and preoperative human neutrophils respectively.     
Taken together, these models reproduce the redox relationship between resting and 
activated/respiratory burst neutrophils to that found in perioperative samples.  Specific 
limitations of each model should be considered.  Mitochondrial inhibitor experiments could 
only be incubated for short periods of time (30 minutes), due to the fragility of isolated 
incubated neutrophils – the rate of apoptosis within freshly isolated neutrophils was 70% at 
this time point.  The transition of priming to depression of the respiratory burst as 
Myxothiazol dose increased from 1uM to 10uM suggests a critical dose exists, beyond which 
ROS scavenging mechanisms become overwhelmed and lipid peroxidation ensues with ROS 
amplification.  While undifferentiated HL60 cells have been shown to contain functional 
PHOX machinery (Muranaka et al., 2005), it is possible that the quantity of PHOX present is 
very much less in undifferentiated as compared to DMSO differentiated cells, and that this is 
responsible for the reduced burst responses, rather than tonic activity of resting cellular 
ROS levels.   
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Further corroborative evidence could not be provided through manipulation of HL-60 ROS 
levels – attempts to augment and scavenge HL-60 ROS and alter respiratory burst function 
produced opposite results to those expected.  The addition of MitoTEMPO increased 
baseline mitochondrial ROS in undifferentiated cells, which may possibly be explained by 
complex interactions between oxidative and reductive complexes with MitoTEMPO, or by 
non-specific cellular location or molecular targets of the probes and antioxidants used.   
 
 
5.4.4 Conclusions 
1. Whole blood postoperative neutrophil mitochondria possess a hyperpolarised 
mitochondrial membrane potential and have greater levels of mitochondrial ROS than 
matched preoperative samples.   
2. Increased resting mitochondrial ROS may impair the neutrophil respiratory burst. 
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Chapter 6 – Neutrophil pyruvate kinase and perioperative 
respiratory burst  
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6.1 Introduction 
Investigations into the regulation of the neutrophil respiratory burst have largely focussed 
upon the phosphorylation and assembly of PHOX subunits (Segal, 2005).  However, 
substrate level control is also plausible because of the dramatic changes in neutrophil 
metabolism which accompany the respiratory burst.  Pyruvate kinase, a rate limiting step of 
neutrophil glycolysis (Fauth et al., 1993), is upregulated within neutrophils during 
inflammatory responses (Oehler et al., 2000) and the isoform expressed within human 
neutrophils is subject to redox regulation (Kechemir et al., 1989).  Having demonstrated a 
plausible relationship between resting neutrophil ROS and activated neutrophil respiratory 
burst within Chapter 5, Chapter 6 will explore whether oxidative inhibition of the glycolytic 
enzyme pyruvate kinase regulates the human postoperative respiratory burst by limiting the 
supply of NADPH substrate  
Granulocytes may utilise both exogenous glucose and intracellular glycogen (Weisdorf et al., 
1982). Neutrophil activation promotes glucose uptake by MAP Kinase/HIF-α driven 
translocation Glucose Transport 1 (GLUT1) – responsible for passive/constitutive uptake of 
glucose (Carruthers, 1990) to the cell surface (Schuster et al., 2007), while exogenous 
glucose, up to a plateau of 10mmol/L, increases both the PMA respiratory burst and lactate 
production (Oehler et al., 2000; Schuster et al., 2007; Tan et al., 1998).   
The principal substrate of respiratory burst is NADPH, synthesised through the hexose 
monophosphate shunt (Figure 1.4).  G6PDH regulates the entry of glucose substrate into 
the hexose monophosphate shunt, and within murine stem cells G6PDH activity is regulated 
by NADPH:NAD (Filosa et al., 2003).  The G6PDH inhibitor dehydroepiandrosterone 
abolishes the PMA stimulated respiratory burst plus associated glucose consumption 
(Bender and Van Epps, 1985; Oehler et al., 2000), but leaves other processes such as 
chemotaxis unaffected (Bender and Van Epps, 1985).  Neutrophils have a six-fold higher 
expression of glucose-6-phosphate dehydrogenase than lymphocytes (Beck, 1958).         
The hexose monophosphate shunt competes directly with glycolysis for glucose-6-
phosphate (Fig 1.3).  Fluorometric analysis of glycolytic mass action ratios within human and 
guinea pig neutrophils has identified that the enzymes hexokinase, phosphofructokinase and 
pyruvate kinase are the rate limiting steps (Beck, 1958; Minakami, 1968).  These guinea pig 
neutrophils were harvested from a chemical peritonitis model, meaning they are 
primed/activated cells and may therefore be of greater relevance to human postoperative 
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neutrophil investigations.  By contrast, many studies into neutrophil metabolic control have 
been performed within animal and cell line models which do not address the changes that 
occur during established inflammation.   
Several human genomic investigations of human leukocytes have identified a rapid change in 
expression of genes related to metabolic processes, with upregulation of glycolytic and 
downregulation of mitochondrial genes (Fessler et al., 2002; Malcolm et al., 2003; Zhang et 
al., 2004).  Furthermore, the addition of low doses of endotoxin to human volunteers  
promotes cellular metabolic changes without an increase in circulating cytokine levels, 
underlining the importance of  metabolic reprogramming during inflammation (Haimovich et 
al., 2014).  Within a series of trauma patients an increase in respiratory burst from day 1 
which peaked at day 5 was accompanied by similar increases in pyruvate kinase protein 
expression and activity (Oehler et al., 2000).  Collectively these genomic, proteomic and 
metabolic investigations suggest that pyruvate kinase is upregulated during pro-inflammatory 
responses, and is a rate limiting step in the formation of NADPH (Fig 1.4).  
Pyruvate kinase is composed of up to four subunits which combine to form three distinct 
isoforms and whose expression is tissue specific. The different isoforms share several 
regulatory mechanisms, including the phosphorylation and allosteric modulation of subunit 
shape that determines the transition from inactive dimers to active heterodimers.  For 
example, binding of fructose 1,6 bisphosphate, to a series of tyrosine (tyr) residues favours 
heterodimer formation (‘feed forward regulation’) (Mazurek et al., 2005), while  
phosphorylation of tyr105 prevents fructose 1,6 bisphosphate from binding (Hitosugi et al., 
2009).  Conversely, ATP acts as a negative allosteric regulator.  The tetramer must 
disassemble for subunits to alter their function. 
In addition to these shared regulatory mechanisms of all pyruvate kinase isoforms the PKM2 
isoform of pyruvate kinase is also sensitive to oxidative regulation.  Diverse types of cancer 
cells share a common metabolic phenotype termed the Warburg effect, where glycolytic 
activity is increased and mitochondrial oxidative phosphorylation depressed.  This metabolic 
phenotype maintains ATP production while simultaneously increasing flow to the hexose 
monophosphate shunt, generating NADPH for glutathione antioxidant pathway, and ribose 
sugars for cell cycle progression / anabolism.   PKM2 has also been identified in neutrophils 
(Kechemir et al., 1989). 
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Physiological concentrations of specific oxidative products – including O2
- and H2O2 – may 
interact with a host of cellular signalling cascades and metabolic processes (Dröge, 2002; 
Janssen-Heininger et al., 2008; Jones, 2008).  Cysteine residues are particularly susceptible 
to oxidation, and dimerise via a disulphide bridge to form cystine (McDonagh et al., 2009) 
(Fig1.2).  PKM2 is inhibited by oxidation at cys358 within the catalytic site, which diverts 
glucose-6-phosphate to hexose monophosphate shunt (Mazurek et al., 2005, 2002).  
Transgenic substitution of PKM2 Cys358 for Ser358 renders the enzyme insensitive to ROS 
inhibition and impairs tumour growth (Anastasiou et al., 2012).  Oxidative control of 
pyruvate kinase orthologs is widely preserved between species (Cumming et al., 2004; 
Maeba and Sanwal, 1968; McDonagh et al., 2009) . 
DASA10 is a small molecular activator of PKM2 Cys358 that may be used to investigate 
redox regulation of PKM2.  DASA10 is a substituted N, N diarylsulfonamide which prevents 
oxidative H2O2 inhibition of PKM2 Cys358, preserving heterodimerisation and increasing 
baseline function 2.8-fold (Anastasiou et al., 2012).  The DASA10 compound must be 
applied before the ROS insult in order to provide protection (Anastasiou et al., 2012), 
because subunit reassembly prevents access the regulatory site. 
Since neutrophils also express the PKM2 (Kechemir et al., 1989) isoform of pyruvate kinase, 
the neutrophil hexose monophosphate shunt may be subject to redox regulation in a 
manner similar to cancer cells.  Redox regulation of PKM2 may therefore be a key regulator 
of postoperative neutrophil metabolism and innate immunity.   
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6.1.1 Hypothesis 
Oxidative inhibition of the glycolytic enzyme pyruvate kinase determines postoperative 
impairment of respiratory burst by limiting supply of NADPH substrate.  
 
6.1.2 Aims 
1. To describe perioperative resting and activated neutrophil glucose uptake and glycolytic 
activity. 
2. To determine how preservation of pyruvate kinase activity with DASA affects the 
perioperative respiratory burst. 
3. To determine whether DASA may prevent oxidative stress induced inhibition of the 
respiratory burst. 
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6.2 Methods 
Patient sample collection, laboratory techniques and protocols are described in General 
Methods. 
6.2.1 Perioperative neutrophil glucose uptake  
The effect of extracellular glucose concentration upon the respiratory burst was determined 
by comparing the PMA stimulated respiratory burst of isolated neutrophils in the absence, 
or presence, of glucose 10mM in preoperative samples. 
Next, whole blood neutrophil glycolytic activity was determined at rest, following PMA 
activation and under oxidative stress (Myxothiazol 10µM).  Briefly, PMA and Myxothiazol 
were added for 10 minutes each, and all samples incubated for an equal amount of time 
overall. Whole blood glucose, lactate, pH and ionised calcium were measured using 
Radiometer ABL800 Flex blood gas analyser. 
Perioperative glucose uptake was similarly determined at rest, following PMA activation and 
after addition of Myxothiazol 10µM using the fluorescent glucose analog 2-NBDG.  
6.2.2 Redox regulation of pyruvate kinase 
The effect of PMK2 small molecule activator DASA upon neutrophil redox status and 
glycolysis was determined in whole blood.  DASA was prepared in DMSO vehicle.  DASA 
(100µM) was added immediately before each assay was performed.  Resting oxidative stress 
and PMA stimulated respiratory burst were quantified with Rhodamine-123, as previously 
described, and extracellular glucose and lactate concentrations measured with Radiometer 
ABL800 Flex blood gas analyser.  DASA respiratory burst experiments were then repeated 
within paired preoperative and postoperative samples. 
The capacity for DASA to maintain neutrophil respiratory burst in the presence of a 
subsequent oxidative challenge was then assessed.  Since application of Myxothiazol (10µM) 
to isolated neutrophils for 10 minutes was shown to reduce the respiratory burst (Chapter 
5), this dose was chosen.  Dose response experiments with DASA were performed in the 
isolated neutrophil system, and a 10µM dose was shown to increase respiratory burst by a 
similar magnitude as 100µM dose in whole blood system. Isolated neutrophils were 
incubated with DASA 10µM for 10 minutes, prior to addition of myxothiazol for 10 minutes 
and resting plus PMA activated responses recorded. 
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6.3 Results 
6.3.1 Patient characteristics 
Assay Total 
number 
Age 
(median, 
[IQR])  
(years) 
Male 
(n, [%]) 
Surgical speciality 
(n, [%]) 
 Patient  
study  
source 
    Hepato- 
biliary 
Gynae- 
cology 
Urology Maxillo- 
facial 
Gastro- 
intestinal 
Ortho- 
paediacs 
Breast  
Glucose + PMA + DHR 
Fig 6.1 AB 
7 60 
(54-64.5) 
5 [71] 2 [29] - 1 [14] - 3 [43] 1 [14] - VISION 
Myxothiazol: blood 
glucose, lactate and pH 
Fig 6.1 CDE 
5 71 
(69-73) 
2 [40] - - 2 [40] - 1 [20] 2 [40] - VISION 
2-NBDG dose response 
Fig 6.2 A 
2 61, 71 1 [50] - - 1 [50] - - 1 [50] - VISION 
2-NBDG + PMA 
(Preop-POD1) Fig 6.2 BC 
5 63 
(56-69) 
5 [20] - - 1 [20] - 1 [20] 3 [60] - VISION 
2-NBDG + 
Rotenone/Myxothiazol 
Fig 6.2 DE 
4 61 
(53-68) 
3 [75] - - 2 [50] - 2 [50] - - VISION 
DASA + DHR 
Fig 6.3 A 
8 59 
(53-62) 
3 [38] 1 [13] - - - 5 [63] 2 [25] - VISION 
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DASA + PMA + DHR 
Fig 6.3 BC 
8 59 
(53-62) 
3 [38] 1 [13] - - - 5 [63] 2 [25] - VISION 
DASA + PMA:  
Blood glucose & lactate 
Fig 6.3 DE 
5 71 
(69-73) 
2 [40] - - 2 [40] - 1 [20] 2 [40] - VISION 
DASA + PMA/E.coli  
+ DHR 
(preop-POD1) 
Fig 6.4 ABCD 
5 71 
(69-73) 
2 [40] - - 2 [40] - 1 [20] 2 [40] - VISION 
DASA 100µM ± PMA  
+ DHR 
Fig 6.5 AB 
4 66 
(62-74) 
1 [25] - 1 [25] 2 [50] - 1 [25] - - VISION 
DASA 10µM ± PMA  
+ DHR 
Fig 6.6 CDF 
5 65 
(58-65) 
3 [60] 1 [20] 1 [20] 2 [40] - - 1 [20] - VISION 
DASA 10µM + CD16 10 63 
(57-67) 
6 [60] 1 [10] 1 [10] 2 [20] - 1 [10] 5 [50] - VISION 
DASA 10µM ± 
Myxothiazol + DHR 
5 71 
(69-73) 
2 [40] - - 2 [40] - 1 [20] 2 [40] - VISION 
 
Table 6.1 Characteristics of the patients for Chapter 6 experimental assays.  
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6.3.2 Perioperative neutrophil glucose uptake 
Figures 6.1 and 6.2 suggest that the neutrophil respiratory burst uses extracellular glucose 
as a metabolic substrate, supporting similar observations from other authors (Oehler et al., 
2000; Tan et al., 1998).  Specifically, the presence of extracellular glucose increases the 
respiratory burst (Fig6.1A,B) and PMA neutrophil activation promotes a fall in extracellular 
glucose concentration (Fig 6.1C) plus increased transportation of the fluorescent glucose 
analog 2-NBDG (Fig6.2B). Extracellular lactate concentrations were unchanged.  The 
induction of oxidative stress with Myxothiazol 10µM did not alter resting or activated 
neutrophil glucose uptake, but did increase extracellular lactate concentration and reduce 
extracellular pH (Fig6.1 D,E).   
Having established that the respiratory burst utilises extracellular glucose, next I investigated 
whether glucose uptake differed between preoperative and postoperative neutrophil 
preparations.  The fluorescent glucose analog 2-NBDG has been widely used to investigate 
glucose uptake in a diverse range of cell types (Gandhi et al., 2009; Yamada et al., 2007). 
Dose response experiments demonstrated that 1µM 2-NBDG provided optimal 
fluorescence conditions for FACS analysis (Fig 6.2 A); 2-NBDG is intensely fluorescent and 
saturated the detector at higher concentrations.  Postoperative resting and PMA activated 
2-NBDG were increased when compared to preoperative control samples (Fig 6.2 B,C).  
In chapter 5 I demonstrated that Rotenone 10µM (respiratory complex I inhibitor) primed 
the respiratory burst and Myxothiazol 10µM (respiratory complex III inhibitor) inhibited it.  
Here, the addition of rotenone and myxothiazol to neutrophil preparations did not affect 
resting neutrophil glucose uptake (Fig 6.2 D,E).   
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Figure 6.1 Glycolytic profile of neutrophils at rest, following PMA activation and 
under myxothiazol 10µM redox stress. 
AB Typical plot and population data for PMA stimulated respiratory burst following the addition of 
extracellular glucose to isolated granulocytes, suspended in phosphate-buffered saline. Glucose added 
immediately before burst assay. Wilcoxon matched pairs test used. C D E Change in whole blood 
extracellular glucose/lactate/pH following the addition of Myxothiazol and PMA activation.  Assays performed 
simultaneously on each test sample using Radiometer ABL 800 blood gas analysed.  Myxothiazol incubations 
for 30 minutes, PMA incubations for 10minutes.  The total incubation times were all identical.   
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Figure 6.2 Neutrophil uptake of glucose analog 2-NBDG following surgery and 
addition of respiratory complex inhibitors. 
Isolated neutrophils used throughout. 2-NBDG was added for 10 minutes and incubated at 37oC, then 
washed twice and resuspended in PBS.  A. Dose response experiment to find optimal concentration of 2-
NBDG. B C Perioperative change in 2-NBDG in resting and PMA activated granulocytes.  D E The effect of 
Rotenone and Myxothiazol upon resting granulocyte uptake of 2-NBDG.  Cells were incubated with 
Rotenone/Myxothiazol for 30 minutes prior to addition of 2-NBDG. 
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6.3.3 DASA stimulation of pyruvate kinase.   
DASA is a highly specific molecule which both prevents the oxidative inhibition of, and 
activates, PKM2.  The addition of small molecule activator DASA increased whole blood 
PMA respiratory burst without affecting baseline ROS production (Fig 6.3 A,B,C) or 
extracellular glucose concentration (Fig 6.3 D).  
Figure 6.3 The effect of PKM2 activator DASA upon  
whole blood respiratory burst and glycolytic profile. 
DASA was added immediately before each assay – no additional incubation time.  A Baseline ROS production 
following addition of DASA 100uM.  B PMA stimulated respiratory burst following addition of DASA 100µM.  
C D Extracellular glucose and lactate concentration following addition of DASA and PMA, Wilcoxon matched 
pairs test used.  Here, whole blood samples were incubated with DASA for 10 minutes and PMA for 10 
minutes.  Total incubation times the same.  
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Next, paired preoperative and postoperative whole blood respiratory burst responses were 
compared in the presence of DASA.  DASA consistently increased preoperative but not 
postoperative PMA (Fig 6.4 A,B) and E. coli burst responses (Fig 6.4 C,D).   
 
Figure 6.4. Perioperative effect of DASA 100µM upon whole blood PMA and E. 
coli stimulated respiratory burst. 
DASA 100µM was added immediately before each burst assay – no additional incubation time. A B C The 
effect of DASA upon perioperative PMA stimulated respiratory burst; (A) typical plot, (B) fold-change in 
respiratory burst, = MFIPMA/MFIresting C D The effect of DASA upon perioperative E. coli stimulated respiratory 
burst, = MFIE. coli/MFIresting.    
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6.3.4 DASA reversal of Myxothiazol mediated respiratory burst 
inhibition 
DASA must be added to PKM2 prior to oxidative challenge for oxidative protection 
(Anastasiou et al., 2012), which has been explained through conformational change and 
access to relevant allosteric site.  Therefore, the ability of DASA to augment preoperative, 
but not postoperative respiratory burst suggests that postoperative PKM2 may be subject to 
oxidative inhibition.  In chapter 5, I demonstrated that Myxothiazol causes an increase in 
baseline neutrophil ROS and impairs the respiratory burst.  Therefore, I tested the 
hypothesis that preincubation of resting preoperative neutrophils with DASA could prevent 
the Myxothiazol driven inhibition of the respiratory burst.  
My investigations have shown that myxothiazol works reliably within isolated neutrophil 
preparations, but not within whole blood (Chapter 5).  Therefore, I began by testing the 
effects of DASA within an isolated system.  DASA 100µM – as used in whole blood 
experiments above – reduced the PMA burst (Fig 6.5 A,B).  However, subsequent resting 
with a lower dose, DASA 10µM, increased the PMA burst (Fig 6.5 C,D,E), similar to whole 
blood experiments above. 
Isolated neutrophils were then incubated with DASA 10µM for 10 minutes prior to addition 
of Myxothiazol 10µM and characterisation of respiratory burst responses.  Neither 
preincubation with DASA 10µM or 100µM preserved the PMA respiratory burst in the 
presence of Myxothiazol (Fig 6.6). 
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Figure 6.5 The effect of DASA upon isolated granulocyte                                
PMA stimulated respiratory burst. 
Paired t-test used throughout.  DASA was added immediately before each assay – no additional incubation 
time. A B The effect of DASA 100µM upon resting (A) ROS production and (B) PMA stimulated respiratory 
burst. C D E F The effect of DASA 10µM upon (A) resting ROS production, (B) cell surface CD16 expression 
(C, D) typical plot and population data for PMA stimulated respiratory burst. 
 
218 
 
 
 
 
Figure 6.6 The effect of preincubation with DASA upon myxothiazol mediated 
inhibition of the PMA stimulated respiratory burst in isolated granulocytes. 
DASA added for 10 minutes, Myxothiazol for 30minutes and PMA for 10 minutes.  Total incubation times 
were all identical.  A DASA 10µM. B DASA 100µM. 
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6.4 Discussion 
 
6.4.1 Key Findings 
 
1. The magnitude of the neutrophil respiratory burst is partly determined 
by the availability of metabolic substrate.  PMA activation promoted a fall in 
the concentration of extracellular glucose and an increase in the intracellular 
transport of the fluorescent glucose analog 2-NBDG within isolated neutrophil 
preparations, supporting findings from other authors that suggest activated 
neutrophils utilise extracellular glucose (Oehler et al., 2000; Tan et al., 1998). 
Isolated neutrophil preparations demonstrated a greater PMA respiratory burst in 
the presence of glucose 10mM, although the recording of measurable burst 
responses in the absence of extracellular glucose suggests that both intracellular and 
extracellular glucose reserves are used during neutrophil activation. 
 
Together, these data suggest that the availability of extracellular metabolic substrate, 
and consequently competition between glycolysis and hexose-monophosphate shunt 
for glucose-6-phosphate, may affect the magnitude of the respiratory burst. 
 
2. Resting and PMA activated postoperative neutrophils demonstrate 
increased 2-NBDG uptake when compared to paired preoperative 
controls.  These data suggest either an increase in baseline metabolic rate, or a 
reduction in intracellular glucose reserves, within postoperative neutrophils. The 
divergence between this increase in glucose uptake and the previously identified 
reduction in postoperative respiratory burst would support an increase in resting 
neutrophil substrate use. 
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3. The PKM2 activator DASA consistently increased the preoperative 
neutrophil respiratory burst.  DASA is a highly specific molecule which activates 
the PKM2 isoform of pyruvate kinase but not the more common PKM1.  These data 
suggest that PKM2 activity may regulate the respiratory burst, supporting findings 
from trauma patient neutrophils (Oehler et al., 2000).   
 
4. DASA does not consistently increase the postoperative neutrophil 
respiratory burst.  These data suggest that the postoperative metabolic profile and 
regulation of respiratory burst is different to preoperative cells.  Since DASA can 
only prevent, but not reverse, oxidative inhibition of PKM2, this finding supports the 
hypothesis that raised resting oxidative stress within postoperative cells is 
responsible for inhibition of the respiratory burst.  Alternatively, postoperative 
neutrophils may contain an additional rate limiting step which leaves them unaffected 
by DASA stimulation.   
 
 
5. DASA cannot prevent Myxothiazol 10µM / ROS induced impairment of 
the respiratory burst within isolated neutrophils.  These data do not support 
the hypothesis that postoperative oxidative inhibition of PKM2 is responsible for the 
impaired respiratory burst.  However, as described in chapter 5, this short-term 
Myxothiazol ROS model is not completely consistent with the postoperative 
phenotype, and that these differences may be responsible for the observed DASA 
resistance.  
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6.4.2 Interpretation of key findings  
These experiments have identified several differences within the perioperative metabolic 
responses of neutrophils which are associated with functional changes in neutrophil immune 
function.  The preoperative neutrophil respiratory burst is consistently increased in the 
presence of DASA, a highly specific small molecule activator of PKM2.  By contrast, 
postoperative neutrophils are often resistant to DASA and demonstrate increased glucose 
uptake at rest and when activated.    
DASA activates and prevents oxidative inhibition of the PKM2 isoform.  Therefore, the 
ability of DASA to increase the respiratory burst in preoperative neutrophils suggests that 
the neutrophil respiratory burst may be subject to metabolic (glycolytic) regulation.   
DASA was specifically designed to investigate the role of PKM2 regulation within cancer 
cells.  Within my experiments, the effect of DASA upon metabolic flux in neutrophils 
appears to be opposite to that in lung cancer cells.  Within cancer cells DASA activation of 
PKM2 reduces NADPH synthesis by increasing flow through glycolysis. Here, within 
neutrophils DASA appears to increase flux through the hexose monophosphate shunt 
because the respiratory burst is increased, which implies an increase in NADPH formation.  
These divergent results within neutrophil and cancer cells may be explained by differences in 
the outflow of hexose monophosphate shunt between terminally differentiated neutrophils 
and highly anabolic cancer cells.   In cancer cells the carbon skeletons from hexose 
monophosphate shunt may form ribose sugars thereby supporting nucleotide synthesis and 
ultimately promote cell cycle progression.  However, within neutrophils these carbon 
skeleton return to glycolysis proximal to pyruvate kinase (Figure 1.4), supported by the  
reported increase in neutrophil lactate production which follows PMA activation (Oehler et 
al., 2000). 
The relative resistance of postoperative neutrophils to DASA supports the presence of 
oxidised PKM2 within postoperative cells, since it is established that DASA prevents, but 
cannot reverse, oxidative inhibition within the PKM2 isoform (Anastasiou et al., 2012).  
Therefore, beyond the specific established allosteric regulators of pyruvate kinase function 
by both immediate and distant substrates and products, these data support an additional 
regulatory mechanism, whereby resting neutrophil oxidative stress may act as a transducer 
to regulate activated cell immune effector mechanisms.   
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Since DASA may prevent but not reverse oxidative inhibition of PKM2, I attempted to 
prevent Myxothiazol mediated inhibition of the respiratory burst through the prior addition 
of DASA.  However, DASA did not prevent Myxothiazol induce inhibition of the respiratory 
burst within this model.  Although this observation does not support the hypothesis for 
oxidative regulation of PKM2 within neutrophils, limitations within the experimental model 
may also be responsible.  In earlier experiments, I found that Myxothiazol 10µM increased 
apoptosis as well as impairing the respiratory burst.  Therefore, apoptotic demands for ATP 
may limit flux through pentose phosphate pathway.  Alternatively, the ROS generation 
within this Myxothiazol model may overwhelm physiological buffering, consume NADPH 
through glutathione and cause non-specific lipid peroxidation and cellular injury.  
Cellular metabolism is subject to complex regulatory processes, with multiple steps that 
involve substrate availability, feedback inhibition and compartmentalisation (Srere, 1994), 
that are difficult to fully replicate in vitro.  There are alternative explanations for these 
postoperative experimental observations.  These include the development of an alternative 
rate determining step within the formation of NADPH, competition for NADPH and an 
inability to utilise NADPH.   
The rate determining step maybe competition for glucose-6-phosphate between glycolysis 
and the hexose monophosphate shunt.  Together, observations of DASA resistance and 
increased glucose uptake suggest an increased rate of cellular ATP consumption.  
Alternatively, postoperative mitochondrial dysfunction may place an increased demand on 
less efficient glycolytic ATP production – if mitochondria do indeed make a meaningful 
contribution to (postoperative) neutrophil ATP production.    
Increased glucose uptake has been reported in neutrophils from trauma patients (Oehler et 
al., 2000).  These observations would also be compatible with a population of immature 
circulating neutrophils.  Data from a HL60 model found increased Glucose-6-Phosphate 
Dehydrogenase and hexose monophosphate shunt activity within DMSO differentiated cells 
when compared to undifferentiated cells (Ahmed et al., 1993).  Alternatively, partially 
activated postoperative cells may have depleted glycogen reserves.  In these settings 
glycolysis is already running at maximal capacity to meet the raised metabolic demands of 
these cells, providing the additional rate limiting step described above. 
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NADPH is required for other cellular processes beyond the neutrophil respiratory burst, 
such as the maintenance of glutathione – an important antioxidant pathway.  The presence 
of increased postoperative resting oxidative stress is compatible with increased glutathione 
turnover.  Therefore, the failure of DASA to increase the respiratory burst DASA may be 
explained by competition for NADPH.  Finally, the PHOX function may be impaired such 
that it is insensitive to increases in NADPH.  Again, immature precursors may have 
insufficient amounts of PHOX – a hypothesis supported by HL-60 data comparing PHOX 
content of undifferentiated promyelocytes and DMSO differentiated cells (Ahmed et al., 
1993) - although other regulatory processes that alter enzyme function may also be 
responsible. 
 
This study supports the more extensive observational literature concerning the genomic 
responses that occur within the circulating leukocyte transcriptome from humans with 
systemic inflammation, which collectively report an upregulation of glycolytic, and down 
regulation of mitochondrial genes (Calvano et al., 2005; Xiao et al., 2011).  Healthy 
volunteer experiments have revealed how low dose endotoxin challenge – at doses 
insufficient to promote release of systemic cytokines – are associated with altered 
expression of metabolic genes (Haimovich et al., 2014).  Taken with the mechanistic data 
from this study, these observations support the concept of metabolic regulation of 
neutrophil immune function.   
 
6.4.3 Strengths and weaknesses 
This study identified metabolic differences in postoperative neutrophils when compared to 
matched preoperative control samples. Paired sampling is important because comorbid 
disease, age and therapeutic interventions may affect neutrophil metabolism.  By using 
individually matched control samples, the direct effect of these premorbid factors upon the 
experimental signal can be minimised.  However, how these premorbid factors interact with 
surgery/anaesthesia remains unknown.  Since all assays were not performed in the same 
patients, it is not possible to extrapolate the study findings to a universal postoperative 
phenotype.   
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These postoperative data extend the literature concerning metabolic function of human 
neutrophils during established inflammation, since most human data has been obtained from 
healthy volunteers – including the widely accepted fluorometric data describing the rate 
limiting steps of neutrophil glycolysis.  My findings suggest a shared regulatory mechanism 
with cancer cells, which  adds to the wider literature describing similarities between cancer 
cell biology and inflammatory processes (Hotchkiss et al., 2014).  
Whole blood samples were used where possible, including for preoperative and 
postoperative DASA experiments.  DASA is a highly specific activator molecule, widely 
investigated and published within cancer literature and considered to act solely upon PKM2.  
Therefore, its ability to manipulate neutrophil function at the same doses used within the 
cancer literature directly supports the presence of PKM2 within neutrophils.  Nonetheless, 
as with any drug therapy, alternative off-target effects may be responsible.  Some authors 
have proposed that 2NBDG may become metabolised to a non-fluorescent colour (Yamada 
et al., 2007), however the experiments in this study compared different treatments over 
identical time periods, therefore these differences should be controlled for.  
The complex nature of metabolic networks makes the interpretation of relatively isolated 
experimental results challenging, and are compounded by the modest evidence base 
describing metabolic profiles of human neutrophils from humans with active inflammation.  
Assuming DASA is acting upon PKM2, the data presented within this chapter may be 
explained by either the presence of oxidised PKM2 within postoperative samples, or 
alternatively by the presence of an additional rate determining step.  These two explanations 
may be differentiated by measuring the rates of glycolysis and hexose monophosphate shunt 
reactions within preoperative and postoperative samples, as originally performed in resting 
cells in the 1960s and 1970s using fluorometric measurement techniques (Beck, 1958; 
Minakami, 1968). 
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6.4.4 Conclusions 
1. The metabolic profile of postoperative neutrophils is different to their matched 
preoperative counterparts, and may include increased resting glucose uptake.  
2. The glycolytic enzyme PKM2 may be involved in the regulation of the neutrophil 
respiratory burst and may be subject to postoperative oxidative inhibition by mitochondrial 
ROS. 
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Chapter 7 – Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
227 
 
7.1 Introduction 
This thesis has demonstrated how the study of patients undergoing major elective surgery 
may provide a translational model of human sepsis.  This surgical model provides the 
methodological advantages of laboratory research within human subjects.   Ex-vivo assays 
may therefore be performed in a controlled manner using human tissues and cells.  Surgical 
patients receive a relatively homogenous inflammatory insult at a known time, permitting 
the collection of individualised pre-insult control samples and precisely timed post-insult 
samples. 
Using the surgical model, this thesis has identified impairments of neutrophil immune and 
metabolic function on postoperative day two.  These impairments had improved by 
postoperative day five, and may predispose to the development of postoperative infections, 
non-infective complications and chronic, non-resolving inflammation.   
Two different laboratory models of mitochondrial oxidative stress reproduced key features 
of the postoperative functional immune impairment. The most notable immune defect was a 
reduction in the neutrophil respiratory burst, a process which consumes NADPH that is 
supplied by the hexose monophosphate shunt.  Substrate flow through hexose 
monophosphate shunt and glycolysis are intrinsically linked, and a key glycolytic regulatory 
enzyme was identified as a possible target for this mitochondrial redox signal.  Chemical 
manipulation of PKM2 function reproduced many features of the perioperative immune 
phenotype.   
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7.2 Summary of key findings 
 
1. Major elective surgery may provide a translational model of human sepsis 
which overcomes many of the methodological challenges of sepsis studies.  
Most translational sepsis studies in humans do not use all the information available to 
determine whether infection is present, and employ control groups whose baseline 
immunological profiles are dramatically different to the study population.  By 
contrast, patients undergoing major elective surgery are extensively phenotyped and 
receive a planned and relatively homogenous inflammatory insult - provided specific 
enrolment criteria are used.  Consequently, each patient may act as their own 
preoperative control and measurements/blood sampling may occur at specified post-
insult time points, facilitating accurate interrogation of dynamic inflammatory 
processes.  Highly conserved genomic and metabolic responses to DAMP and PAMP 
signals provide biological plausibility to this model. 
 
2. The neutrophil respiratory burst is impaired on postoperative day two, 
when the circulating white cell counting is increased.  Whole blood and 
isolated neutrophil investigations revealed a significant reduction in respiratory burst 
following activation with clinically relevant E. coli bacteria and PMA, a potent 
activator of Protein Kinase C.  Neutrophil cell surface CD16 was significantly 
reduced on postoperative day two, compatible with diminished phagocytosis.  These 
defects had begun to improve by postoperative day five. 
 
 
3. Postoperative neutrophil mitochondria may have impaired functionality. 
Postoperative neutrophil mitochondria are hyperpolarised, and liberate increased 
amounts of superoxide. 
 
 
4. Mitochondrial dysfunction may be mechanistically responsible for the 
impairment of postoperative neutrophil effector function.  Two distinct 
models of mitochondrial dysfunction that increased ROS production both down 
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regulated the respiratory burst.  Mitochondria may therefore act as inflammatory 
signal transducers, with mitochondrial ROS acting upon cytoplasmic targets to 
regulate the respiratory burst.    
 
 
5. Mitochondrial ROS may regulate the respiratory burst by limiting the 
supply of NADPH substrate, through oxidative inhibition of pyruvate 
kinase M2.  Pyruvate kinase is a rate limiting step in neutrophils isolated from 
human healthy volunteers and from peritoneal fluid of guinea pigs with peritonitis.  
Within cancer cell biology PKM2 function is an established regulatory mechanism 
that determines flux through glycolysis and the hexose monophosphate shunt.  The 
PKM2 small molecule activator DASA - which can activate non-oxidised PKM2 - 
increased the preoperative but not postoperative respiratory burst.   
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7.3 Translational relevance of results 
 
7.3.1 The surgical model of inflammation 
Decades of translational critical care research has failed to deliver a single 
immunomodulatory agent that has been reliably demonstrated to improve clinical outcome 
(Angus et al., 2000; Lehmann et al., 2014; Ranieri et al., 2012; Rimmer et al., 2012; Sprung et 
al., 2008).  This thesis has identified several challenges to the rational design and of sepsis 
studies, including uncertainties surrounding diagnosis, sample timing to the index insult and 
the identification of appropriate control populations.  Therefore, translational investigations 
of sepsis are maybe being performed within patients who have not been reliably 
demonstrated to have an infection, and comparisons made to control groups whose baseline 
immunological status may be very different to the study population.   
The importance of comparing paired preoperative control samples with carefully timed 
postoperative samples is underlined by the data presented within chapters 4 to 6, which 
describes the perioperative neutrophil immune and metabolic phenotype.  The variation in 
baseline immune function and the specific time window during which functional impairment 
occurs mean these experimental signals would have been missed if all the postoperative 
samples were grouped together and compared to a separate and poorly defined control 
population, as can happen during sepsis studies.  
Biological plausibility of the surgical model is provided by studies that have shown how 
similar human inflammatory responses to traumatic and infective injury are at genomic 
(Haimovich et al., 2014; Xiao et al., 2011), molecular (Matzinger, 1994), local and systemic 
(Matzinger, 1994; Seong and Matzinger, 2004) levels.  This surgical model would not replace 
the use of animal models during early investigations, nor the need for pragmatic 
effectiveness studies of novel therapies within critically unwell patients.  What the surgical 
model offers is a translational bridge between these two extremes, providing the 
methodological advantages of laboratory studies within a human immune environment. 
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7.3.2 Postoperative neutrophil immune impairment (tolerance) 
This thesis has revealed that patients undergoing major elective surgery have an impaired 
neutrophil respiratory burst on postoperative day two, which has begun to improve by 
postoperative day five, as well as a down regulation of CD16 receptors which mediate the 
recognition and phagocytosis of pathogenic microorganisms.  The magnitude of respiratory 
burst depression is similar to that found in patients with alcoholic hepatitis superimposed 
upon cirrhosis (Mookerjee et al., 2007).  Therefore, the nature, magnitude and timing of this 
functional impairment make it a plausible candidate for development of infectious and non-
infectious complications, through the following mechanisms: 
 
7.3.2.1 Predisposition to infectious complications   
Gross reductions in human neutrophil numbers, and absolute absence of the respiratory 
burst are associated with an increased incidence of sepsis and soft tissue infection 
(Anderson et al., 1985; Kuderer et al., 2006; Morgenstern et al., 1997). Similarly, within 
critically ill patients who are not being treated for an infection, those with diminished 
neutrophil burst and phagocytosis are more likely to develop a subsequent nosocomial 
infection (Stephan et al., 2002).  Within animal models of haemorrhagic shock, neutrophil 
depletion increases systemic bacterial translocation (Deitch et al., 1990).  Therefore, it is 
possible that the 90% reduction in postoperative neutrophil burst responses, and other 
deficits, described in chapter 4 may lead to an increased risk of postoperative infection.   
Impairment of the respiratory burst will likely lead to a wider impairment of other 
neutrophil immune functions.  The respiratory burst is not just responsible for direct killing 
of bacteria, but also provides the electromotive potential for optimisation and activation of 
granule contents and is absolutely required for the formation of neutrophil extracellular 
traps (NETs) (Segal, 2005).   
 
7.3.2.2 Protection from tissue damage and non-infectious complications 
Postoperative neutrophil impairment may protect against non-infectious complications by 
limiting autotoxic neutrophil activities.  Bacterial killing and removal may cause collateral 
tissue injury (Chollet-Martin et al., 1996; Nathens et al., 1997; Steinberg et al., 1994), and 
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activated neutrophils may also enter non-inflamed tissues to cause remote damage (Lowell 
and Berton, 1998).   
Experimental blockade of neutrophil CD11b/CD18 receptor prevents neutrophil 
transmigration across endothelium and limits tissue oedema and injury.  In contrast to 
endotoxin translocation data, lung injury models which include blunt chest trauma 
(Raghavendran et al., 2005) and ‘double-hit’ chest trauma plus caecal ligation and puncture 
(Perl et al., 2012) and lung stretch injury all report a protective effect from neutrophil 
depletion (Kotani et al., 2004).  Similarly, neutrophil depletion protects against hepatic 
ischaemic reperfusion injury (Poggetti et al., 1992) and may hasten sterile wound closure 
(Dovi et al., 2003).  Knockout of tyrosine kinase signalling – necessary for adhesion 
dependent activation of the respiratory burst – confers renal and hepatic protection within a 
murine LPS model of sepsis (Lowell and Berton, 1998).  These model data are supported by 
observational clinical data from critically ill patients (Chollet-Martin et al., 1996; Steinberg et 
al., 1994).   
The increased susceptibility of postoperative neutrophils to lose mitochondrial membrane 
potential, and therefore enter apoptosis, under conditions of stress (described in chapter 5) 
may confer additional protective properties.  Apoptotic neutrophils downregulate 
expression of many proinflammatory genes, and their ingestion by macrophages favours an 
anti-inflammatory macrophage phenotype (Ariel et al., 2006; Fadok et al., 1998; Kobayashi et 
al., 2003).  Injection of apoptotic neutrophils provides protection within an LPS model of 
inflammation (Ren et al., 2008). 
7.3.2.3 Predisposition to chronic inflammation 
Failure to switch off inflammation in a timely manner may lead to a non-resolving state of 
chronic inflammation (Fullerton et al., 2013; Lawrence and Gilroy, 2007).  Data from 
patients with chronic granulomatous disease – who possess an absent respiratory burst – 
suggest that capacity to mount an adequate initial inflammatory response is necessary for 
the timely resolution of that response.  As well as a predisposition to infection, patients with 
chronic granulomatous disease also develop foci of sterile inflammation, (Hampton et al., 
2002; Hatanaka et al., 2004; Kasahara et al., 1997; Morgenstern et al., 1997).  Neutrophils 
isolated from these patients demonstrate increased secretion of IL-8 (Hatanaka et al., 2004), 
prolonged survival (Kasahara et al., 1997) and reduced uptake by macrophages (Hampton et 
al., 2002).  Murine models of chronic granulomatous disease demonstrate sustained and 
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exaggerated lung inflammation (Davidson et al., 2013; Deng et al., 2012; Schauer et al., 2014; 
Segal et al., 2010, 2007), as well as a predisposition to autoimmune arthritis that may be 
prevented through reactivation of PHOX (Hultqvist et al., 2004).  Impaired NET formation 
may partly explain this phenomenon.  The respiratory burst is necessary for formation of 
NETs, which act to retain inflammatory mediators, thereby preventing systemic propagation 
of local inflammatory responses. 
 
7.3.3 Postoperative neutrophil metabolic dysfunction 
The genomic revolution that has swept through cancer cell biology has led to an expanded 
understanding of gene product function, and how these products interact in complex 
networks to regulate cellular processes.  The classification and nomenclature of these gene 
products has changed accordingly.   It is now appreciated that many oncogenes and tumour 
suppressor genes actually have a primary metabolic role within non-cancerous cells 
(Boroughs and DeBerardinis, 2015).  It follows that these metabolic changes are now 
considered prime movers of phenotypic change, rather than simply suppliers of metabolic 
products.   
The concept of metabolic regulation of cellular functions may similarly revolutionise how we 
conceptualise inflammation, and is supported by genomic descriptions of leukocytes from 
trauma patients and healthy volunteers who have received endotoxin, which include a 
decline in mitochondrial gene expression (Calvano et al., 2005).  In particular,  the 
administration of low doses of endotoxin which are insufficient to induce measurable 
changes in systemic cytokine levels may promote metabolic reprogramming of circulating 
leukocytes, while higher doses of endotoxin promote metabolic reprogramming before 
classical immunological changes are evident (Haimovich et al., 2014).  Activated neutrophils 
are highly metabolically active, therefore even modest changes in metabolic profile may have 
dramatic effects in function. 
My experiments that postoperative neutrophil mitochondria may have impaired 
functionality, which would support the genomic investigations above.  Specifically, 
postoperative mitochondria were hyperpolarised and displayed an increased production of 
mitochondrial ROS, the same phenotype which has been identified within neuronal 
mitochondria (Abramov et al., 2005, 2004).  
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7.3.3.1 Parallels with cancer cell metabolism: The Warburg effect 
The Warburg effect describes a metabolic signature common to many cancers.  The 
principal features are an increased rate of glycolysis, depression in the rate of oxidative 
phosphorylation with increased flux through the hexose monophosphate shunt (Hsu and 
Sabatini, 2008; Vander Heiden, M. G., Cantley, L.C., Thompson, 2009).  Therefore, 
perioperative neutrophils demonstrating mitochondrial dysfunction in parallel with an 
increased rate of glucose uptake, mirrors this phenotype.  It is therefore possible that other 
core features of Warburg metabolism may be relevant to postoperative neutrophil biology: 
• PI3/Akt/mTOR pathway.  Within cancer cells this promotes cellular proliferation 
and anabolism.  In neutrophils PI3K/Akt activates a range of inflammatory 
transcription factors such as NF-kB, c-jun and FosB (Ratajczak-Wrona et al., 2013), 
and in context of Fas engagement promotes apoptosis (Alvarado-Kristensson et al., 
2002).   
• AMP-kinase (AMPK) activation.  AMPK is activated by an increase in AMP:ATP 
ratio, which signals a bioenergetic debt and promotes utilisation of alternative energy 
sources to glucose (Winder and Hardie, 1999).  Within neutrophils AMPK activation 
reduces TLR4 induced neutrophil activation and is protective in an LPS model of lung 
injury, consistent with the postoperative phenotype. 
• JAK/STAT stimulation of PIM1-PIM2.  JAK/STAT is a common signalling 
pathway in many malignancies, activated by a range of cell surface receptors and 
promotes gene transcription.  In neutrophils JAK/STAT pathway is engaged by a 
range of cytokine receptors, including G-CSF , GM-CSF and IL-6 (Futosi et al., 2013), 
promoting differentiation and inhibiting apoptosis.  PIM1-PIM2 genes and products 
are not well characterised in neutrophils. 
 
7.3.3.2 The functional significance of mitochondrial dysfunction 
Regulation of constitutive apoptosis by neutrophil mitochondria is widely described, and 
established within the literature (Liu et al., 2003; Maianski et al., 2004; Murphy et al., 2003; 
Pryde et al., 2000.  The initiation of neutrophil apoptosis promotes the down-regulation of 
many neutrophil immune processes at level of gene expression.  This thesis provides 
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evidence that neutrophil mitochondria may have an extended signalling role, and act as signal 
transducers during inflammatory responses which activate and inhibit the respiratory burst 
responses through interaction with cytoplasmic metabolic responses.  Two different models 
of mitochondrial dysfunction were presented.  Both induced resting mitochondrial oxidative 
stress and reduced activated respiratory burst responses.  Within macrophages, depletion 
of autophagy proteins has been shown to promote mitochondrial ROS synthesis (Nakahira 
et al., 2011). 
   
7.4 Unifying explanations for immunological and metabolic 
impairments within postoperative neutrophils 
This thesis has presented and explored the relationship between functional impairment of 
neutrophil immune and mitochondrial function through transmission of oxidative stress 
signals.  Regulation via PKM2 was proposed as the target for this oxidative signal.  In 
addition to this proposal, there are several alternative, but overlapping explanations for the 
experimental observations I have made.  
Many of these explanations focus upon the supply, demand and competition for metabolic 
substrates ATP and NADPH.  Although the respiratory burst directly utilises NADPH, the 
supply of ATP may be directly relevant to the respiratory burst, since it is necessary for the 
many cellular processes which occur in parallel during neutrophil activation, such as 
cytoskeletal rearrangement for trafficking of organelles and phagolysosomes.  ATP demand 
may also directly impact upon the supply of NADPH to the respiratory burst, since 
glycolysis and hexose monophosphate shunt both compete for glucose-6-phosphate.  
Although outflow from hexose monophosphate shunt does return to distal glycolytic 
pathway, this is at the expense of the first synthetic step for ATP (Figure 1.4).   
Since the hexose monophosphate shunt feeds off and returns into glycolysis, these two 
processes will be subject to reciprocal regulation, which may manifest directly through open 
competition for shared substrate, or indirectly through extrinsic regulation of enzyme 
activity.   
Competition for substrate may be interpreted as a limitation of bioenergetic ATP supply.  
My data suggest increased resting and activated neutrophil glucose uptake, in the presence 
of a diminished burst, which is compatible with increased metabolic utilisation for glucose-6-
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phosphate, limiting respiratory burst substrate within postoperative neutrophils.  The loss of 
mitochondrial membrane potential may be a manifestation of limited bioenergetic reserve.  
Failure of DASA, a PKM2 activator, to stimulate the postoperative respiratory burst may 
also be interpreted as substrate limitation, i.e. postoperative neutrophils are functioning at 
metabolic capacity therefore cannot increase output any further. 
Increases in postoperative neutrophil ATP demand may be explained by the presence of 
immature neutrophils or by partially activated neutrophils, both of which will be subject to 
intensive gene expression and protein synthesis.   
 
7.4.1 The relevance of mitochondrial dysfunction 
The dysfunctional postoperative mitochondrial phenotype suggested within chapter 5 may 
limit neutrophil immune function through limited synthesis of ATP or other 
synthetic/transport processes dependent upon mitochondrial membrane potential.  The 
presence of impaired mitophagy would reduce efficiency of ATP synthesis.  
Although neutrophils are traditionally considered to be solely dependent upon glycolytic 
ATP, the addition of respiratory complex inhibitors does diminish neutrophil ATP 
concentration (Minakami, 1968; Sbarra and Karnovsky, 1959).  Most of these experiments 
were performed within neutrophils collected from healthy volunteers (i.e. non-inflamed) 
humans, or model animals.  The bioenergetic behaviour of neutrophils in established human 
inflammation has not been adequately addressed before.  Therefore, it is possible that 
postoperative neutrophils do rely upon mitochondria for generation of ATP, and that 
dysfunctional mitochondria may be a limiting factor in neutrophil function through 
bioenergetic mechanisms.   
Alternatively, mitochondrial ATP may serve a non-bioenergetic role.  There is a precedent 
for this through Pannexin I/P2Y2 mediated chemotaxis, which relies upon the autocrine 
release of mitochondrial ATP (Bao et al., 2014).  The release of nucleotides by necrotic cells 
is an important clearance signal (Elliott et al., 2009), therefore this mechanism may also 
facilitate neutrophil clearance of apoptotic cells. 
Mitochondria may act as inflammatory signal transducers.  Neutrophil mitochondria are 
known to coordinate apoptosis, integrating a range of intrinsic/extrinsic signals to determine 
output of Bcl-2 homologs (Brenner and Mak, 2009; Reed, 2006).  In a similar manner, 
237 
 
mitochondrial may act as inflammatory signal transducers through the release of 
mitochondrial ROS.  Several processes relevant to inflammation have been described which 
may lead to the release of mitochondrial ROS species.  In this manner, ROS are not simply a 
toxic by-product, but an important signal that regulates expression of the inflammatory 
phenotype.  For example, mitochondrial potassium channels may provide a mechanism for 
ROS induced mitochondrial dysfunction since O2
- and H2O2 directly promote their opening 
(Gao and Mann, 2009), alternatively mitochondrial ROS could cause generalised 
mitochondrial impairment through peroxidation.   
The production of mitochondrial ROS may be explained through several mechanisms 
related to oxidative phosphorylation, including hyperpolarisation due to reduced distal 
electron acceptors leading to inefficient electron transport (Vincent et al., 2004), specific 
dysfunction of individual respiratory complexes, loss of supracomplex organisation limiting 
efficiency of electron transfer or impairment of scavenging processes such as mitochondrial 
superoxide dismutase.  Respiratory complexes are also involved in biochemical pathways 
that proceed independently of oxidative phosphorylation, for example oxygen sensing 
through complex III-ROS–HIF signalling (Brunelle et al., 2005).  My data describe differential 
perioperative effects of complex I inhibition.  It is also possible that impaired mitophagy, for 
example through diminished PINK1/Parkin expression, may lead to persistence of damaged 
mitochondria and unchecked mitochondrial ROS release.    
Although ATP production is considered the primary role of mitochondria, there are other 
essential biochemical and metabolic processes which rely upon the electromotive potential 
generated by respiratory complexes.  The presence of increased ROS production may 
therefore be considered a barometer for mitochondrial health, with a proportional 
impairment of these other processes.  Relevant processes to the postoperative phenotype 
include calcium homeostasis, anion flux through VDAC channels  and integrin signalling 
(Colombini, 2004).  In reality these processes are closely related, for example VDAC 
activity favours a reduction in ROS formation (Zhou et al., 2011).  Alternatively 
mitochondrial dysfunction may be associated with release of mtDNA, an established DAMP 
providing a universal inflammatory stimulus (Nakahira et al., 2011) in a manner analogous to 
gut derived endotoxin. 
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7.4.2 Cellular targets for mitochondrial ROS signalling 
This thesis has focussed upon redox regulation of PKM2 as a regulator of postoperative 
neutrophil immune function.  However, in addition to PKM2 there are several other 
possible targets.  The molecular specificity of ROS signalling makes it an ideal mechanism to 
propagate cell-wide signals, coordinating the activity of structurally distant targets which 
share common amino acid residues around functional or allosteric sites.  
7.4.2.1 Pyruvate kinase M2 (PKM2) 
Oxidative regulation of substrate flow through glycolysis and hexose monophosphate shunt 
is an established feature of the cancer cell biology (Warburg effect).  This thesis has 
presented data strongly supporting presence of redox sensitive PKM2 within neutrophils.  
Specifically, postoperative neutrophils are subject to redox stress and are less responsive to 
the highly specific PKM2 activator DASA.  Therefore, it is plausible that PKM2 may act to 
regulate flow through glycolysis and the hexose monophosphate shunt.  Central to this 
argument is regulation of PKM2 through heterodimerisation, where oxidation of cys358 
leads to a change in quaternary structure which prevents further access to the site.  
Consequently, DASA can protect from, but not reverse oxidative inhibition.   
The PKM2 isoform has a second unique property, it may translocate to the nucleus and act 
as a transcription factor.  Within cancer cells EGFR-activated ERK2 phosphorylates PKM2, 
but not PKM1, to promote nuclear translocation (Yang et al., 2012).  Nuclear PKM2 induces    
c-myc expression, leading to GLUT1 and positive feedback PKM2 expression.  Transgenic 
translocation-deficient PKM2 blocks the Warburg effect within a mouse glioblastoma model. 
It follows that neutrophil PKM2 may direct gene transcription in a similar manner. 
7.4.2.1 Hypoxia inducible factor (HIF)  
HIF was initially identified as a mediator of hypoxic adaptation and inflammatory signalling, 
but has since been shown to be activated following many other inflammatory stimuli 
(Klimova and Chandel, 2008).  The key signal for stabilisation of HIF is the production of 
mitochondrial ROS at respiratory complex III (Brunelle et al., 2005), or possibly respiratory 
complex II (Dikalov, 2011).  Pharmacological inhibition of respiratory complex III is an 
established experimental tool for investigation of HIF signalling (Dikalov, 2011).  
HIF activation has pleiotropic molecular effects, many of which combine to promote 
glycolysis and inhibit oxidative phosphorylation and mitochondrial biogenesis.  HIF is 
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intimately associated with the control of autophagy, which may liberate endogenous 
metabolic reserves during times of energy starvation, as well as being responsible for 
physiological cellular turnover.  Here a decline in leukocyte ATP and rise in AMP signals 
metabolite stress, promoting a decline in AMP-kinase and increase in HIF1-α, which signals 
autophagy (Zhang et al., 2010).  Sub-inflammatory doses of endotoxin have been shown to 
promote the same changes in AMP-kinase and HIF-1(Haimovich et al., 2014).  AMP-kinase 
regulated mitochondrial biogenesis (Jäger et al., 2007) acts in synergy with growth signal 
integrating mTOR (Papandreou et al., 2006; Semenza et al., 1994; Zhang et al., 2007). 
 
7.4.2.2 Redox regulation of inflammatory gene expression 
Neutrophils are subject to intense gene regulation and protein synthesis (Calvano et al., 
2005; Teles et al., 2012; Xiao et al., 2011).  Several transcription factors display altered 
DNA binding following ROS driven oxidation (Kolls, 2006), including NF-kB (Han et al., 
2013) and Nrf2 (Davidson et al., 2013; Segal et al., 2010).  The addition of respiratory 
complex I and III inhibitors to neutrophils has been shown to stabilise NF-kB and promote 
cytokine expression (Zmijewski et al., 2009, 2008).  NRF2 is involved in antioxidant and 
cytoprotective responses, revealing how ROS may promote their own detoxification 
(Davidson et al., 2013; Segal et al., 2010).  These processes may be intrinsically linked to 
regulation of mitochondrial function, since transcription of key apoptotic signals, which 
target mitochondria, are altered by NF-kB and PI3K (Edwards et al., 2004).  As discussed 
above, PKM2 may enter the nucleus and serve as a transcription factor.  The time scale of 
transcriptional changes is compatible with the functional changes on postoperative day two, 
and may account for shorter term classical priming or tolerance through interaction of 
transcription factors with other signalling pathways, such as MAPK pathway. Gene silencing 
has been previously reported as a possible mechanism of immune tolerance (Liu et al., 2011; 
McCall and Yoza, 2007). 
7.4.2.3 The NLRP3 inflammasome   
Within macrophages the NLRP3 inflammasome has emerged as a key regulator of innate 
immunity, responsible for the release of proinflammatory mediators IL-1B and IL-18 through 
cleavage of caspase-1 (Stutz et al., 2009).  The depletion of autophagy mediators has been 
shown to promote NLRP3 mediated inflammation, through preservation of dysfunctional 
mitochondria (Nakahira et al., 2011).  Here, the depletion of mitophagy signalling proteins 
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leads to the persistence of ROS generating mitochondria, and activation of the NLRP3 
inflammasome.  The NLRP3 inflammasome has been identified within neutrophils and is 
necessary for the synthesis of neutrophil IL-1β, however beyond this it remains less well 
characterised than within monocytes (Karmakar et al., 2015).   
7.4.2.4 Direct regulation of NADPH oxidase 
There is evidence for direct signalling between mitochondrial NADPH oxidase and NADPH 
oxidase (Dikalov, 2011), although most of these studies have investigated the Angiotensin-II-
NOX pathway (rather than PHOX) and the exact site of ROS/NADPH interaction remains 
speculative.  Within HAEC cells, SOD2 knockdown prevents angiotensin-II stimulated 
NADPH oxidase activity (Dikalova et al., 2010) and accumulated mitochondrial damage 
within rabbit aortic smooth muscle cells is associated with diminished NOX1 mRNA 
expression (Wosniak et al., 2009).  The mitochondrial-NOX communication may be 
reciprocal, promoting positive feedback and further ROS production.  Depletion of p22phox 
causes a significant reduction in Angiotensin-II stimulated mitochondrial ROS production 
(Mehta and Griendling, 2007).  There is no evidence from CGD patients than diminished 
respiratory burst function alters metabolic function, since glycolysis/oxidative 
phosphorylation appear unchanged (Borregaard and Herlin, 1982). 
 
7.4.3 A neutrophil specific manifestation of a global metabolic 
phenotype.  
Systemic inflammatory responses are associated with body wide metabolic reprogramming.    
Since the bioenergetics and synthetic requirements of different cells types vary, the various 
changes of cellular function which accompany inflammatory responses may be the product 
of a common metabolic phenotype interacting with each cell’s specific metabolic 
requirements.  For example, within highly anabolic cells the hexose monophosphate shunt is 
a source of ribose sugars, while platelets possess few mitochondria and have no nucleus to 
support mRNA synthesis.  In this setting acquired mitochondrial dysfunction could 
represent a common pathological mechanism of clinically different states (Neustadt and 
Pieczenik, 2008).   
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7.4.4 A consequence of circulating, immature neutrophil precursors.   
The short life span of circulating neutrophils, typically estimated to be one day (Luo and 
Loison, 2008; Maianski et al., 2004; Pillay et al., 2010), combined with the release of 
immature neutrophils during systemic inflammatory responses suggests that the 
postoperative phenotype may be partly explained by an increase in the proportion of 
circulating immature cells.  Within septic patients the presence of immature neutrophil 
precursors (myelocytes and metamyelocytes) may have prognostic significance (Mare et al, 
2015) 
Immaturity is unlikely to be the sole explanation, because postoperative bone marrow 
derived neutrophils demonstrate a diminished burst response when compared to 
preoperative control bone marrow (Chapter 4), which supports a global change in the 
entire neutrophil pool.  Nonetheless there are similarities between immature neutrophils 
and the postoperative cells I have described. 
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7.5 Clinical relevance 
 
7.5.1 Clinical study design 
This thesis supports the use of major elective surgery as a translational model for sepsis, 
serving as a bridge between model organism studies and clinical sepsis research.  The 
addition of this extra layer of investigations would help refine experimental hypotheses and 
questions so clinical studies within critically ill may be better designed to isolate/identify the 
experimental signals in question.  This also implies that the many studies already performed 
within surgical patients may serve as a valuable resource for sepsis research.  Looking to the 
future, perioperative medicine is a rapidly expanding field.  Firstly, this will hopefully provide 
information and observations which may push sepsis research onwards.  Secondly, collusion 
between perioperative and critical care research will be mutually beneficial. 
Moving beyond surgery, similarities between other patient groups and septic patients may 
mean that observations within these other groups are relevant to septic patients.  For 
example, mechanisms underlying anergic immune responses within cancer patients may be 
relevant to similar responses within long stay ICU patients.  The effect of surgery upon 
cancer patients may therefore provide a tool to investigate effects of acute-on-chronic 
inflammation. 
7.5.2 Assays of inflammation 
The postoperative functional impairments of neutrophil function described within this thesis 
occur at a time when routine laboratory markers of inflammation, such as CRP and white 
cell count, are increased.   
The development of clinical assays of more specific markers of immune function may 
improve patient care in many ways.  At present, clinicians may only guess at how effective 
the immune response a patient is mounting.  This is because the two critical variables are 
unknown: infective burden/potency and the magnitude of the immune response.  Therefore, 
a septic patient may deteriorate because they mount an insufficient or excessive immune 
response.  The development of validated immune assays would also be directly relevant to 
future studies of immune modulating agents.   
243 
 
7.5.3 Novel targets for immunomodulation 
Metabolic changes are a feature of the inflammatory response.  Therefore, metabolic targets 
may potentially be used to regulate inflammation within patients.  Many established 
therapeutic agents have direct metabolic actions, such as metformin which inhibits 
mitochondrial respiratory complex I.  Within the cancer literature many chemotherapy 
agents have been shown to have metabolic activities, for example cyclosporin-A  inhibits 
lymphocyte glycolysis (Röpke et al., 2000).   
 
 
7.6 Further work 
 
7.6.1 Extension of the postoperative immune function and metabolic 
postoperative phenotype 
Functional analysis may be extended through specific assays of bacterial killing, chemotaxis 
and NET formation. The metabolic phenotype may be explored in several ways.  Firstly, in 
vitro assays of isolated neutrophil mitochondria may provide insight into how function of 
specific respiratory complexes changes over perioperative period.  These assays may be 
performed within whole neutrophils, using the Seahorse respirometer (Chapter 2), or 
within isolated mitochondria using a Clarke electrode.  Similarly, for glycolysis, the function 
of individual enzymes may be quantified to determine precisely how these activities change 
during human inflammatory responses – these assays have only been performed within 
‘healthy’ human cells before.   
 
7.6.2 Correlation with clinical outcome 
It is possible that increased and decreased neutrophil functions may be beneficial or harmful.  
Therefore, this study may be extended to follow the relationship between functional 
changes and clinical outcome.  This is a necessary step before studies of immune modulation 
could be attempted. 
244 
 
Beyond this, the surgical model may also provide a tool to investigate the 
immunosuppressive phase of sepsis, using tools such as latent virus reactivation (Limaye et 
al., 2008; Luyt et al., 2007) and colonisation by opportunistic and gut derived pathogens 
(Guan et al., 2013).  Cancer patients share many of the immunological defects of sepsis, 
therefore elective surgery within cancer patients offers a further opportunity to simulate the 
critically unwell patient.   
 
7.7 Conclusions 
Major elective surgery may provide a valuable translational model of human sepsis, which 
overcomes many of methodological challenges presented by patients with an established 
illness.  Postoperative neutrophils demonstrate a reversible impairment of neutrophil 
respiratory burst, as well as features that support mitochondrial dysfunction, that may be 
relevant to development of postoperative complications, and therefore outcomes in sepsis.  
These metabolic changes may regulate immune function through novel signalling molecules 
such as mitochondrial ROS, as well as the delivery of metabolic substrate to these 
processes.  Investigations into metabolic regulation of cancer cells have revolutionised 
cancer research, and further characterisation of metabolic responses within human sepsis 
may offer similar benefits and identify new therapeutic targets. 
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APPENDIX A – Experimental assay details for studies 
included in Chapter 3.
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Author 
(Year) 
 
Clinical 
Setting* 
Experimental protocol# ROS substrate $ Burst stimulus 
(Santos et 
al., 2012) 
Septic patients  DCFH-DA P.aeruginosa, S.aureus 
(Paunel-
Görgülü 
et al., 
2011) 
Trauma patients WB, ?AC [FC:morph/-vecd14] DHR PMA 
(Bruns et 
al., 2011) 
Septic patients 
(cirrhosis) 
Gran, Hep, DG: Percoll,? (Abs) [FC] DHR E. coli, fmlp, PMA 
(Shih et 
al., 2010) 
Trauma patients WB, Hep [FC:morph] SOD inhibition of Cyt c fMLP 
Kasten et 
al. 2010) 
Trauma patients Gran, Hep, DG:Ficoll-Hypaque+Dextran, HL (abs) 
[trypan blue] 
Scopoletin, HPO FN attached 
(Valente 
et al., 
2009) 
Trauma patients PBL, EDTA, HL, (FN attached) [confocal] DHR PMA 
(Kawasaki 
et al., 
2007) 
Surgical patients PBL, Hep [FC:morph] DHR E. coli 
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Fröhlich 
et al. 
2006) 
Surgical patients WB, Hep [FC:morph] DHR fMLP, PMA 
(Martins 
et al., 
2003) 
Septic patients PBL, Hep, DG:Ficoll lymph sep 1.077 [FC:morph] DCF fMLP, LPS, PMA, S.aureus 
(Barth et 
al., 2002) 
Septic patients WB, Hep [FC:morph] DHR E. coli 
(Mariano 
et al., 
2001) 
Septic patients 
(RRT) 
WB, Hep [FC:morph] Luminol (HV neu) Patient sera 
(Quaid et 
al., 2001) 
Trauma patients Gran, EDTA, Lo/Hi centrifugation, HL [Giesma stain] Scopoletin, HPO FN attached, PMA, TNF-α 
(Wiezer 
et al., 
2000) 
Surgical patients Gran,EDTA, DG: Histopaque1077, HL, (FN) [">95% 
pure"] 
DHR PMA (stop with BSA) 
Ahmed et 
al. 1999) 
Septic patients PBL, hep, DG: Lymphoprep, IL [FS:morph] DHR (tissue+blood neu) fMLP 
(Shih et 
al., 1999) 
Surgical patients Gran, hep, DG: dextran-70, Ficoll-Hypaque, HL 
[FS:morph] 
SOD inhibition of Cyt c fMLP 
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(Ertel et 
al., 1999) 
Trauma patients Gran, EDTA, DG: Ficcol-Paque, HL [Wright stain] DHR (HV neu) BALF,CSF,fMLP 
(Ogura et 
al., 1999) 
Trauma patients Gran, hep, DG: Histopaque 1077, IL [FC:cd-15] DCFH fmlp 
(Pascual et 
al., 1998) 
Septic patients WB, ?, "lysis soln" [FC:morph] Lucigenin (Patient+HV 
neu), 
Patient+HV serum 
 
 
Table A1 Experimental assay details for respiratory burst studies 
#Experimental protocol:  format: cell used, anticoagulation, separation technique:colloid used, lysis step. (Additional substances added) [Identification of neutrophils]. 
WB=Whole blood, Gran=granulocytes, PBL=peripheral blood leukocytes. ?AC=anticoagulant not detailed, Hep=heparin, EDTA=Ethylenediaminetetraacetic acid.  
DG:density gradient. HL=hypotonic lysis, IL=isotonic lysis.  Abs=cultured with antibiotics, FN=cultured in fibronectin coated plates. FC=flow cytometer, morph=forward 
scatter/side scatter on flow cytometer used to identify neutrophils 
$DCFH-DA=2',7'-dichlorodihydrofluorescein diacetate; DHR=Dihydrorhodamine 123; PMA=Phorbol 12-myristate 13-acetate; fMLP=Formyl-Methionyl-Leucyl-
Phenylalanine; SOD=Superoxide Dismutase; Cyt c=Cytochrome C, HPO=Horseradish peroxidase; FN=Fibronectin; HV=Healthy volunteer; TNF-α=Tumour necrosis factor 
α; BSA=Bovine serum albumin; BALF=Bronchoalveolar lavage fluid; CSF=cerebrospinal fluid. 
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Author/Year Clinical 
Setting 
Experiment 
protocol# 
Tolerance 
induction* 
Tolerance assay$ Experimental Readout& 
(Liu et al., 
2011) 
Septic 
patients 
Plasma: EDTA. WB:  
[FC:CD 14 
LPS, ?dose, ex-vivo,  
1hr, WB 
PBL, qRT-PCR, TNF-α. PBL, ChIP, SIRT1 and RelB @ TNF-
α promoter. 
(Buttenschoen 
et al., 2009) 
Surgical 
patients 
PBMC: ?, DG: 
Ficoll/Isopaque. 
LPS 0.2ng/ml,ex-vivo, 
6hrs, WB. 
WB SN, ELISA, TNF-α 
Il-1ß IL-6. 
MNF, qRT-PCR, TLR-2 TLR-4 
(Pachot et al., 
2008) 
Septic 
patients 
PBMC: ?, DG:Ficoll-
plaque, BD Pharm Lyse 
Buffer. Monocyte: cd14 
MACS isolation. 
Unstimulated monocyte, mAb, HLA-
DR 
WB, qRT-PCR, CX3CR1.  
Monocyte, mAb, CX3CR1. 
(West et al., 
2007) 
Septic 
Patients 
WB: Hep.  [FC:morph] LPS, 10ng/ml, ex-vivo, 
15min WB 
Plasma, ELISA,  TNF-α. WB, mAb, MAPK ERK1/2 
(Härter et al., 
2004) 
Septic 
patients 
PBMC: Hep, 
DG:histopaque, IL, 
[FC:cd14] 
LPS 1ug/ml / MALP2 
2nM, ex-vivo, 4/16hrs 
, neu+monocyte 
Neu+monocyte, 
ELISA, IL-8 TNF-α 
Neu+mono, mAb, TLR2 TLR4 
(Flohé et al., 
2004) 
Surgery in 
trauma 
patients 
WB: Hep.  [FC:CD-14] LPS, 10ng/ml, ex-vivo, 
14hrs, WB.  (abs) 
Plasma, ELISA, TNF-α 
IL-10. WB mAb HLA-
DR CD14 
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(Arnalich et 
al., 2003) 
Septic 
patients 
Monocytes: ?, DG:Ficoll-
Hypaque Plus, adh-sep 
(abs). 
LPS, 10/ng/ml / 
100ng/ml, ex-vivo, 
1hr, monocyte. 
Monocyte, qRT-PCR, 
TNF-α IL-6 
IRAK-M TLR-4 
(Heagy et al., 
2003) 
ICU patients WB (discarded):, Hep. LPS, 10ng/ml,ex-vivo, 
3hrs, WB. 
Plasma, ELISA, TNF-α, 
IL-6 
LOS, VFD, WCC, Infection 
(Calvano et 
al., 2003) 
Septic 
patients 
WB: ?AC, TNF-α. 
Monocytes: ?, Rosette 
Sep enrichment, cell sort 
with CD15, confirm 
CD14 
LPS, 10ng/ml, ex-vivo, 
24hrs 
Plasma, ELISA, TNF-α Monocyte, mAb, TLR2 TLR4 CD14. 
Monocyte, qRT-PCR cd14 TLR4 
TLR2, MD-2. 
(Sfeir et al., 
2001) 
Septic 
patients 
Monocytes: Citrate, 
DG:Nycoprep, adh-sep 
[FC:CD14] 
LPS, 1ug/ml, ex-vivo, 
16hrs, monocytes. 
Monocyte, ELISA,TNF-
α IL10 TGF-ß 
Repeat with anti-IL-10+anti TGF-ß 
(Kawasaki et 
al., 2001) 
Surgical 
patients 
WB: Hep/EDTA. LPS, 10ng/ml, ex-vivo, 
4hrs, WB. 
Plasma, L929 cell 
cytotoxicity, TNF-α. 
Plasma, ELISA, IL-10. 
WB, mAb, HLA-DR CD14 
(Heagy et al., 
2000) 
Septic 
patients 
WB (discarded): Hep.  
[FC:CD14] 
LPS, 10ng/m, ex-vivo, 
3hrs, WB (abs) 
Plasma, ELISA, TNF-α WB, mAb, CD14 45 TNF-αIC 
(Bergmann et 
al., 1999) 
Septic 
patients 
PBMC: Citrate, DG:Ficoll. LPS, 1ug/ml, ex-vivo, 
1-3hrs, WB. 
Plasma, ELISA,  TNF-α, 
IL-1, IL-6 
MNF, Nblot, TNF-α IL-1 IL-6 
Table A2 Experimental assay details for monocyte endotoxin tolerance studies 
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#Experimental protocol:  format: cell used, anticoagulation, separation technique: colloid used, lysis step. (Additional substances added) [Identification of neutrophils]. 
WB=Whole blood, Discarded=blood used from aspiration of dead-space in venous cannulas, PBMC=Peripheral blood mononuclear cells. ?AC=anticoagulant not detailed, 
Hep=heparin, EDTA=Ethylenediaminetetraacetic acid.  DG: density gradient. HL=hypotonic lysis, IL=isotonic lysis.  Abs=cultured with antibiotics, FC=flow cytometer, 
morph=forward scatter/side scatter on flow cytometer used to identify monocytes.   
*Tolerance induction: Agent, dose, location, exposure time, blood product (additional agents).  LPS=Lipopolysaccharide, WB=Whole blood, neu=neutrophil, 
abs=antibiotics 
$Tolerance assay: Blood product, assay, target. PBL=Peripheral blood leukocyte, ELISA= Enzyme-linked immunosorbent assay, qRT-PCR = quantitative real time 
polymerase chain reaction, mAb = monoclonal antibody,  
&Experimental Readout: Blood product, assay, target.  ChIP=Chromatin Immunoprecipitation, Wblot = Western blot, Nblot = Northern blot, LOS=Length of ITU stay, 
VFD=Ventilator free days, WCC=White cell count.  
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Author (Year) Clinical Setting Experimental# 
protocol 
Apoptosis readout* Cell types$ 
(Roger et al., 
2012) 
Septic 
patients 
WB: ?AC Hoeschst dye CD4, CD8(CD3+ 
CD4-) 
(Bandyopadhyay 
et al., 2012) 
Trauma patients PBMC: ?AC, DG:Ficoll-Hypaque, 
NTSR. 
Annexin-V, 7AAD.  Caspase-10IC T cell 
(White et al., 
2011) 
Septic 
patients 
PBMC:  EDTA, Lymphoprep. mRNA: BAX, BCL-2, BIM. PBMC 
(White et al., 
2011) 
Surgical patients 
(infective 
complications) 
PBMC: EDTA, Lymphoprep. mRNA: BAX, BCL-2, BIM. PBMC 
(Zhang et al., 
2011) 
Septic 
patients 
PBL: ?AC, VersaLyse). 
Lympho. (?,DG: Ficoll + cd14 neg 
selection. 
Annexin-V.  Caspase-3, PD-1 CD4, CD8, CD19 
(Guignant et al., 
2011) 
Septic 
patients 
WB: ?AC. PD-1 CD4 
(Vaki et al., 2011) Septic 
patients 
HV Lympho + subject serum: Hep, 
DG: Ficoll-Hypaque. Serum 
incubation for 24hrs, adh-sep (non 
adherant analysed). 
Annexin-V. Caspase-3 activity. 
CD95. 
CD4 
(Słotwiński et al., 
2011) 
Surgical patients WB. 
Lympho,: Hep, DG:Lymphoprep, ?, ?. 
Bax, Bcl-2, Caspase-3 9, Fas, 
PARP-1, TNFR1. 
Lymphocytes 
253 
 
(Gogos et al., 
2010) 
Septic 
patients 
PBL: EDTA, IL. Annexin-V, 7-AAD CD4, CD8, 19, CD56 
(Hoogerwerf et 
al., 2010) 
Septic 
patients 
Lympho: Hep, IL, cell sort CD4. Microarray: 30 genes CD4 
(Yousef et al., 
2010) 
Septic 
patients 
PBL: EDTA, IL. Annexin-V, 7-AAD CD3, CD19 
(Turrel-Davin et 
al., 2010) 
Septic 
patients 
WB: EDTA. 
PBMC: EDTA, DG: Ficoll-Paque, 
'lysed'. 
Annexin-V.  Bcl-2, Caspase-3. 
mRNA: BAK, BAX, BCL-XL,BID, 
BIM, FAS 
CD4, CD8, CD19 
(Pelekanou et al., 
2009) 
Septic 
patients 
PBL: Hep, IL. Annexin-V, PI CD4, CD8, CD19, 
CD56 
(Resident et al., 
2009) 
Surgical patients PBL: Citrate, VersaLyse. Annexin-V,PI Lymphocytes (FC 
morphology) 
(Delogu et al., 
2008) 
Septic 
patients 
"Isolated PBMC" Annexin-V, 7AAD, DiOC6.  Bcl-2, 
Caspase-3 8 9, Fas, FasL. 
PBMC 
(Weber et al., 
2008) 
 
Septic 
patients 
PBL. (EDTA, HL). PCR=Paxgene Annexin-V, 7AAD. Bcl-2, 
Caspase-3. mRNA: BCL-2, BCL-XL, 
BID, BAK. 
CD4, CD8, CD19.  
mRNA=WB 
(Roth et al., 
2003) 
Septic 
patients 
PBMC: EDTA, DG:Ficoll Annexin-V, 7AAD. ACE,  IL-1ß, 
IL-10.  sCD95, sTNFR1. 
CD3. Serum 
cytokines. 
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(Le Tulzo et al., 
2002) 
Septic 
patients 
PBL: EDTA, Othro-lysis. Annexin-V, 7AAD. CD95, 
CD95L, TRAIL-R1, TRAIL-R2. 
CD4, CD8 (CD4-
CD3+), CD19 
(Hotchkiss et al., 
2001) 
Volunteer endotoxin PBMC: EDTA, DG:Ficoll. Annexin-V, 7AAD PBMC 
(Delogu et al., 
2001) 
Septic 
patients 
Fixed cadaveric/(intraoperative) 
spleens 
Lightmicroscopy. 
Immunohistochemistry (inc 
caspase 9). Annexin-V, PI. 
Splenic tissue. 
B cells, CD20, CD4, 
CD8, CD3, NK. 
(Pellegrini et al., 
2000) 
Surgical patients Lymphocytes: Hep, DG:Lymphoprep 7AAD CD4, CD8 
(Delogu et al., 
2000) 
Trauma patients PBMC +T-cells: (Hep, DG:Ficoll-
Hypaque, adh-sep NTSR) 
PI (loss of) T cell, PBMC 
(Hotchkiss et al., 
2000) 
Surgical Lympho: Hep, DG: Lymphoprep, ?. 7AAD. Bcl-2, Fas FasL, p35. CD4, CD8 
(Hotchkiss et al., 
1999) 
 
Trauma patients Fixed intraoperative bowel tissue. Light microscopy. 
Immunohistochemistry 
(Cytokeratin 18). Hoechst dye. 
Lymphocyte 
aggregates within 
bowel biopsy. 
(Sasajima et al., 
1999) 
Septic 
patients 
Fixed cadaveric/(intraoperative) 
spleen tissue. 
Light microscopy.  
Immunohistochemistry (inc 
Caspase-3, Bcl-2). DAGE, 
TUNEL. 
Lymphocyte 
aggregates within 
bowel and spleen 
biopsies. 
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(Sugimoto et al., 
1998) 
Surgical patients Lympho: ?,Lymphoprep, IL. DAGE Lymphocytes 
(Roger et al., 
2012) 
Surgical patients PBMC:  Hep, DG:Lymphoprep. Fas. mRNA: FASL CD4 
Table A3 Experimental assay details of lymphocyte apoptosis studies 
#Experimental protocol.  Format: “cell used:  (anticoagulation, separation technique: colloid used, lysis step). <Additional substances added>”. WB=Whole blood, 
PBMC=Peripheral blood mononuclear cells, PBL= Peripheral blood leukocytes, Lympho=lymphocytes. ?AC=anticoagulant not detailed, Hep=heparin, 
EDTA=Ethylenediaminetetraacetic acid.  DG=density gradient:colloid used. HL=hypotonic lysis, IL=isotonic lysis.  Abs=cultured with antibiotics, FC=flow cytometer, 
morph=forward scatter/side scatter on flow cytometer used to identify monocytes.   
*Apoptotic readout. Italics indicate genes/ribonucleic acid gene products.  PI = Propidium iodide, 7AAD= 7-Aminoactinomycin D, FLICA = fluorochrome inhibitors of 
caspases, TUNEL = Terminal deoxynucleotidyl transferase dUTP nick end labelling, DNA agarose gel electrophoresis 
$Cell type studied. PBMC - peripheral blood mononuclear cell, FC=flow cytometry (i.e. forward scatter/side scatter), WB=Whole Blood. 
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